Measuring Knowledge and Attitudes Regarding the Use of Pharmacogenetic Testing among Patients and Prescribers: Diffusion of Innovation Theory by Muflih, Suhaib Mohammad
Nova Southeastern University
NSUWorks
College of Pharmacy Student Theses, Dissertations
and Capstones College of Pharmacy
1-1-2017
Measuring Knowledge and Attitudes Regarding the
Use of Pharmacogenetic Testing among Patients
and Prescribers: Diffusion of Innovation Theory
Suhaib Mohammad Muflih
Nova Southeastern University
This document is a product of extensive research conducted at the Nova Southeastern University College of
Pharmacy. For more information on research and degree programs at the NSU College of Pharmacy, please
click here.
Follow this and additional works at: https://nsuworks.nova.edu/hpd_corx_stuetd
Part of the Pharmacy and Pharmaceutical Sciences Commons
All rights reserved. This publication is intended for use solely by faculty, students, and staff of Nova
Southeastern University. No part of this publication may be reproduced, distributed, or transmitted
in any form or by any means, now known or later developed, including but not limited to
photocopying, recording, or other electronic or mechanical methods, without the prior written
permission of the author or the publisher.
This Dissertation is brought to you by the College of Pharmacy at NSUWorks. It has been accepted for inclusion in College of Pharmacy Student
Theses, Dissertations and Capstones by an authorized administrator of NSUWorks. For more information, please contact nsuworks@nova.edu.
NSUWorks Citation
Suhaib Mohammad Muflih. 2017. Measuring Knowledge and Attitudes Regarding the Use of Pharmacogenetic Testing among Patients and
Prescribers: Diffusion of Innovation Theory. Doctoral dissertation. Nova Southeastern University. Retrieved from NSUWorks, College of
Pharmacy. (1)
https://nsuworks.nova.edu/hpd_corx_stuetd/1.
iii 
 
MEASURING KNOWLEDGE AND ATTITUDES REGARDING THE USE OF 
PHARMACOGENETIC TESTING AMONG PATIENTS AND PRESCRIBERS: 
 DIFFUSION OF INNOVATION THEORY 
 
 
By 
 
 
SUHAIB MOHAMMAD MUFLIH 
 
 
 
 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of                
Doctor of Philosophy  
College of Pharmacy 
Nova Southeastern University 
Fort Lauderdale, Florida 33328 
 
 
 
September 2017 
 
 
 
Dissertation Advisor: Barry A. Bleidt, PhD, PharmD, RPh, FAPhA, FNPhA 
iv 
 
ABSTRACT 
 
An Abstract of a Dissertation Submitted to Nova Southeastern University in Partial 
Fulfillment of the Requirements for the Degree of Doctor of Philosophy 
 
MEASURING KNOWLEDGE AND ATTITUDES REGARDING THE USE OF 
PHARMACOGENETIC TESTING AMONG PATIENTS AND PRESCRIBERS: 
 DIFFUSION OF INNOVATION THEORY 
By 
 SUHAIB MOHAMMAD MUFLIH 
September 2017 
Background: Healthcare providers play a key role in patient care. Their knowledge and 
attitudes may play a critical role in the incorporation of pharmacogenetic (PGx) testing into 
routine practice. The knowledge and attitudes of patients are also equally important in 
determining the rate of diffusion and the adoption of PGx testing. This study aims to test 
Rogers’s diffusion of innovation theory to identify and evaluate the influence of 
knowledge, attitudes, and sociodemographic characteristics of patients and physicians on 
the adoption of PGx testing in current clinical settings.   
Method: A cross-sectional, descriptive survey design was implemented. The sample 
consisted of patients with chronic diseases and licensed physicians. One-way analysis of 
variance (ANOVA), linear regression, and path analysis were performed to test the 
research hypotheses. 
Results: Limited knowledge regarding PGx testing was prevalent among patients, despite 
good attitudes. While the total PGx testing knowledge score was predicted significantly by 
levels of education, prior experience, and innovativeness, the total attitude score was 
predicted significantly by gender, relative advantage, compatibility, complexity, and 
trialability. The acceptance of PGx testing by patients was significantly influenced by their 
attitudes towards PGx testing and its perceived characteristics. Physicians expressed low 
levels of knowledge regarding PGx testing; however, the majority had favorable attitudes 
toward its potential clinical advantages. The total PGx testing knowledge score was 
predicted significantly by gender, type of practice setting, and prior experience. Physicians’ 
attitude score was predicted significantly by gender, relative advantage, and compatibility 
of PGx testing. Barriers to the adoption of PGx testing were reported. The acceptance of 
PGx testing by physicians was significantly influenced by the perceived characteristics of 
PGx testing and the perceived need for testing. 
 
 
 
Conclusion: This dissertation successfully evaluated the relationship among several 
factors adapted from Rogers’s theory and the adoption of PGx testing. The research is 
expected to provide the scientific community with an increased understanding of the 
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decision-making process surrounding PGx testing. It will help identify the key factors and 
barriers that may have a significant influence on the direction of the future implementation 
of PGx testing, which will ultimately assist patients and physicians with therapeutic 
decisions. 
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Chapter 1 
 
Introduction 
 
Pharmacogenetics (PGx) is a new and dynamic field of medicine.  The term PGx was 
first coined by the German geneticist Friedrich Vogel (1959) and has recently become an integral 
component of clinical practice.  This is due to the completion of the Human Genome Project in 
2003 and the availability of cutting-edge DNA technology.  The major role of PGx testing is to 
determine genetic-based variations in drug responses by finding associations between genetic 
differences and observable clinical traits in individual patients.  This allows for careful clinical 
evaluation of potential drug toxicity and effectiveness prior to the initiation of a specific drug 
therapy.   Yet, despite the prospective benefits of PGx testing in the improvement of both 
medication safety and efficacy in many therapeutic areas, its acceptance and use in medical 
practice are still limited. 
Since physicians play a key role in patient healthcare, their knowledge and attitudes may 
play a critical role in the incorporation of PGx testing and genetically recommended therapy into 
routine practice.  Equally important are the knowledge and attitudes of patients, who may also 
affect the rate of diffusion as stated in Rogers’s diffusion of innovation theory and the adoption 
of PGx testing (Rogers, 2003).  
This dissertation investigates different factors associated with patients’ and physicians’ 
acceptance of PGx testing. Participants’ knowledge and attitudes toward PGx testing are 
evaluated as a set of variables that constitutes the basis of Rogers’s diffusion of innovation 
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theory.  The research method was a cross-sectional descriptive survey.  The surveys of patients’ 
and physicians’ knowledge and attitudes were derived from the relevant literature and were 
tested and developed further to accommodate the framed objectives of this study.  Then, eligible 
participants were invited to complete the survey.  Results were analyzed using a One-way 
ANOVA, linear regression, and path analysis models.  
This chapter describes the background of the problem and how Rogers’s diffusion of 
innovation model can be used to address the statement of the problem. Additionally, the chapter 
illustrates the purpose of the study, the research questions and hypotheses, the rationale, and the 
need for the study. 
Background to the Research Problem  
Variations in the human deoxyribonucleic acid (DNA) sequence play a significant role in 
the development of diseases.  These DNA variations may also cause a differential response to 
pathogens, chemicals, drugs, and vaccines (Lazaridis and Petersen, 2005; Zhang et al., 2015).  
Each individual has a unique set of genetic markers represented by DNA sequences located in 
specific regions of the chromosomes that may help predict his/her response to medications and 
the risk of developing a particular disease (Ginsburg and McCarthy, 2001).  Research conducted 
under the genome-wide association study (GWAS) has helped identify genetic variations that 
result in differential health outcomes (Chasman et al., 2004; Shiffman et al., 2012; Srivastava, 
2003; Thompson et al., 2005).  Researchers have utilized this information to develop efficient 
strategies for the detection, treatment, and prevention of various diseases and pathophysiological 
conditions.  GWAS typically searches the human genome obtained from different individuals for 
single-nucleotide polymorphisms (SNPs) associated with defined traits or major diseases.  The 
role of genetic variability is relevant to medical practice as it eventually enables healthcare 
3 
 
practitioners to customize treatments and prevention strategies to a patient’s unique genetic 
makeup.  So far GWAS has successfully identified the association of genetic variations with 
many chronic diseases such as type 2 diabetes mellitus (DM), Parkinson's disease, heart 
disorders, obesity, Crohn's disease, and prostate cancer (Eeles et al., 2009; Nalls et al., 2013). 
Presently the potential benefits of major therapeutic classes (e.g., analgesics, 
antipsychotics) have been observed in less than half of patients (Spear et al., 2001).  Although 
many non-genetic factors such as age, body weight, and disease states cause individual variation 
in drug response, the inherited genetic differences among individuals can significantly alter the 
pharmacokinetic and pharmacodynamic properties of medications (Roden and George Jr, 2002).  
Genetic influences on drug response vary widely among patients.  The highest beneficial 
response (80%) was expressed among patients receiving selective cyclooxygenase-2 (COX-2) 
inhibitors, while the lowest response (25%) was reported among patients receiving 
chemotherapeutic medication (Spear et al., 2001). 
PGx research is aimed at investigating the roles of genetic differences among individuals 
that impact their response to different medications.  The ultimate goal of PGx is to determine the 
role of genetic variations in drug response by finding associations between genetic differences 
(e.g., CYP2C19 *2/2 genotype) and physical changes (e.g., poor metabolizer phenotype) in 
individual patients (Hagymási et al., 2011; Tomalik-Scharte et al., 2008).  This relatively new 
genetic field allows for careful evaluation of potential drug toxicity and effectiveness prior to the 
initiation of a specific drug therapy (Benhaim et al., 2012; Kitzmilleret al., 2011; Wang et al., 
2011).  For instance, the human genome encoding cytochrome P450 enzymes (CYPs) is 
responsible for oxidative metabolism and bio-activation of around 75% of currently prescribed 
medications (Guengerich, 2007).  Inter-individual variations in the genetic sequences involved in 
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coding CYP450 enzymes may result in a reduced, amplified, or complete loss of functionality in 
the metabolizing enzymes and, consequently, an alteration in the pharmacokinetics of susceptible 
medications and inter-individual variability.  According to Lee et al. (2002), the inter-individual 
variability of the DNA sequence for the CYP2C9 gene is responsible for about a 30% to 90% 
reduction in the enzymatic activity, which typically alters warfarin clearance and the total daily 
dose. 
Drug-related complications are problematic for patients and healthcare systems.  Adverse 
drug reactions (ADRs) can result in serious injuries, hospitalizations, and even death.  A 
combined retrospective patient chart review and patient survey study conducted at eleven general 
internal medicine sites in the greater Boston area found that among 2,248 patients who self-
reported prescription medication use, 18% indicated ADRs associated with their prescription 
medications (Gandhi et al., 2000).  Notably, there was no significant association between gender, 
age, race, level of education, or insurance status and the reported ADRs.  The survey also 
revealed that 49%, 48%, and 35% of the 397 patients who experienced ADRs reported 
discomfort, seeking medical attention, and interference with daily activities, respectively 
(Gandhi et al., 2000). 
ADRs are a considerable factor leading to mortality and morbidity.  A meta-analysis of 
39 prospective studies was conducted to estimate the total incidence of serious ADRs among 
patients staying in the hospital and those who were admitted to the hospital due to an ADR in the 
US (Lazarou et al., 1998).  The study estimated a total of 2,216,000 (6.7%) hospital patients 
experienced ADRs and approximately 106,000 (0.32%) death cases were attributed to ADRs in 
1994.  The study ranked ADRs as the fifth leading cause of death in the U.S. during that year.  A 
more recent national estimate of annual emergency department visits due to ADRs reported 
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approximately 700,000 adverse drug event cases annually between 2004 and 2005, in which 
16.7% required hospitalization (Budnitz et al., 2006). 
The treatment of chronic diseases often requires long-term use of medications. Patients 
with chronic diseases whose physicians do not assess their response to medications are more 
likely to have inadequate therapy management (Brown and Bussell, 2011; Gordon et al., 2007).  
Moreover, the lack of time and communication between patients with chronic diseases and their 
healthcare providers potentially increases patients’ risk of experiencing medication-related 
complications (Gandhi et al., 2000; Østbye et al., 2005).  Effective chronic disease management 
reinforces the need to improve physicians’ knowledge about inter-individual variabilities to 
improve quality of prescribing and minimize medication adverse events among patients 
responsible for self-administration of their chronic disease medications. 
Recent studies have focused on differences in the genetic makeup of individuals that 
contribute to variation in therapeutic outcomes and increased susceptibility to adverse effects of 
chronic disease medications.  Understanding the effect of genetic differences in drug response 
among patients enables healthcare providers to select the most appropriate therapeutic choices.  
It also helps them reduce side effects that may necessitate urgent medical attention.  For 
example, variation in metabolism of simvastatin due to genetic differences is associated with 
mild to severe myopathy (Owczarek et al., 2005).  Likewise, impaired metabolism of clopidogrel 
is associated with an increased risk of bleeding (Ma et al., 2011).  Currently 150 drugs with PGx 
information on their labels (drug package inserts) have been approved by the Food and Drug 
Administration (FDA, 2016), indicating that PGx variability should be considered before the 
drug is prescribed. 
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Various studies have recognized the importance of PGx in personalized medicine and 
how the adoption of this tool will primarily help focus on drug selection and dosing (Benhaim et 
al., 2012; Ginsburg and McCarthy, 2001; Kitzmiller et al., 2011).  The integration of PGx testing 
in routine medical practice may help improve clinical outcomes, minimize ADRs, and boost 
patients’ perception regarding the safety and efficacy of their medications.  Consequently, PGx 
can potentially impact patient adherence to chronic disease medications and may result in more 
healthcare cost-savings (Haga and LaPointe, 2013; McWilliam et al., 2006). 
PGx has become a new field of pediatric research as it has the potential to improve health 
outcomes for children. Green et al. (2016) reviewed 65 drugs with FDA-approved PGx 
information in search of a safe and effective use of therapeutic medications in children.  Out of 
the 65 drug package inserts, 28 included prescribing recommendations that were identified based 
on specific genetic biomarkers (e.g., glucose-6-phosphate dehydrogenase testing is 
recommended before starting treatment with rasburicase).  Four drug package inserts indicated 
only the availability of genetic tests, three drug package inserts indicated contraindications to use 
based on a patient’s genetic makeup, seven drug package inserts mentioned cautions/avoid use or 
consider an alternative, and five drug package inserts recommended dosage adjustments.  
Finally, nine drug package inserts included more than one prescribing recommendation.  The 
authors emphasized the role of PGx in rational use of medications to achieve optimal therapeutic 
outcomes and decreased ADRs. 
Today PGx testing could potentially play a significant role in drug selection and may help 
minimize ADRs associated with chemotherapeutics and psychiatric drug use (Kitzmiller et al., 
2011); however, integrating genetic testing more widely into general diagnostic and prescribing 
practices has not yet materialized.   Studies have shown that lack of awareness and limited 
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knowledge among patients and physicians have been two of the most significant factors 
contributing to the slow adoption of PGx testing (Rogausch et al., 2006; Stanek et al., 2012). 
Unclear ethical guidelines on protection and use of genetic information, unavailability of PGx 
tests, lack of evidence supporting the clinical utility, and inefficient administrative and regulatory 
policies are also contributing factors to the limited adoption of PGx testing (Ghaddar et al., 2011; 
Moaddeb and Haga, 2013). 
Theoretical Framework 
The Everett Rogers’s diffusion of innovation model has been widely used in several 
disciplines such as political science, public health, communications, technology, and education 
(Dooley, 1999).  It provides an explanatory framework of the domains that have strong 
influences on the decision to adopt an innovation or new technology (Rogers, 2003).  This theory 
explains the reasoning for the adoption of a new technology as well as the rate of adoption.  The 
present study uses the conceptual framework of Rogers’s diffusion of innovation theory to 
examine the impact of factors, in particular innovation decision-making processes, on the 
acceptance of PGx testing by patients and physicians. 
According to Rogers’s theory, people in any defined population go through five stages of 
the innovation-decision process (knowledge, persuasion, adoption, implementation, and 
confirmation) as a reaction to an innovation.  During the knowledge stage, an individual attempts 
to learn more about the innovation: what the innovation is and how and why it works.  Following 
the knowledge stage, the individual starts developing favorable or unfavorable ideas.  According 
to Rogers, the formation of a favorable attitude toward an innovation does not always lead 
directly or indirectly to an adoption.  Knowledge and persuasion are the major stages that 
potentially affect an individual’s decision-making regarding adoption or rejection of the 
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innovation.  If the individual decides to accept the innovation, then it will be put into practice.  
After decision-making process and the innovation is already in practice, the confirmation stage 
occurs, whereby the individual seeks support for his/her decision to avoid the discontinuance or 
rejection of the innovation.  
Rogers’s theory provides a number of factors that influence the knowledge and attitude 
stages.  These factors include prior experience, perceived need for innovation, innovativeness, 
rurality, sociodemographic variables (e.g., age, level of education), and communication behavior, 
which are knowledge stage attributes.  During the knowledge stage and before making the 
adoption decision regarding innovations, an individual should become aware of the existence of 
the innovation.  Prior experience about the innovation helps decrease the uncertainty of that 
innovation and facilitate its rate of adoption.  While awareness and knowledge regarding a 
particular innovation may potentially create a need for it, an individual may also start searching 
for an innovation that could meet his/her needs.  Furthermore, an individual’s innovativeness 
could affect his/her willingness to accept an innovation relatively earlier than other members in 
the same social system.  According to Rogers, implementing innovations occurs greatly in large 
urban areas due to the availability of resources.  Sociodemographic variables may also play a 
role in the adoption of innovation; Rogers found a positive correlation between education levels 
and adoption of innovations.  Finally, channels of communication may play a significant role in 
creating knowledge and impact the rate of adoption.  Individuals usually start seeking 
information regarding an innovation only after they become aware of its existence. 
The characteristics of innovation (i.e., relative advantage, compatibility, complexity, 
trialability, and observability) described by Rogers may explain an individual’s attitudes toward 
different innovations and also determine the rate of adoption.  Innovations that are perceived as a 
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better alternative to existing options will be adopted at a higher rate.  Similarly, innovations that 
are greatly perceived as well suited with existing values and norms will be accepted faster.  Easy 
to use and simpler innovations also will be rapidly adopted.  Innovations that can be tried and 
tested before making the decision to adopt will be adopted at a higher rate.  Finally, innovations 
that are more visible and noticeable will be more readily adopted.  All these factors were 
operationalized in this study based on the theoretical lens of Rogers’s theory to generate target-
specific variables that could be assessed from the participants in the sample.  Rogers’s diffusion 
of innovation model will be further discussed in the next chapter. 
Statement of the Problem  
Although PGx holds great promise to enhance clinical outcomes of patients and may 
assume a key role in predicting ADRs, its integration in medical practice has been implemented 
to a limited extent.  Aspects beyond medical facts, including knowledge and attitudes of patients 
and healthcare professionals, need be addressed.  Many studies reported that the lack of adoption 
of PGx testing could be due to the fact that patients and physicians are unaware of the need for 
testing, do not trust or understand the current evidence of the benefits, or doubt the potential 
cost-effectiveness of the testing (Haddy et al., 2010; Perlis et al., 2009; Priest et al., 2006).  Other 
factors that may also impact the acceptance of PGx testing are the lack of adequate PGx 
educational programs and well defined practice guidelines for the use and interpretation of these 
tests (Haga et al., 2012a; Rogausch et al., 2006). 
A few studies have been conducted to measure patients’ and physicians’ knowledge and 
attitudes toward PGx testing.  While some recognized a major lack of knowledge and experience 
about genetic tests among physicians, others found that physicians were less likely to have 
positive attitudes toward the use of PGx testing because of their own concerns about 
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understanding phenotyping, patient confidentiality, and patient eligibility for health insurance.  
These studies also revealed that some positive advantages of PGx were perceived by physicians 
who have more favorable attitudes toward the role of PGx testing in improving general health 
and minimizing the frequency of drug-related complications. Similarly, based on existing 
studies, there was a lack of knowledge and awareness about genetic testing among patients with 
chronic diseases, and this lack of knowledge affected their decision to undergo PGx testing.  Yet 
most patients expressed positive attitudes, were generally supportive of PGx testing, and felt it 
would be of advantage toward their health.  
Since individualized medicine is not fully developed for most drugs, PGx testing has not 
been recommended by expert committees due to the lack of conclusive and sufficient evidence 
that testing improves health outcomes.  There have been barriers to the implementation of PGx 
testing in clinical settings reported by several studies, especially lack of awareness and limited 
knowledge among patients and physicians, lack of clinical practice guidelines that strongly 
support the clinical utility of PGx testing, physicians’ concerns about patient confidentiality, and 
patients’ ability to afford the testing (Fargher et al., 2007; Ghaddar et al., 2011; Haddy et al., 
2010; Rogausch et al., 2006).  Nevertheless, the number of available PGx tests has increased 
drastically since 2004, as some ongoing clinical trials are completed (Frueh et al., 2008).  
Physicians’ awareness, understanding, and attitudes regarding PGx testing may play a key role in 
the rapid diffusion of these genetic tests in clinical practice.  Moreover, the knowledge and 
attitudes of the general public may play a decisive role in the wider acceptance of PGx testing in 
society.  Data from previous studies indicate that the public is open to the adoption of new 
technology for the betterment of health (Haddy et al., 2010; Rogausch et al., 2006). 
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The lack of knowledge and variable attitudes toward PGx testing appear to be dominant 
barriers within healthcare systems.  Few studies exist on this topic, and most have been 
conducted on patients and physicians outside Florida.  Only a few publications have focused on 
knowledge and attitude toward PGx testing among patients with chronic diseases (Calsbeek et 
al., 2007; Cuffe et al., 2014; Lachance et al., 2015; Morren et al., 2007; Trinidad et al., 2015).  
Additionally, there have been very few studies that adequately demonstrate the impact of patients 
and physicians knowledge and attitudes on the adoption of PGx testing based on Rogers’s 
diffusion of innovation theory (Armstrong et al., 2003; Dressler et al., 2014; Nielsen and 
Moldrup, 2007).  Relying only on the findings of existing studies to draw broad conclusions 
about the knowledge and attitudes towards PGx testing among patients and physicians may not 
be representative of the heterogeneous population of Florida.  
More research is needed to understand if and how patients’ and physicians’ knowledge 
and attitudes contribute to the adoption of PGx testing.  Knowledge and attitudes toward PGx 
testing are critical to expanding this evolving field of science.  The implementation of PGx in 
routine medical practice and future personalized medicine will ultimately depend upon patients’ 
and physicians’ acceptance of these tests and related recommendations. 
There is a significant gap concerning knowledge and attitudes toward PGx testing among 
patients with chronic diseases and physicians in the State of Florida that may be related to their 
uncertainty to adopt PGx testing with promising health outcomes.  Due to the relationship among 
knowledge, attitudes, and the adoption of innovation explained by Rogers’s diffusion of 
innovation theory, this study focused on the measurement of knowledge and attitudes as they 
relate to the acceptance of PGx testing. 
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Purpose of the Study  
This study aimed to identify and evaluate the influence of knowledge, attitudes, and 
sociodemographic characteristics of patients and physicians on the adoption of PGx testing as a 
diagnostic tool in the current clinical settings.  In order to achieve a better understanding of 
decision-making processes toward PGx testing and the strategies that help foster efficient 
adoption, this study was based on Rogers’s diffusion of innovation theory, which has been 
widely accepted as a theoretical model to explore diffusion and adoption of innovations.  The 
knowledge and attitudes toward PGx testing were compared among patients filling their 
prescriptions for their chronic conditions at the Nova Southeastern University (NSU) Clinic 
Pharmacy in Fort Lauderdale, Florida, who would be willing to reject or accept PGx testing, if 
available, for one of their chronic disease medications.  The knowledge and attitudes toward PGx 
testing were also compared among physicians who would be willing to reject or accept PGx 
testing, if available. 
Research Questions and Hypotheses 
Previous scholarly work has independently evaluated patients’ and physicians’ 
knowledge and attitudes toward PGx testing (Calsbeek et al., 2007; Cuffe et al., 2014; Haga et 
al., 2012a; Haga et al., 2012c; Henneman et al., 2006; Kobayashi and Satoh, 2009; Lachance et 
al., 2015; Lanktree et al., 2014; Morren et al., 2007; Nielsen and Moldrup, 2007; Stanek et al., 
2012; Stanek et al., 2013; Taber and Dickinson, 2014; Trinidad et al., 2015; Walden et al., 2015).  
Pursuing this work, the goal of this study was to increase understanding of several factors 
(sociodemographic characteristics, knowledge, and attitudes) that may play a role in the early 
adoption of PGx testing among patients and physicians by answering the following research 
questions: 
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Research Question 1A: 
What is the association between patients’ knowledge of PGx testing and their gender, 
age, ethnicity, level of education, area of living, prior experience, innovativeness, and perceived 
need for innovation? 
H0 (1A): Gender, age, ethnicity, level of education, area of living, prior experience, 
innovativeness, and perceived need for innovation are not significantly associated with 
knowledge of PGx testing among patients. 
Research Question 1B: 
What is the association between physicians’ knowledge of PGx testing and their gender, 
age, ethnicity, medical specialty, type of practice setting, duration of practice, prior experience, 
innovativeness, and perceived need for innovation? 
H0 (1B): Gender, age, ethnicity, medical specialty, type of practice setting, duration of 
practice, prior experience, innovativeness, and perceived need for innovation are not 
significantly associated with knowledge of PGx testing among physicians. 
Research Question 2A:  
What is the association between patients’ attitudes toward PGx testing and relative 
advantage, compatibility, complexity, trialability, and observability of PGx testing? 
H0 (2A): The relative advantage, compatibility, complexity, trialability, and observability 
are not significantly associated with attitudes toward PGx testing among patients. 
Research Question 2B: 
What is the association between physicians’ attitudes toward PGx testing and relative 
advantage, compatibility, complexity, trialability, and observability of PGx testing? 
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H0 (2B): The relative advantage, compatibility, complexity, trialability, and observability 
are not significantly associated with attitudes toward PGx testing among physicians. 
Research Question 3A: 
Do knowledge, attitudes, perceived characteristics of innovation, and sociodemographic 
characteristics significantly influence the acceptance or rejection of PGx testing among patients? 
H0 (3A): There is no relationship between patients’ willingness to accept PGx testing and 
their knowledge of PGx testing, attitudes toward PGx testing, perceived characteristics of PGx 
testing, and sociodemographic characteristics. 
Research Question 3B: 
Do knowledge, attitudes, perceived characteristics of innovation, and sociodemographic 
characteristics significantly influence the acceptance or rejection of PGx testing among 
physicians? 
H0 (3B): There is no relationship between physicians’ willingness to accept PGx testing 
and their knowledge of PGx testing, attitudes toward PGx testing, perceived characteristics of 
PGx testing, and sociodemographic characteristics. 
Rationale and Need for the Study 
Advances in the knowledge regarding human genetic variation and its relation to drug 
responses have increased significantly since the completion of the Human Genome Project in 
2003.  Yet, despite the prospective benefits of PGx testing in improving both medication safety 
and efficacy in many therapeutic areas, the literature shows that the use of PGx testing remains 
limited in many clinical settings.  Further aspects beyond medical facts, including knowledge 
and attitudes of patients and physicians, need be studied.  Although the FDA has reviewed more 
than 150 labels of prescription medications to include information regarding the impact of 
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genetic variation on medication safety and efficacy (FDA, 2016), the integration of more 
widespread genetic testing into general diagnostic and prescribing practices has not yet occurred, 
possibly due to the limited knowledge and awareness among patients and physicians. 
Research is needed to understand if and how patients’ and physicians’ knowledge and 
attitudes contribute to the adoption of PGx testing and use of the results to guide prescribing.  
Haga et al. (2012a) indicated that 76% of physicians were unaware of the drug package inserts 
including PGx information, and only 13% of physicians indicated they felt comfortable ordering 
PGx testing.  Available studies on sociodemographic characteristics and geographic locations 
that did not include Florida were conducted a few years ago; since then, much has changed in the 
field of PGx testing.  
This study primarily focused on the initial factors that prompt patients or physicians to 
either reject or accept the utilization of PGx testing according to Rogers’s theory.  A more 
thorough understanding of the underlying barriers that influence the decision-making process can 
be expected to have important benefits for promoting personalized medicine.  Florida has an 
increasingly diverse general population; thus, a unique opportunity exists to update the 
knowledge on the use of PGx testing and gather information from a culturally diverse population 
filling their prescriptions at the NSU Clinic Pharmacy.  The contribution of this research is 
expected to significantly advance patients’ and physicians’ knowledge, improve their attitudes 
toward the use of PGx testing, and encourage them to utilize testing not only for drugs available 
with PGx information, but potentially to inform other treatment decisions currently or in the 
future.  For example, the results of PGx testing for one or more enzymes involved in the 
metabolism of a particular drug could possibly inform useful treatment decisions for other future 
prescribed medications that share the same metabolic enzymes (Mills et al., 2013).  Additionally, 
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this study measured the influence of certain sociodemographic factors on the willingness of a 
patient to use PGx testing.  Thus, it may advance physicians’ understanding of patients’ needs 
and subsequently the need for change in their current clinical practice.  
Patients with chronic conditions are of a growing concern in the U.S. due to their high 
risk of morbidity and mortality responsible for almost 80% of all causes of death in 2010 
(Murphy et al., 2012).  Studies have shown that patients with chronic diseases who were less 
motivated to manage their conditions had a lower rate of medication adherence that impacted 
their health outcomes (Balkrishnan, 2005; Kripalani et al., 2007).  Moreover, patients’ concerns 
regarding the appropriateness of their medications, the possibility of having ADRs, and lack of 
communication between patients and physicians could negatively influence the optimal outcome 
of their chronic conditions (Gordon et al., 2007; Stevenson et al., 2004).  Stevenson et al. (2004) 
showed that increasing the role of patients in decision-making and considering patients’ 
preferences toward treatment options have potential benefits on their health outcomes.  As such, 
patients’ perceptions of their medication suitability, as well as understanding the rationale behind 
switching to other medications and/or different doses, have a favorable impact on their health 
(Balkrishnan, 2005; Gordon et al., 2007).  Therefore, more careful assessments of chronic 
condition medications are needed to provide patients with more information about their therapy 
of choice and potential side effects, which could enhance their medication utilization.  The 
findings of behavioral research on the acceptance of a new clinical tool such as PGx testing 
could help support the informed prescribing process.  
Definitions of Variables and Concepts 
In order to achieve a better understanding of the decision-making process in PGx testing 
and which strategies would help foster its efficient adoption, this study aimed to identify and 
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evaluate the impact of knowledge and attitudes of patients and physicians in the adoption of PGx 
testing as a diagnostic tool in the clinical settings.  What follows is a definition of relevant 
variables within Rogers’s diffusion of innovation theory. 
Knowledge Stage 
Individuals become aware of the existence of an innovation and collect more information 
to gain a better understanding of its characteristics.  The following are antecedents to the 
knowledge stage: 
● Innovativeness: the degree to which an individual is willing to accept the innovation 
relatively earlier than other members in the same social system. 
● Prior experience: the degree to which an individual is aware or familiar with the innovation 
prior to making an adoption decision. 
● Perceived need: the degree to which an individual believes in the utility of the innovation. 
● Work environment: the location of an individual workplace (i.e., urban, rural). 
● Sociodemographic variables: gender, age, ethnicity, level of education, and area of living. 
● Communication channels: the most effective resources of generating knowledge about an 
innovation.  
Persuasion Stage 
Individuals acquire positive and negative attitudes toward the innovation.  The following 
are attributes of adopters’ attitudes toward the characteristics of innovation: 
● Relative advantage: the degree to which an individual believes that the value in the 
innovation is higher than what it replaces.  Greater perception of advantages leads to a 
higher rate of adoption. 
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● Compatibility: the degree to which the innovation deviates from the existing values, 
practice, and prior experiences.  Greater perception of compatibility leads to a higher rate 
of adoption. 
● Complexity: the degree to which the innovation is perceived as difficult to understand or 
use.  Simpler innovations are accepted at a relatively higher rate.  
● Trialability: the degree to which the innovation can be tested or tried before adoption.  The 
ability to try an innovation reduces the level of perceived uncertainty and ultimately 
increases the rate of adoption. 
● Observability: the degree to which the results and effects of the innovation are noticeable 
by individuals.  Per Rogers’s theory, individuals who can more easily see the results of the 
innovation will be more likely to adopt it. 
Characteristics of Innovations 
 The characteristics of innovations perceived by an adopter include relative advantage, 
compatibility, complexity, trialability, and observability, which could potentially influence the 
rate of adoption of innovations.  
Pharmacogenetics 
 The study of inherited genetic differences that influence an individual’s responses to 
drugs (Nebert, 1999).  The term is often used interchangeably with the term pharmacogenomics, 
but there is a difference.  The distinction is fully explored in  
Chapter 2.  
Pharmacogenomics 
 A comprehensive study of all genetic variants within an individual or across a population 
to relate their multiple effects on drug response (Evans and Relling, 1999). 
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Chronic Conditions 
 A health problem such as cardiovascular disease, asthma, and cancer that lasts for at 
least three months (Goodman et al., 2013; National Center for Health Statistics [NCHS], 2011).  
Almost 50% of U.S. adults have at least one chronic condition (CDC, 2017; Ward et al., 2014). 
Chronic Medications 
 Medicines prescribed over a long period of time (at least three months) to control or 
manage chronic diseases (e.g., antihypertensive and antidiabetic medications). 
Summary 
PGx testing is a relatively new diagnostic clinical tool.  It provides an opportunity to 
tailor medications based on an individual’s genetics.  Several studies have recognized the 
potential benefits of PGx testing to evaluate possible drug toxicity and increase drug 
effectiveness; however, the slow uptake of PGx testing in clinical practice has resulted in limited 
information about the acceptance of PGx testing among patients and physicians.  The objective 
of this study was to test Rogers’s diffusion of innovation theory on the adoption of PGx testing.  
It is expected to contribute to the existing literature by identifying a set of potentially modifiable 
variables that may affect the adoption of PGx testing by patients and physicians, thus increasing 
understanding of the decision-making process surrounding PGx testing and identifying the key 
factors and barriers that may highly influence the direction of future implementation of PGx 
testing in routine clinical practice. 
In the next chapter the theoretical framework is discussed.  Along with a description of 
the potential clinical utility of PGx and pharmacogenomics to inform treatment decisions, a 
review of the relevant studies found in the literature is undertaken.
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Chapter 2 
 
Literature Review 
 
Published works related to patients’ and physicians’ knowledge and attitudes 
toward PGx testing are presented and discussed in this chapter.  Rogers’s diffusion of 
innovation theory, which was adopted as the conceptual framework for this research, is 
examined in the first part of this review.  The concepts of PGx and pharmacogenomics 
are described in the second part.  The relevant literature is reviewed in the last part of this 
chapter to support the current research questions and hypotheses.  
Literature Search Method 
Potentially relevant studies were identified by searching MEDLINE EBSCO, 
EMBASE, and Google Scholar for all articles written in English that reported results 
based on surveys, interviews, or focus groups.  To narrow the scope of search, the 
following keywords that describe the current dissertation project were used: knowledge, 
awareness, attitudes, perception, views, perspectives, opinions, adoption, 
pharmacogenomics, pharmacogenetics, pharmacogenetic testing, genetic factors, 
diffusion of innovation, barriers, drug response physicians, doctors, clinicians, chronic 
diseases, patients, and public.  These keywords were searched in combination using the 
Boolean operators “AND, OR, and NOT.”  Then the corresponding titles and abstracts 
were carefully reviewed to assess their potential relevance to this dissertation.  Included 
were all the works conducted on patients and physicians to assess their knowledge and/or 
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attitudes toward PGx testing up to 2017.  Studies conducted on genetic diseases or 
genetic factors linked to diseases were excluded.  After applying inclusion and exclusion 
criteria, 40 studies were identified.  After subsequent scrutiny, 27 studies were selected. 
Diffusion of Innovation Theory 
Rogers’s diffusion of innovation theory provides a useful framework for 
evaluating the factors that might affect acceptance of an innovation such as PGx testing 
among patients and physicians (Rogers, 2003).  According to Rogers, adoption is defined 
as “full use of an innovation as the best course of action available” and rejection is 
defined as “not to adopt an innovation.”  An innovation is described as “an idea, practice, 
or object that is perceived as new by an individual.” 
Five distinctive stages are identified: knowledge, persuasion, decision, 
implementation, and confirmation (see Figure 2.1). The knowledge and persuasion stages 
were operationalized, defined, and measured in this study using patients’ and physicians’ 
perspectives to generate specific items.  Knowledge is gained when an individual learns 
of the innovation’s existence and obtains more information to determine how it functions.  
Having enough information at this stage helps override the problem of uncertainty about 
the mechanism by which the innovation’s capacity solves an individual’s problems. 
 
Figure 2.1: Illustration of the various stages in implementing an innovation as adapted 
from Rogers’s diffusion of innovation theory. 
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The persuasion stage occurs when an individual’s attitude toward the innovation 
changes from positive to negative or vice versa.  Availability of new knowledge, along 
with the individual’s attitude, plays a critical role in the adoption decision of the 
innovation.  The decision process takes place when an individual is involved in making 
his/her own choice to adopt or reject the innovation.  Implementation occurs later when 
an individual makes a decision to adopt and utilize the innovation. Afterwards, an 
individual starts seeking support for his/her decision.  At this point, confirmation occurs 
and the individual decides to make full use of the innovation or discontinue it. 
Rogers’s diffusion of innovation theory has been applied in several health studies.  
Helitzer et al. (2003) applied it to examine the acceptance of telemedicine and its 
components for an efficient delivery of healthcare services.  Chew et al. (2004) used it to 
assess the acceptance by family physicians of the Internet as an innovative tool for 
clinical and public health topics.  Zhang et al. (2015) applied it to measure patients’ 
acceptability for consumer e-health services, and Dodson (2012) applied it to measure the 
adoption of PGx testing among oncology nurses.  These studies demonstrated that 
Rogers’s theory provides a useful theoretical framework for promoting health behavior or 
adopting relatively new medical tools. 
Rogers’s theory identifies five adopter categories based on the number of 
individuals who adopt the innovation in a given time period.  The adopter categories 
include innovators, early adopters, early majority, late majority, and laggards (see  
Figure 2.2).  These categories are presented as segments of a bell-shaped curve and 
indicate innovativeness defined as the extent to which an individual is relatively early in 
adopting  new ideas.  Innovators are the first to try new ideas regardless of the level of 
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Figure 2.2: Illustration of a normal distribution encompassing adopter categories as 
described by Rogers’s diffusion of innovation theory. 
 
uncertainty.  Early adopters come later and serve as role models and opinion leaders for 
the remaining categories; their well informed decision-making greatly influences the 
majority of the social system.  Early majority and late majority adopters represent the 
largest section of the social system; they adopt an innovation and start adoption as a 
result of interpersonal networking and peer adoption and recommendation.  The late 
majority is generally skeptical and reluctant to adopt an innovation due to high levels of 
perceived uncertainty; however, increasing peer pressure may persuade them to adopt.  
Laggards are the last to adopt an innovation; their slow decision to adopt is likely because 
they are more suspicious of innovations and have no opinion leadership. 
 
The successful application of Rogers’s theory helps investigate the factors 
affecting the rate of adoption among potential adopters; it also helps target those who are 
usually classified as the late majority or laggards to shift into an earlier adoption stage for 
a more efficient use of the PGx testing tool.  A limited number of studies have examined 
the rate of PGx testing adoption among physicians.  Stanek et al. (2012) conducted a 
cross-sectional survey that showed physicians who were early adopters of PGx testing 
were more likely to be practicing in an urban setting with a long duration in overall 
medical practice (15-29 years) and had previous experience ordering genetic testing.  The 
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study also found that early adopters of PGx testing were influenced by medical specialty; 
the highest adoption rates were reported by oncologists (69%), much higher than those of 
family medical practitioners (12%) or nonsurgical specialists (10%).  In comparison to 
late adopters of PGx testing, a larger percentage of early adopters had received PGx 
training in their undergraduate and postgraduate studies.  In contrast, late adopters were 
more likely to be male, older, and with a longer duration of medical practice than early 
adopters.  Physician age and gender had no significant association with early adoption of 
genetic testing. 
This research study focused on the first two stages of the Rogers’s diffusion of 
innovation theory.  The first step of the decision-making process focused on initial 
awareness and knowledge of an innovation.  Although knowledge does not guarantee 
successful adoption of an innovation, it is essential to motivate individuals to seek more 
information relevant to the innovation.  Subsequently individuals begin to shape their 
own attitudes concerning that innovation.  After learning more about the innovation and 
becoming more involved with it by forming positive or negative attitudes, the individual 
must then be persuaded to choose to accept or reject the innovation.  A meta-analysis of 
75 studies, conducted and summarized by Tornatzky and Klein (1982), reported that the 
more relative advantage, compatible, simple, trialable and visible the innovation is, the 
more likely it is to be adopted and put in practice.  
Pharmacogenetics and Pharmacogenomics 
Recent studies have increasingly focused on the evolving role of both PGx and 
pharmacogenomics in dealing with the impact of genetic variations on drug response.  
Typical variability in an individual’s response to medications creates challenges in 
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prescribing the correct medication and the optimal dosage regimen.  The human genome 
encodes tens of thousands of proteins.  These proteins play a crucial role in several 
pathways of drug metabolism, disposition, and therapeutic effects. SNPs, DNA sequence 
variants, are considered the inherited basis of inter-individual variability in drug response 
(Collins et al., 1998).  Across the human genome, the identification of a large number of 
SNPs could serve as database of genetic markers to predict an individual’s susceptibility 
to diseases or altered drug responses.  For instance, SNPs of the genes that encode drug 
metabolizing enzymes (e.g., CYP2C9, CYP2D6) have been associated with impaired 
metabolism and variable drug responses for warfarin and codeine, respectively (Evans 
and Relling, 1999).  Therefore, to improve medication safety and efficacy among 
genetically susceptible individuals, an adjusted dose of warfarin to achieve the 
therapeutic anticoagulant effect can be predicted on CY2C9 SNPs.  Similarly, selecting 
an individual-specific dose of codeine is important to improve pain relief (Evans and 
Relling, 1999). 
With the completion of the Human Genome Project in 2003, more information 
about the entire collection of human genes has become available for research.  To 
promote the scientific understanding of human genetics, research has begun to identify 
not only common disease-causing genetic variants, but also the relationship between 
genetic variants and drug response (Manolio et al., 2008).  The field of PGx examines a 
single gene-drug interaction, which is determined by the impact of genetic variation (i.e., 
SNPs) on drug metabolism and disposition in the human body.  For example, genetic 
polymorphism of drug-metabolizing enzymes CYP2C9 could potentially impact the 
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anticoagulant effect of warfarin; similarly, genetic polymorphism of CYP2C19 could 
potentially impact the antiplatelet effect of clopidogrel (Roden et al., 2011).  
Emerging data about the relationships between phenotypes and genetic variants in 
multiple genes have advanced the understanding of variable drug response (Manolio et 
al., 2008).  Thus, the term pharmacogenomics has become more recently used to indicate 
the existence of multiple genetic variants modulating drug response (Roden et al., 2011).  
Pharmacogenomics examines multiple genetic variants within an individual or across a 
population to relate their multiple effects to drug pharmacokinetics and drug response.  In 
addition to the genetic variability in drug pharmacokinetics, pharmacogenomics also 
investigates additional candidate genes encoding drug molecular targets that control the 
effect of drugs on the body (pharmacodynamics).  For example, polymorphisms in 
CYP4F2, CYP2C18, EPHX1, and GGCX genes may alter the pharmacokinetic and 
pharmacodynamics of warfarin and contribute to its heterogeneous response (Roden et 
al., 2011). 
The majority of prescribers rely on conventional drug therapy, treating patients as 
large homogenous groups regardless of whether or not there is a genetic component 
influencing the outcome of drug therapy (Vogenberg et al., 2010).  When considering a 
shift into more accurate prescribing based on the genetic profiles, however, PGx and 
pharmacogenomics may help find more appropriate treatment for individual patients 
(Vogenberg et al., 2010).  PGx and pharmacogenomics should be integrated into current 
medical practice, as they continue to hold substantial promise to improve drug 
therapeutic outcomes among genetically susceptible patients. 
27 
 
Patients’ Knowledge of Pharmacogenetic Testing 
Studies have shown that unsuccessful implementation and decreased utilization of 
genetic testing are linked to the lack of knowledge and negative attitudes toward genetic 
testing.  For example, Calsbeek et al. (2007) assessed and established that less perceived 
medical knowledge about genetic testing and more perceived social knowledge of genetic 
testing were responsible for the poor attitudes toward PGx testing in patients with chronic 
diseases such as asthma, DM, and cardiovascular disease (CVD).  They also found that 
perceived genetic knowledge was inadequate, particularly among older and less educated 
patients.  The authors reported that knowledge and attitudes toward genetic testing did 
not significantly change over a follow-up period of two years.  It should be noted that the 
strength of their study was its longitudinal nature and that its results corresponded with 
Rogers’s diffusion of innovation theory.  However, the study had limitations that could 
compromise its findings.  Its sample size might not have been sufficient to detect small 
changes in knowledge and attitudes over a period of two years, and it did not clearly 
define PGx testing.  
These findings were supported by another study in which Morren et al. (2007) 
observed that patients with chronic diseases, including CVD, asthma or chronic 
obstructive pulmonary disease (COPD), DM, musculoskeletal disease, cancer, 
neurological disease, and gastrointestinal disease, were not able to make decisions 
regarding genetic testing.  This was not due to their uncertainties about the PGx testing, 
but the lack of knowledge and awareness about genetic testing that affected their decision 
to undergo PGx testing.  In contrast, Haga et al. (2012b) found that almost 80% of study 
participants heard of the term genetic testing, and less than 2% of them had been ordered 
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PGx testing to predict drug response.  They also found that White and female 
participants, as well as those with a college degree, were more aware of genetic testing 
than the rest of the sample. 
Utilizing a national representative sample of patients with chronic diseases, 
Morren et al. (2007) found that perceived genetic knowledge was limited, particularly 
among older and less educated patients.  Despite the limited knowledge and low 
awareness, more positive attitudes toward genetic testing were found among younger and 
more educated patients.  One of the strengths of their work was the use of a large sample 
size; the study also significantly contributed to the knowledge base by suggesting 
variables that might influence the adoption of PGx testing.  A limitation, however, was 
the use of few response options that might have estimated less accurately participants’ 
knowledge and attitudes.  Another limitation was that it used the term genetic testing in 
general and avoided using the term PGx testing. 
A study surveying 3,000 patients in Denmark, conducted by Nielsen and Moldrup 
(2007), revealed results similar to those of the Morren et al. (2007) study, namely, the 
public had poor knowledge but good attitudes toward PGx testing.  Nielsen and Moldrup 
(2007) also reported that prior use of medical tests and perceived needs for PGx testing 
were related to the general knowledge and attitudes toward PGx testing, as well as the 
future use of these tests.  Their work was influential because it was based on Rogers’s 
diffusion of innovation theory and the adapted variables provided consistent results with 
the theory.  Its weakness, however, was the potential selection bias that might have 
occurred, since only individuals with Internet access could participate. 
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Understanding factors that could influence the acceptance of well established 
innovations may support the design and conduct of this dissertation.  Or and Karsh 
(2009) performed a systematic review to identify the variables influencing patients’ 
acceptance of consumer health information technology (IT) applications, which enables 
them to electronically manage their health information.  The review reported an 
association between patient-related factors and their adoption decision.  Among the 52 
reviewed studies, more than half found that higher education and prior experience were 
associated with increased acceptance.  Age was examined in 39 studies, and it did not 
show a consistent effect on the acceptance of health IT application.  Gender demonstrated 
no effect in the majority of the studies, either.  Six studies reported that lack of familiarity 
and perceived benefits were negatively associated with patients’ acceptance of health IT 
applications.  
In 2015 a qualitative study was conducted to explore patients’ attitudes regarding 
the role of PGx testing in reducing ADRs and improving medication efficacy (Trinidad et 
al., 2015).  Patients taking chronic disease medications for mental health disorders were 
recruited.  Results showed that the majority of patients were less familiar with the impact 
of inter-individual genetic differences in medication response and only a few believed 
that this variability was inheritable.  The authors reported that participants perceived the 
potential benefits of PGx testing on improving their medication response and reducing 
the challenges of avoiding ADRs.  This project was important because it enriched the 
existing literature about PGx testing from the perspective of patients with mental disease.  
A cross-sectional study was conducted on cancer patients, evaluating their 
willingness to accept and pay for PGx testing (Cuffe et al., 2014).  Findings revealed that 
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the majority of patients (85%), regardless of their lack of knowledge, perceived that PGx 
testing would help in detecting the therapeutic benefit of medications and avoiding 
chemotherapy-induced toxicities.  The majority of adjuvant and metastatic patients were 
willing to accept PGx testing if it was offered free with a one-day waiting period for 
testing results.  The majority of the participants were also willing to pay out of pocket for 
this innovation and devote several weeks of waiting time to receive the testing results.  
Almost 15% of the participants were reluctant to accept PGx testing, however, because 
they were worried about the potential of these genetic tests to disclose information about 
the inheritability of cancer.  The strength of this work was the validity of the comparisons 
between patient groups to detect the perceived benefits of PGx testing.  The reliability of 
the findings also was supported by measuring participants’ willingness to pay for PGx 
testing.  Yet recruiting participants from one cancer center limited the generalizability of 
the findings, plus differences in patients groups’ sociodemographic characteristics might 
have led to biased statistical results. 
Patients’ Attitudes toward Pharmacogenetic Testing 
Lachance et al. (2015) conducted a survey among three groups of individuals: 
healthy volunteers, heart failure (HF) patients, and heart transplant recipients.  The 
researchers compared the opinions of each group on PGx testing.  All three groups 
expressed high expectations and hope about the usefulness of PGx testing, but were 
concerned about the confidentiality of the testing results.  Healthy volunteers had higher 
concerns about confidentiality, employability, and insurability compared to HF and heart 
transplant patients, and the majority of participants expressed concerns about undergoing 
PGx if there was no suitable alternative drug available.  The authors reported that 24%, 
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13%, and 17%, respectively of healthy volunteers, HF patients, and heart transplant 
recipients were more likely to consider genetic testing only if the targeted disease of 
interest was treatable.  The study’s strength was providing a valid comparison between 
healthy and unhealthy participants’ perspectives toward PGx testing.  It also enlightened 
future studies to address the need for complete confidentiality, enhanced educational 
programs, and public awareness.  Its lack of generalizability to the target population was 
a limitation.  In addition, there might have been a selection bias insofar healthy 
individuals might have been less interested in PGx testing than participants with chronic 
diseases.  
In 2015 a qualitative study showed that participants taking carbamazepine and 
antidepressants commonly suffered from multiple drug reactions and reported a lack of 
therapeutic benefit.  These patients required assurance of the optimal therapeutic outcome 
of PGx testing and whether or not they were on the correct medications (Trinidad et al., 
2015).  Based on Rogers’s diffusion of innovation theory, the association between 
knowledge and attitudes of patients toward PGx testing is vital to achieving effective use 
of testing.  But the lack of adequate knowledge about PGx testing can lead to 
apprehension among patients, even though they may agree with the benefits of testing 
(Trinidad et al., 2015).  The authors reported that patients expressed positive attitudes 
toward the clinical advantages of PGx testing; however, most of them had concerns that 
might possibly outweigh the perceived benefit of PGx testing.  These concerns included 
vulnerability to unauthorized access to genetic information, risk of discrimination in 
health insurance, and employability.  Similar results were reported by Haddy et al. (2010) 
when chronically ill patients emphasized the potential advantage of PGx testing but were 
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worried about the potential discrimination and unauthorized access to genetic 
information.  Both Trinidad et al. (2015) and Haddy et al. (2010) provided a distinctive 
qualitative insight on the potential barriers of accepting the use of PGx testing.  Their 
findings could not, however, be extended to the whole target population. 
Trinidad et al. (2015) also showed that the fear of discrimination and 
stigmatization was more prevalent among patients with mental health conditions than 
healthy patients.  Participants were concerned about not receiving the therapeutic dose or 
correct medication if their physicians relied solely on the results of PGx testing and 
overlooked their patients’ feedback on prescribed psychotropic medications.  Therefore, 
some patients perceived PGx testing as an additional source of information about drug 
response rather than the only source.  The study contributed to the understanding of a 
specific population prior to the transition of PGx innovation into practice, as emphasized 
by Rogers’s diffusion of innovation theory.  
A longitudinal study of undergraduate medicine and science students at three 
Canadian universities aimed to assess the students’ attitudes regarding the use of PGx 
testing for psychotropic medications, assuming that these tests would result in the best 
therapeutic outcomes (Lanktree et al., 2014).  Nine out of ten participants expressed 
positive attitudes toward PGx testing and its use for the optimal selection of psychotropic 
medications.  About 78% of participants raised concerns about potential discrimination 
and the potential of using the results for non-clinical reasons.  Sociodemographic 
characteristics such as age, sex, race, and religion group were not significantly associated 
with the students’ attitudes.  The strength of this work was that it contributed to the 
understanding of the use of PGx testing in psychiatric patients who usually experience a 
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wide range of ADRs; its weakness was the use of a convenient sample with a potential 
selection bias. 
In a random digital phone survey among U.S. adults, Haga et al. (2012b) 
concluded that people expressed interest in PGx testing to find out about ADRs and seek 
help with drug and dosage selection.  The authors indicated that White participants with a 
higher educational degree and prior experience of side effects expressed greater positive 
attitudes toward PGx testing than the rest of the sample.  They established that people 
would be less likely to use PGx testing if their genetic information was shared for non-
clinical purposes.  The strengths of this study were its large number of participants and its 
novel insight about the association of sociodemographic characteristics and several 
benefits of PGx testing as perceived by the public.  The limitations included an unclear 
definition of PGx testing, lack of a theoretical base, and inadequate description of the 
methods. 
In a study conducted in Australia, Haddy et al. (2010) enrolled 35 individuals who 
personally had, or had an immediate family member with, a chronic medical condition. 
Patients were generally positive about PGx testing and were supportive of its use as a 
medical tool to help individualize treatment decisions rather than worrying about the 
negative effects of medications.  Most participants, however, expressed concerns about 
the ability of PGx testing to determine future sensitive diseases (e.g., mental diseases) 
because of the potential for discrimination by insurance companies and employers.  The 
study also revealed some potential barriers to the successful implementation of PGx 
testing, including concerns regarding storage of PGx testing results, the privacy of 
genetic information, and the cost of the test.  
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Rogausch et al. (2006) reported that 35% of patients with asthma or COPD 
expressed concerns about adverse results of PGx testing if a therapeutic alternative was 
not available while the available drugs were ineffective or caused serious ADRs.  
Patients’ low expectations regarding PGx testing results were evidenced in that 69% and 
44% of patients believed that they would be at a disadvantage with employers and health 
insurance companies, respectively.  The majority of patients strongly felt that PGx testing 
would be advantageous to optimize their medication therapy in terms of avoiding taking 
wrong medications (75%), selecting a medication that best worked for them (63%), and 
avoiding ADRs (63%).  The possibility of unavailable therapeutic options recommended 
by the genetic testing worried 72% of patients.  Moreover, the study revealed that age and 
gender were major predictors of a hopeful attitude.  The strength was its use of a large 
sample size to assess patients’ and physicians’ opinions regarding the use of PGx testing 
in a common chronic disease; however, providing participants with a leaflet explaining 
PGx with examples might have created self-report response bias.  In addition, the 
findings might not have been generalized because the study focused on only two chronic 
disorders. 
The authors also reported that younger patients were more likely than older 
patients to be optimistic about the useful application of PGx testing, while female patients 
were more likely than male patients to have fears and anxieties.  Approximately one-half 
of physicians had favorable attitudes toward recommending PGx testing for their patients 
prior to the initiation of the therapy (e.g., anti-asthma medications) only if PGx testing 
was covered by health insurance.  Additionally, physicians were concerned that patients 
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would be discriminated by health insurance companies if undesirable genetic testing 
results were disclosed to them. 
A qualitative study was conducted in North-West England to explore the views of 
patients regarding autoimmune conditions and the views of healthcare professionals on 
PGx testing (Fargher et al., 2007).  The study revealed that patients eligible to obtain PGx 
testing related to their immunosuppressant agents had positive attitudes.  Patients also 
had high expectations of the benefits of PGx services providing healthcare practitioners 
were confident in interpreting and explaining the testing results.  The authors suggested 
that the gap between patients’ anticipated benefits of PGx testing and barriers to 
delivering PGx testing in clinical practice illustrates the need for awareness, educational, 
and training programs to facilitate the integration of PGx testing into clinical practice.  
Similar findings were reported by Moaddeb et al. (2015), who evaluated the experiences 
and feasibility of applying PGx testing in five community pharmacies.  They revealed 
that offering PGx testing services for patients taking clopidogrel and simvastatin was 
feasible; however, additional training and effective communication between patients and 
physicians were required for an enhanced clinical use of these genetic tests.  The Fargher 
et al. (2007) study’s strength was that it helped design future research that would shed 
light on the urgent need for PGx education and training programs, and how these factors 
may affect the dissemination of PGx testing, although there was a weakness concerning 
generalizability of the results. 
Patients should be given sufficient details to understand the pros and cons of PGx 
testing to assist in decision making.  For example, a single gene in the human genome 
may influence the therapeutic effects of many prescribed medications; as a result, PGx 
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tests could potentially help in choosing the most effective available therapies, with the 
correct dose, and reduce the risk of drug-drug interactions for numerous treatments.  The 
possibility of genetic discrimination, confidentiality of the testing results, the ability of 
providers to effectively translate and explain the testing results, feelings of being denied 
access to treatment, the cost of the tests, and the lack of evidence-based clinical 
information may impact the decision to adopt PGx testing (Fargher et al., 2007; Haddy et 
al., 2010; Rogausch et al., 2006). 
A study conducted on a sample of Dutch individuals found that the perceived 
compatibility and benefits of genetic testing played a role in patients’ decision-making 
for accepting these tests (Henneman et al., 2006).  The authors revealed that having more 
information on genetics or a higher level of education might not increase participants’ 
attitudes or their acceptance of genetic testing.  Supporting the findings by Morren et al. 
(2007) and Rogausch et al. (2006), they established that variables such as genetic 
knowledge, education, age, and gender were not significantly associated with positive 
attitudes regarding PGx testing.  This study was informative since it used a representative 
random sample of participants as well as valid and reliable instruments to accurately 
measure participants’ responses, but it lacked a theoretical framework to evaluate the 
relationships among variables linked to the acceptance of these tests; it also had a 
selection bias.  
Kobayashi and Satoh (2009) surveyed patients in Japan to assess their attitudes 
toward PGx and the role of genomic markers associated with ADRs.  The majority of 
patients (88%) had optimistic attitudes toward the role of PGx in medicine and 75% were 
willing to be tested to investigate the effects of genetic differences on drug response. 
37 
 
Regardless of age and gender, proportionately more patients were likely to have their 
DNAs tested in PGx research when expecting severe reactions to drugs than when taking 
medications.  The authors concluded that positive attitudes and greater perceived needs 
for PGx among patients increased their acceptance of PGx research investigating the role 
of genetic differences in medication response and medication safety, although concerns 
about protecting private health information, utilizing testing results in research, and 
finding an association between their genetic structure and the possibility of having ADRs 
were expressed by patients.  Patients expressed higher perceived benefits and positive 
attitudes (81%) toward PGx as a clinical tool than did the general public (70%); however, 
they were more reluctant to contribute to the field of PGx by donating their DNAs than 
were the general public (Kobayashi and Satoh, 2009).  The strength of this study was that 
the authors identified several variables influencing patients’ attitudes toward PGx testing, 
and thus helped future studies to explore the actual roles of patients’ medical conditions 
and severity of experienced side effects in decision-making. Its weakness was that PGx 
testing was not well defined in the study, and a potential of selection bias existed. 
Summary of Patients’ Knowledge and Attitudes toward Pharmacogenetic Testing 
A comprehensive review of the literature reveals a paucity of studies regarding 
patients’ knowledge and attitudes toward PGx testing. Lack of awareness and limited 
knowledge regarding PGx testing were prevalent among patients despite good attitudes.  
Although patients are generally supportive of PGx testing and optimistic about its 
potential therapeutic benefits, their concerns about confidentiality, employability, 
insurability, and cost are seen as potential barriers to accepting PGx testing.  Many 
studies have emphasized the need for awareness programs directed at the general patient 
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population to facilitate the clinical implementation of these genetic tests.  A summary of 
the advantages and disadvantages of PGx testing is presented in Table 2.1. 
Table 2.1 
Summary of Potential Advantages and Disadvantages of PGx Testing from the Patient 
Perspective Identified in the Literature Review 
Advantages Disadvantages 
- Reducing ADRs - Negative impact on patients’ insurability  
- Preventing ineffective or incorrect 
medication 
- Negative impact on patients’ employability 
- Breach of confidentiality 
- Predicting the most effective 
medication 
- Concerns about physicians’ over-reliance on 
testing results 
- Restoring patients’ confidence in 
the drug-prescribing process 
- Denial of certain treatment options 
- Increased anxiety about negative testing 
results (i.e., unavailability of a suitable drug) - Increasing patients’ awareness of 
their conditions - Disclosing information about the risk of pre-
existing conditions - Improving patients’ adherence to 
prescribed medications 
 
 
Prescribers’ Knowledge of Pharmacogenetic Testing 
According to research carried out by Powell et al. (2012) utilizing a sample 
of family and internal medicine physicians in North Carolina, 39% of participants were 
aware of genetic testing and only 15% felt competent to answer genetics-related 
questions.  More than half of the physicians who were aware of genetic testing did not 
perceive its clinical benefits.  The majority of those physicians expressed concerns 
regarding unavailability of clinical guidelines, the clinical utility of these tests, and 
complexity of testing result interpretation.  The likelihood of insurance and employment 
discrimination based on genetic testing results were less frequently reported.  Physicians 
50 years or older were more likely to be cognizant of genetic testing than younger 
physicians.  Male physicians were more likely to feel comfortable answering genetics-
related questions than female physicians.  This study provided preliminary findings for 
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more specific genetic testing such as PGx testing and was based on a relatively large 
sample size and appropriate instruments to capture variables of interest.  Its weakness 
was the use of a convenient sample that limited the generalizability of the findings. 
A large, nationally representative survey of U.S. physicians showed that the lack 
of adequate knowledge was probably the main factor influencing the implementation of 
PGx testing by healthcare providers (Stanek et al., 2012).  The study reported that most 
physicians across the U.S. had no formal coursework related to PGx during their 
educational years.  For instance, only 15% and 23% reported receiving information on 
PGx during their undergraduate or graduate training, respectively.  The authors also 
reported that only 10% of physicians believed that they had enough information and 
training to introduce PGx testing into clinical practice.  Few physicians recognized the 
benefits of PGx testing in improving drug effectiveness (9%), adherence (4%), and 
lowering ADRs (10%).  Almost 10% reported prior experience with ordering PGx testing 
for their patients.  Physicians who were aware of the availability of PGx testing and who 
believed that genetic difference can cause variability in drug response were more likely to 
be early adopters of PGx testing.  Furthermore, the authors revealed that early adopters 
were more likely to be oncologists or surgeons and had intermediate to long years of 
medical practice (i.e., 15-29 years).  Male physicians 40 years or older and working in 
urban areas were more likely to be future adopters.  The majority of physicians (67%) 
refused to order the test and indicated that they did not have enough information about 
PGx.  These findings highlight a need to increase physicians’ knowledge and attitudes to 
appropriately integrate PGx testing into daily clinical practice and communicate testing 
results to their patients in order to help them with decision making.  The study was large 
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and representative, and indicated reliable results, but it lacked a theoretical framework. 
Unfortunately, it did not provide additional clarifications on the relationship between 
attitudes and adoption of PGx testing.  
Rogausch et al. (2006) showed that physicians’ lack of knowledge and familiarity, 
in addition to the fearful attitudes toward PGx testing, may impact their decision to 
implement this technology in the future.  Inadequate information about the clinical utility 
of these tests and the lack of clear clinical guidelines were described as new challenges to 
the physicians’ decision-making process to accept PGx testing.  In other words, 
physicians were portrayed as willing to consider PGx testing as an area of research rather 
than its clinical application.  
According to research carried out by Haga et al. (2012a), physicians’ levels of 
knowledge and experience with PGx testing decreased their preparedness to use genetic 
testing for their patients.  The study reported that only 16% of participants received 
training about PGx in medical school or post-graduate training, and almost 76% were 
unaware of PGx information in drug package inserts.  Different results were reported by 
Stanek et al. (2012): a small percentage of physicians (29%) received training about PGx 
in medical school or post-graduate training, and 39% indicated learning about PGx from 
drug package inserts.  Haga et al. (2012a) also reported that only 13% of physicians felt 
comfortable ordering PGx testing.  Physicians had other concerns related to 
communicating confounded testing results, reimbursement issues, and the lack of practice 
guidelines and recommendations regarding PGx testing.  This study was enlightening 
because its major findings have been reported by other studies and it supported the need 
for incorporating PGx into educational curricula and training programs, but it had a 
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selection bias and an incomplete and inadequate description of the statistical analyses 
performed.  
Shields et al. (2005) conducted a national survey to assess the adoption of genetic-
based smoking cessation treatment among 1,120 U.S. primary physicians.  The study 
aimed to predict physicians’ attitudes and decision-making about the future use of PGx 
testing that may become available in individualized treatment cessation therapy.  Most 
participants were in practice with fewer than five other physicians and in urban areas.  
Over 75% of respondents received some formal training in clinical genetics from 
different sources such as medical school (57%), continuing medical education (CME) 
courses (47%), clinical genetics rotation in medical school (16%), and genetics rotation in 
residency (4%).  Approximately 15% reported that they were early adopters and another 
14% were very optimistic about the benefits of PGx testing on the treatment outcomes of 
nicotine replacement therapy.  Although only 4% reported being well prepared for these 
types of tests, almost 69% of participants were willing to adopt PGx testing for smoking 
cessation treatment.  The study’s strength was that it relied on a large sample randomly 
selected from all U.S. primary care providers (PCPs).  The study method, however, was 
based on a patient scenario rather than on investigating an existing PGx testing, which 
might have underestimated or overestimated the factors influencing the uptake of genetic 
testing into practice.  The underrepresentation of some medical specialties also might 
have limited the generalizability of the findings. 
In a landmark work conducted by Taber and Dickinson (2014) on physicians from 
different specialties, only 13% of participants reported being extremely or very familiar 
with PGx.  Similar results were also reported by others (Haga et al., 2012a; Stanek et al., 
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2012).  Only 11% reported receiving formal training in PGx.  Nearly 32% of 
cardiologists and 12% of psychiatrists had ordered a PGx test.  Barriers to ordering PGx 
testing identified by participants included not knowing what test to order (70%), lack of 
insurance coverage for the PGx tests (53%), uncertainty about the clinical utility of the 
test (52%), and cases in which PGx testing was not applicable (18%).  The study had a 
strong description of methods and provided an updated finding on knowledge deficit, 
which was a major gap in previous studies, but it had a small sample and a possible 
selection bias. 
Genetic differences account for 35-50% of inter-individual variability in warfarin 
anticoagulant responses (Wen and Lee, 2013).  Anticoagulation providers deal with a 
wide range of warfarin dosing requirements that dictate finding an adequate patient-
specific and regular monitoring to avoid serious side effects.  Kadafour et al. (2009) 
assessed the clinical use of PGx testing among anticoagulation providers in North 
America by comparing their knowledge and attitudes.  Most participants (80%) indicated 
that warfarin PGx testing was not available at their sites.  Only about 12% reported using 
these tests.  The study also found that anticoagulation providers’ knowledge was not 
significantly correlated with their attitudes.  Participants who had warfarin PGx testing 
available in their practice sites had a significantly higher knowledge score than those who 
did not.  Similarly, participants who previously used warfarin PGx testing had a 
significantly higher knowledge score than those who had not.  
The authors reported several potential barriers to the acceptance of warfarin PGx 
testing, including the lack of clear evidence of clinical utility, unavailability of the test, 
and lack of PGx knowledge among physicians and patients.  Similarly, Shishko et al. 
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(2015) reported that inadequate educational and training programs for healthcare 
professionals and insufficient education of patients are barriers to the uptake of PGx into 
clinical practice.  The Kadafour et al. (2009) work was one of the largest studies that 
contributed to the literature by addressing the challenges for integrating PGx testing in 
warfarin therapy.  Its weakness was the improper representation of anticoagulation 
healthcare providers in North America.  
Dressler et al. (2014) studied factors that influence the adoption of PGx testing in 
cancer treatment.  They conducted a survey of 94 North Carolina oncologists and 
indicated that most of them believed in the beneficial outcomes of using PGx testing; 
however, only 33% of them were comfortable with their knowledge about PGx testing 
and 37% felt confident in interpreting testing results.  Oncologists in a community setting 
were more likely than oncologists in an academic setting to be early adopters of new PGx 
testing (Oncotype Dx™) that potentially determine the benefit of using chemotherapy, as 
well as more likely to be future adopters of cancer PGx testing.  The authors reported that 
oncologists with more than ten years of medical experience were more likely to be early 
adopters of PGx testing than the rest, although those with fewer years of experience were 
more comfortable about their PGx testing knowledge.  The authors identified the main 
factors that enhance acceptance of cancer PGx testing among oncologists, including 
availability of well-conducted prospective clinical trials, evidence-based studies, and 
professional guidelines.  This study provided additional clarification about the need for 
optimal communication channels and educational programs to appropriately disseminate 
PGx information and influence the acceptance of PGx testing in the clinical practice.  Its 
major limitation was a relatively small sample size. 
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Knowledge should not necessarily be limited to PGx testing only. Knowledge 
about basic genetic variation underlying some health conditions is also imperative to 
optimize the benefits of PGx testing and meet the current standard of care.  For example, 
genetic variants of the β-fibrinogen gene may increase the progression of coronary heart 
disease; more importantly, knowledge about these genetic variations has been useful in 
predicting patients’ responses to statin therapy and improving the overall health outcome 
(Dornbrook-Lavender and Pieper, 2003). 
Genetic testing in the screening and potentially directing the clinical management 
of patients with mutations in the breast cancer genes 1 and 2 (BRCA1 and BRCA2) has 
proven to be one of the most successful tests available (Miki et al., 1994; Smith and 
Isaacs, 2011).  Armstrong et al. (2003) studied how the adoption of BRCA1/2 genetic 
testing initially started and what factors contributed to its subsequent acceptance among 
women who underwent genetic counseling.  The study results reported that only 7% of 
study participants were recommended by physicians to undergo BRCA1/2 screening.  
Most participants excluded physicians as a source of information about BRCA1/2 testing, 
which showed the lack of physicians’ awareness about BRCA1/2 screening tests.  The 
study concluded that participants’ innovativeness and perceptions about compatibility 
(i.e., whether the test fits well with patients’ personal values), not complexity, and 
advantage of the test influenced the adoption of BRCA1/2 genetic testing.  Although 
BRCA1/2 mutations are relatively rare, having a family medical history is a strong 
predictor of the need for BRCA1/2 screening; other factors that might have influenced 
acceptance of genetic testing could have been previously overlooked. 
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This study was influential because it utilized a relatively large sample size and 
was guided by Rogers’s diffusion of innovation theory to explain the factors that 
influence the early acceptance of genetic testing.  In addition, the study demonstrated the 
significance of communication channels in participants’ awareness about an innovation.  
Its major limitation was unavailability of a control group (i.e., women who had not 
undergone genetic counseling), which was required to determine whether the diffusion of 
innovation theory adequately explained the acceptance of genetic testing.  In addition, 
there was a high risk of selection bias.  
Klitzman et al. (2013) surveyed 220 internal medicine physicians to assess their 
use of genetic testing, including PGx testing.  The majority of participants rated their 
knowledge of genetics as very or somewhat poor (74%).  Most participants indicated a 
need for more training relevant to ordering genetic testing (79%), patient genetic 
counseling (82%), interpretation of genetic results (77%), and maintaining patient genetic 
privacy (81%).  The most frequent genetic tests ordered by internists were for Factor V 
Leiden thrombophilia (15%), breast and ovarian cancers (17%), and cardiomyopathy 
(8%).  Only 6% used PGx testing to prevent drug toxicity.  The authors also reported the 
factors that significantly influenced the use of genetic testing: patients’ request to use the 
tests (62%), working in large practices with more than 1,000 patients (67%), availability 
of a genetic counselor for patient referral (62%), and having fewer numbers of African-
American patients in their practice (56%).  Most physicians who adopted genetic testing 
were White, male, 50-59 years old, and had more White patients in their practice.  
This study was important because it included a wide range of genetic tests to 
assess physicians’ acceptance.  The study also revealed that African-Americans might 
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have been deprived of the potential benefits of genetic testing.  The major limitation was 
its use of a non-representative sample.  The study also failed to conduct subgroup 
analysis in order to show the impact of rurality and area of practice on the adoption of 
genetic testing.  
Kudzi et al. (2015) conducted a semi-structured survey study in seven health 
institutions and four academic institutions in Ghana in which the knowledge of PGx 
among healthcare professionals and faculty members was evaluated.  The authors showed 
that the majority of participating physicians were aware of PGx testing as a new clinical 
tool and heard about it from several resources (i.e., colleagues, schools, the Internet).  
While most healthcare professionals rated their perceived knowledge of PGx as good or 
very good, most faculty members rated their perceived knowledge as poor or very poor.  
The study also showed that most healthcare professionals with prior awareness about 
PGx testing were 25-29 years old with five years or less of practice.  Most healthcare 
professionals agreed on the potential benefits of PGx testing in ensuring drug safety and 
improving efficacy, but they were uncertain about its role in cost saving and drug 
discovery.  
The strength of this work was that it interviewed healthcare professionals and 
faculty members to better assess the need for continuous and updated PGx educational 
programs in medical school curricula.  Its main limitation was its reliance on a small and 
selective sample of participants.  A selection bias also might have occurred. 
Prescribers’ Attitudes toward Pharmacogenetic Testing 
Rogausch et al. (2006) showed that while patients were excited to undergo PGx 
testing because of the possibility of being given a suitable anti-asthma drug with fewer 
47 
 
ADRs, both physicians and patients were concerned about the confidentiality of genetic 
information.  Physicians also were concerned about the cost of these PGx tests and feared 
that results would be reported to patients’ insurance companies and workplaces, raising 
the possibility of discrimination.  In addition, physicians working in rural areas had more 
fearful attitudes toward PGx testing than physicians working in urban areas.  The authors 
reported that age, gender, and size of practice were not significantly associated with 
physicians’ views regarding PGx testing.  In line with other reports of healthcare 
providers’ attitudes toward PGx testing (Fargher et al., 2007; Haga et al., 2012c; 
Klitzman et al., 2013; Lanktree et al., 2014; Shields et al., 2005; Stanek et al., 2013; 
Walden et al., 2015), the authors expressed fears toward the potential disadvantages of 
PGx testing in disclosing pre-existing conditions, exposing patients to potential 
discrimination at insurance or workplace, and privacy of genetic health information.  
Fargher et al. (2007) conducted a focus group study of healthcare professionals to 
assess their knowledge, attitudes, and experiences of PGx testing.  Most participants 
agreed on the perceived benefits of PGx testing to guide treatment decisions, although 
they were worried about the possibility of excluding a patient from a specific treatment 
option based on testing results.  Participants also believed that they had a limited role in 
utilizing PGx testing.  Supporting the finding of other studies (Haga et al., 2012c; 
Rogausch et al., 2006), the authors noted that physicians were concerned about the 
potential of identifying a genetic biomarker that might be used as an indicator of 
susceptibility to a particular disease.  They explored healthcare professionals’ views and 
opinions about PGx testing at an early stage to help future studies focus on the 
application of PGx testing in clinical practice.  The major limitations of this study were 
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underrepresentation of some medical specialties in the sample, limited generalizability of 
the findings, and failure to explore the reasons why participants did not feel that they had 
a role in utilizing PGx testing. 
Haga et al. (2012c) found that many physicians and genetic experts had more 
favorable attitudes toward currently prescribing practices than PGx testing.  Respondents 
felt that traditional clinical methods were the most effective technique to determine 
optimal warfarin dosage.  Some physicians raised concerns about the cost of PGx testing 
and insurance coverage.  Yet these physicians showed interest in PGx because of the 
possibility of avoiding severe adverse effects, especially when drugs with a narrow 
therapeutic index such as warfarin were recommended.  Other physicians were concerned 
about the lack of adequate evidence regarding the clinical utility of PGx testing.  Similar 
to other studies (Fargher et al., 2007; Kadafour et al., 2009; Lanktree et al., 2014; 
Rogausch et al., 2006; Walden et al., 2015), the researchers indicated that the paucity of 
test interpretation skills, lack of insurance coverage of PGx testing, delay of treatment, 
and unclear guidelines for the use and regulation of PGx testing might have a negative 
impact on its effective clinical implementation.  The strength of the study was that it 
involved three focus groups to gain more detailed information (i.e., ancillary disease risk 
information) about health professionals’ interest regarding the use of PGx testing.  Its 
limitation was that its small and convenient sample might not have been representative of 
the target population. 
The Kadafour et al. (2009) survey study of anticoagulation providers reported that 
half of the participants agreed or strongly agreed that they were adequately informed 
about warfarin PGx; about half of them responded that they were comfortable 
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interpreting warfarin PGx testing results.  Nearly 26% of the participants agreed or 
strongly agreed about potential clinical benefits of warfarin PGx testing in reducing 
ADRs, and 32% expressed this view regarding achieving a therapeutic outcome quickly.  
Overall, the lack of confidence regarding interpretation of genetic results was associated 
with the lack of PGx knowledge.  A small fraction indicated willingness to recommend 
warfarin PGx testing to their colleagues.  The strengths of the study were the use of a 
large sample size and a real case scenario to better capture the factors influencing the 
uptake of currently existing warfarin PGx testing into practice; the use of tailored 
scenarios helped resolve conflicts among previous studies findings.  However, the study 
might not have accurately reflected the actual knowledge and attitudes of the target 
population of anticoagulation providers.  
The results of a national survey conducted on 597 internists and family medicine 
practitioners showed that over 70% were aware of the availability of PGx testing prior to 
taking the survey, but most felt that they were insufficiently trained to order or use these 
genetic tests (Haga et al., 2012a).  Respondents felt that CME, grand rounds, and training 
in residency were the best sources to learn about PGx testing.  In contrast to the findings 
of the Fargher et al. (2007) study, these researchers reported that the majority of 
participants felt responsible for increasing patients’ awareness of PGx testing, discussing 
testing results with their patients, and integrating the testing results in their patients’ 
medical records.  Only 10% agreed on pharmacists’ roles in determining the optimal 
therapeutic regimen based on PGx testing results.  The study was significant because it 
used a large randomized sample to provide additional clarification about more efficient 
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communication channels and addressed barriers to early adoption of PGx testing, but it 
was susceptible to a form of selection bias. 
A survey conducted on 10,303 physicians in the U.S. reported that virtually all 
respondents believed that genetic testing could influence individual drug response 
(Stanek et al., 2013).  About 42% relied on FDA-approved PGx information in package 
inserts to predict or improve response to medications, and 10% felt that adequate 
knowledge about PGx and its application was acquired.  Out of 1,319 physicians who had 
ordered PGx testing for their patients, 73% believed that PGx testing improved drug 
effectiveness, 80% believed that it reduced toxicity, 61% said that it improved patient 
understanding of their health conditions, and 31% agreed that it improved patient 
adherence to medications.  
This study also reported that physicians who relied on drug package inserts to 
learn more about PGx had significantly greater prior education and adequate PGx 
information than those who did not rely on drug package inserts as a direct source of 
information.  The results also showed that 39% of physicians obtained information on 
PGx testing from drug package inserts and 42% relied on FDA-approved 
recommendations.  As a result, adoption of PGx testing in clinical practice was higher 
among physicians who obtained PGx information from drug package inserts and those 
with prior testing experience.  The study also showed that adoption of PGx testing in 
clinical practice was higher among physicians who perceived the potential benefit of PGx 
testing to their patients.  Other factors associated with obtaining PGx information from 
drug package inserts included older age, greater years of postgraduate experience, using 
the Internet or other colleagues as genetic information sources, and greater stability in 
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their practice careers.  The study was able to explore additional factors associated with 
the dissemination of PGx testing; it provided new findings of the use of FDA-approved 
PGx information in drug package inserts.  The risk of selection bias and inclusion of 
underrepresented groups of physicians limited generalizability of its results.  
Walden et al. (2015) conducted a survey study to assess the opinions of Canadian 
physicians regarding the use of PGx testing to guide the selection and dosing of 
antidepressant and antipsychotic medications.  The study found that 80% of respondents 
expressed optimistic attitudes toward the future of PGx testing as the standard of practice 
for antipsychotic treatment and 76% reported satisfaction for being able to understand 
and interpret the PGx report provided.  There were no gender differences in attitudes 
toward the clinical application of PGx testing; a similar finding was reported by Klitzman 
et al. (2013).  Supporting the findings of Haga et al. (2012c) and Kadafour et al. (2009), 
these researchers reported that the cost of PGx testing and the time needed to receive the 
results were obstacles to accepting the procedure.  The study contributed to the literature 
by proving up-to-date information about physicians’ attitudes toward the use of PGx 
testing after receiving a PGx report for real clinical situations; the small sample size and 
the possibility of selection bias might have limited statistical inference. 
Summary of Prescribers’ Knowledge and Attitudes toward Pharmacogenetic 
Testing 
Only a few studies focus on physicians’ knowledge and attitudes toward PGx 
testing.  Physicians did not feel well informed about the procedure.  Most physicians had 
favorable attitudes toward PGx testing and its perceived benefits in different therapeutic 
areas, but expressed concerns about their inadequate knowledge, ability to interpret 
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genetic testing results, lack of clear clinical guidelines, and patients’ confidentiality.  The 
need for educational initiatives focused on training physicians to increase their 
knowledge base and competency in interpreting and communicating PGx testing results 
to patients.  A summary of the advantages and disadvantages of PGx testing is presented 
in Table 2.2. 
Table 2.2 
Summary of Potential Advantages and Disadvantages of PGx Testing from the Prescriber 
Perspective Identified in the Literature Review 
 Advantage  Disadvantage 
- Determining the appropriate dose or 
drug selection 
- Negative impact on patient health 
insurance eligibility 
- Explaining individual variation in drug 
response  
- Negative impact on employment 
requirements  
- Predicting the most effective 
medication 
- Risk of treatment delay 
- Breaches of confidentiality  
- Reducing serious ADRs - Risk of unintentional disclosure of 
information about disease susceptibility - Improving patient adherence to 
prescribed medications - Lack of insurance coverage 
- Reducing the overall cost of treatment - Lack of clinical guidelines 
 - Uncertainty about clinical utility 
 
 
The research methods applied in this dissertation are discussed in Chapter 3.  
Development of the questionnaire, inclusion criteria, the recruitment process, and data 
collection are described.  A summary of concrete analytical procedures used to address 
the research questions also is presented.
53 
 
Chapter 3 
Methodology 
 
The methodology used in this study is presented in this chapter to assess and 
evaluate the effect of knowledge and attitudes on acceptance of PGx testing using a 
convenient sample of patients and physicians.  The setting in which the study took place 
and the participant pool are described.  Also described are the instruments developed and 
used to collect the data.  Justification of the sample size, the data analysis plan, and 
ethical considerations are discussed. 
Research Design  
A cross-sectional, descriptive survey design was implemented to assess the 
knowledge and attitudes of patients and physicians toward PGx testing.  Cross-sectional 
studies are often used to gain information and answer specific research questions based 
on data collected from a subset of a population at only one point in time (Birch and 
Malim, 1988).  The data collection instrument was a questionnaire containing variables of 
interest.  According to Rogers’s diffusion of innovation theory, several independent 
factors, such as sociodemographic variables (e.g., gender, age, level of education, area of 
living, current practice setting), prior experience with PGx testing, and perceived need for 
innovation and innovativeness can influence an individual’s knowledge of PGx testing.  
Other variables, including relative advantage, compatibility, complexity, trialability, and 
observability, also work as independent variables that may affect an individual’s attitude 
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toward PGx testing.  Knowledge and attitudes toward PGx testing are independent 
variables that can influence the acceptance of PGx testing. 
A large, representative sample was planned for the study.  The probabilities of 
type I and type II errors were set in advance to determine an adequate sample size.  A 
type I error (α) occurs when a researcher rejects a true null hypothesis; failing to reject a 
false null hypothesis is called a type II error (β).  Based on the value of β, a power 
analysis was conducted; power equals to 1 – β. 
G*Power 3.1 was utilized to calculate the appropriate sample size required to 
achieve a sufficient power (Faul et al., 2009).  Cohen’s f2 was utilized for calculating the 
effect size within a multiple regression model in which the independent and the 
dependent variables are continuous (Cohen, 1977).  Cohen’s f2 value, calculated by 
R2 / (1-R2), is an adjusted coefficient of determination indicator of how well a regression 
equation fits the data values.  A medium effect size value of f2 = 0.15 in the analysis of 
variance context was selected.  Using significance level α = 0.05, the minimum sample 
size was determined to consist of 120 observations with up to ten predictors and an actual 
power of 0.80.  Due to the lack of studies that consider the effect size required for this 
type of research, the necessary sample size required to detect a significant effect with 
enough statistical power using a 5% to 7% margin of error and a significance level of 
0.05 was estimated to range between 126 and 180 participants.  
Population and Recruitment of Patients 
Patient recruitment took place at the Nova Southeastern University (NSU) Clinic 
Pharmacy located in Fort Lauderdale, Florida.  Potential participants filling a prescription 
for a chronic disease were personally invited by the author of this dissertation to be part 
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of the study.  A flyer with a brief description of the study was given to patients who 
showed interest in participating.  The eligibility criteria were that potential participants 
had to fill their prescription for at least one chronic disease, were aged 18 years or older, 
spoke English fluently, and were willing and able to provide informed consent (see 
Figure 3.1).  If a patient self-reported at least one chronic disease, more about the 
research project and possible benefits and risks were explained.  If the patient was still 
interested, he/she was given the opportunity to participate in the study and asked to read 
and sign the consent form.  All eligible participants were assured that their decision to 
participate (or not) would not affect their relationship with the NSU Clinic Pharmacy or 
other healthcare providers.  If the potential participant signed the consent form, the 
survey was then administered. 
 
 
Figure 3.1: Illustration of inclusion criteria for patient recruitment. 
 
Population and Recruitment of Prescribers 
NSU physicians, as well as community physicians involved in medication therapy 
decisions, were asked to participate in an online survey.  A letter was emailed with the 
survey to eligible physicians.  Eligible community physicians were also recruited in 
person from three medical conferences held in Florida.  If a potential participant was 
interested, he/she was offered the opportunity to participate in the study using a tablet 
computer to sign the online participating letter and subsequently fill out the 
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questionnaire.  Prescribers’ inclusion criteria included being a physician licensed to 
practice in Florida and currently involved in medication therapy decisions, willing to sign 
the participation letter, and willing to complete the survey online (see Figure 3.2).  
Respondents who successfully completed the survey were offered an incentive ($5 or $10 
gift card) as a token of appreciation.  The first 60 respondents were given $10-gift cards 
and $5-gift cards were assigned to the next 90 expected respondents. 
 
Figure 3.2: Illustration of inclusion criteria for prescriber recruitment. 
 
Development of Patient Survey 
The questionnaire survey used in this study was configured following the format 
of similar studies (Calsbeek et al., 2007; Dodson, 2012; Nielsen and Moldrup, 2007; 
Lachance et al., 2015; Roederer et al., 2012; Rogausch et al., 2006; Zhang et al., 2014).  
Several concepts adapted from Rogers’s diffusion of innovation theory were 
incorporated.  The patient questionnaire had 46 questions.  A copy of the patient 
questionnaire is presented in Appendix A. 
Once the questionnaire was configured, it was tested with nine persons to 
examine the validity of the items.  The results showed an average completion time of nine 
minutes.  Subsequently the format of several questions was changed to make them more 
understandable.  A brief description of PGx testing was provided in the final version.  
The final patient questionnaire began with seven items assessing participants’ knowledge 
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about PGx testing.  This section was followed by 18 items assessing participants’ 
preferences about the use of PGx testing.  Questions about patients’ prior experience with 
genetic testing and their willingness to accept the testing were asked.  The survey 
concluded with sociodemographic items.  Patient survey questions and corresponding 
citations are listed in Appendix B.  The attitude items showed an internal consistency or 
reliability (Cronbach's alpha) score of 0.72, while the knowledge items showed a 
Cronbach's alpha score of 0.65. 
Development of Prescriber Survey  
The questions posed to prescribers also were configured following the instruments 
of previous studies (Dodson, 2012; Roederer et al., 2012; Rogausch et al., 2006; Shaw et 
al., 2011; Taber and Dickinson, 2014).  Several concepts adapted from Rogers’s diffusion 
of innovation theory were incorporated as well.  The prescriber questionnaire had 42 
questions.  A copy of the prescriber questionnaire is presented in Appendix C. 
Six healthcare professionals agreed to participate in testing the survey.  For face 
and content validity purposes, they were asked to explain their reactions to the wording, 
order, and clarity of the questions.  An average completion time of 6.5 minutes was 
reported.  Changes to the questionnaire were made based on the feedback provided; these 
reduced average time of completion to four minutes.  The final prescriber questionnaire 
began with six items assessing participants’ knowledge about PGx testing.  This section 
was followed by 16 items designed to assess participants’ preferences about the use of 
PGx testing.  Questions about prescribers’ prior experience with genetic testing and their 
willingness to accept the testing were asked.  The survey concluded with 
sociodemographic items.  Prescriber survey questions and corresponding citations are 
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listed in Appendix B.  The attitude and knowledge items showed Cronbach’s alpha scores 
of 0.78 and 0.60, respectively. 
Collection of Patient Data 
The original plan for patient data collection was to offer the option of either a 
paper-based or web-based survey.  None of the potential participants showed any interest 
in using a tablet computer to answer the web-based questionnaire.  Thus, after participant 
number 60 was recruited, the option of answering online was no longer offered.  Each 
participant received the questionnaire on a clipboard.  The materials included an adult 
consent form with a general overview of the study and the two-page, 46-item 
questionnaire.  To protect participants’ confidentiality, separate folders were used to 
collect the consent forms and the questionnaires.  After collecting all the survey 
materials, the data were organized with Research Electronic Data Capture (REDCap) 
software, leaving only numbers and variable names to be utilized in the analysis.  This 
software was created by a group of clinical researchers in 2004 at Vanderbilt University 
as a user-friendly data collection tool. REDcap opens a secure survey page and allows 
researchers to have their participant data auto-populated in the server; it also allows 
manual data entry.  The data collected in this study were entered electronically.  Prior to 
data analysis, a data reconciliation process was conducted to verify the accuracy of the 
entered data.  Data analyses were performed using IBM® Statistical Package for the 
Social Sciences (SPSS), version 24.0 and Stata version 14.  
Collection of Prescriber Data 
All prescriber questionnaires were administered and answered online.  The 
questions were programmed into the Snap Survey software (Snap Surveys Ltd.).  NSU 
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physicians and community physicians were invited to complete an online survey about 
PGx testing from July through October 2016.  The survey was terminated after receiving 
150 responses.  The prescriber survey was anonymous; respondents’ identifiable 
information was removed from the responses before downloading them.  
Measurement of Variables  
Patient Variables 
Patients’ knowledge of PGx testing was measured as the number of PGx testing 
questions answered correctly.  Within Rogers’s diffusion of innovation theory, 
knowledge as a dependent variable is influenced by several antecedents, which in this 
study were treated as independent variables.  These included prior experience, perceived 
need for innovation, innovativeness, area of living, sociodemographic variables (e.g., age, 
level of education), and communication channels.  Attitude toward an innovation was 
measured by the number of favorable responses toward PGx testing.  According to 
Rogers’s diffusion of innovation theory, attitude as a dependent variable was influenced 
by several independent variables including relative advantage, compatibility, complexity, 
trialability, and observability of PGx testing (see Table 3.1). 
Prescriber Variables 
  Physicians’ knowledge of PGx testing was measured as the number of PGx 
testing questions answered correctly.  Within Rogers’s innovation of diffusion theory, 
knowledge as a dependent variable is influenced by independent variables such as prior 
experience, perceived need for innovation, innovativeness, area of current setting, 
sociodemographic variables (e.g., age, ethnicity), and communication channels.  Attitude 
toward PGx testing was measured by the number of favorable responses toward PGx  
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Table 3.1 
Measurement of Concepts Utilized in the Patient Survey 
Construct/Variable Measurement Question(s) 
Knowledge of PGx 
testing 
Number of correct answers related to the 
influence of genetic differences on individual’s 
responsiveness to different medications 
1-7 
Attitudes toward 
PGx testing 
Number of positive responses toward the use of 
PGx testing 
11-17, 20, 
23, 24 
Prior experience Whether the adopter is awareness of the 
innovation before adoption 
8, 9 
Innovativeness Whether the patient is reluctant to adopt PGx 
testing until he/she sees it providing useful 
results for other patients 
25 
Perceived need Whether an individual feels that there is a useful 
need for the innovation 
18, 19 
Sociodemographic 
variables 
Gender, age, ethnicity, and level of education 31-35 
Communication 
behavior 
Most effective channels of generating knowledge 
about the innovation 
30 
Relative Advantage Whether the adopter sees a higher value in the 
innovation than what it replaces 
21, 22 
Compatibility Whether the innovation is consistent with the 
existing values and norms 
26 
Complexity Whether the innovation is difficult to understand 
or use 
27 
Trialability Whether the innovation can be tested to reduce 
the uncertainty 
28 
Observability Whether the results and effects of an innovation 
are visible 
29 
Willingness to take 
PGx testing 
Whether patients would like to take PGx testing 
for one of their chronic disease medications 
10 
 
testing.  According to Rogers’s diffusion of innovation theory, attitude as a dependent 
variable was influenced by several independent variables including relative advantage, 
compatibility, complexity, trialability, and observability of PGx testing (see Table 3.2). 
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Table 3.2 
Measurement of Concepts Utilized in the Prescriber Survey 
Construct/Variable Measurement Question(s) 
Duration of 
practice  
Duration of overall medical practice  1 
Knowledge of PGx 
testing 
 
Number of correct answers related to the influence 
of genetic differences on individual’s 
responsiveness to different medications 
2-7 
 
Attitudes toward 
PGx testing 
Number of positive responses toward the use of 
PGx testing 
8-12, 15, 
 17, 19 
Prior experience Whether the physician has ever ordered PGx 
testing for a patient 
25 
Innovativeness Whether the physician is reluctant to adopt PGx 
testing until he/she sees it working for patients 
14 
Perceived need Physician’s acknowledgement that there is a useful 
need for the PGx testing in several instances such 
as a high risk of genetic variant 
21a, 12b 
Area of current 
setting 
Rural, Suburban, or Urban 32 
Sociodemographic 
variables 
Gender, age, ethnicity, and medical specialty 28-31 
Communication 
behavior 
Most effective channels of generating knowledge 
about PGx 
22 
Relative advantage Whether the physician believes that PGx testing is 
beneficial for his/her patients in the selection of a 
medication that would better control their health 
condition in several situations 
20a, 20b 
Compatibility Whether the physician believes that PGx testing is 
compatible with his/her personal values 
13 
Complexity Whether the physician believes that the application 
of PGx testing adds more complexity to the drug 
prescribing process 
18 
Trialability Whether the physician believes that PGx testing is 
worth trying  
16 
Observability Whether the physician has ever talked with a 
patient about PGx testing 
23 
The willingness to 
recommend PGx 
Whether the physician is willing to recommend 
PGx testing to his/her patients 
24 
Factors affecting 
PGx adoption 
Factors that influence physician’s acceptance of 
PGx testing 
26 
Pharmacist role in 
PGx testing 
Whether the physician prefers a pharmacist to 
order and interpret PGx testing  
27 
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Data Analysis 
Descriptive Statistics 
  Univariate analysis was conducted to describe and summarize nominal, ordinal, 
and continuous data.  Measures of central tendency, variation, and normality were used 
for continuous variables, while counts and percentages were used for categorical 
variables.  Seven testing patient knowledge questions and six testing prescriber 
knowledge questions utilized yes/no/not sure responses.  The correct answer for all 
knowledge subscale responses was recoded as one, while the incorrect or “not sure” 
answers were recoded as zero.  Ten testing patient attitude questions and eight testing 
prescriber attitude questions were in the form of a 5-point Likert scale, with 5 being the 
most favorable answer.  Additionally, questions 13-16, 20, and 25-27 (patient data) and 
13, 14, and 17-19 (prescriber data) were reverse coded so that larger values for all the 
questions had the same direction, indicating a more positive attitude.  All Likert scale 
item responses to the attitude statements “Strongly Disagree” or “Disagree” were recoded 
as zero.  The “Neutral” response was recoded as one.  All the “Agree” or “Strongly 
Agree” responses were recoded as two.  Since there were very few responses on some of 
the choices provided for some categorical variables, including age, education, ethnicity, 
and area of living, some levels were merged based on the results appearing in the 
frequency tables.  Similarly, due to a lack of responses in some of the provided choices, 
the options in the variable “communication channels” were also collapsed.   
The PGx testing knowledge subscale, the PGx testing attitude subscale, and the 
perceived characteristics of innovation subscale were created using the Rasch model.  
The Rasch model is a one-parameter logistic model that applies the principles of item 
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response theory (IRT).  This logistic model relates the difficulty of an item to the ability 
of a respondent to answer that item in order to obtain an interval-level score (An and 
Yung, 2014).  Estimates of item difficulty and respondents’ ability are independent of 
each other, making the scale score relatively distribution-free.  After assessing the 
subscales using the Rasch model, some weak items were removed to better measure the 
constructs of interest and ensure validity.  The total summative scores for the PGx testing 
knowledge, attitude, and perceived characteristics of innovation questions were 
calculated for each respondent.  Finally, the reliability of the study constructs (subscales) 
was calculated using Cronbach’s Alpha to examine the internal consistency of each 
subscale.  The extent to which each subscale data deviated from normality was also 
measured (see Tables 3.3 and 3.4). 
Table 3.3 
Cronbach’s Alpha and Shapiro-Wilk (SWilk) Scores for Each Patient 
Subscale No. of Items 
Cronbach’s 
Alpha 
SWilk Test 
(Signif.) 
Knowledge* 7 0.65 0.072 
Attitude 10 0.71 0.600 
Perceived characteristics of innovation** 6 0.69 0.340 
Note. Significance value of the Shapiro-Wilk Test is greater than 0.05; the data are 
normally distributed. *log10 transformation; ** Square transformation 
 
Table 3.4 
Cronbach’s Alpha and Shapiro-Wilk (SWilk) Scores for Each Prescriber Subscale 
Subscale No. of items 
Cronbach’s 
Alpha 
SWilk-Test 
(Signif.) 
Knowledge 6 0.60 0.700 
Attitude* 8 0.78   0.074 
Perceived characteristics of innovation 6 0.60 0.066 
*log10 transformation 
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The gender variable for both patient and physician data was recoded into two 
categories: male or female.  The age variable was recoded into five categories (18-29 
years, 30-39 years, 40-49 years, 50-59 years, and 60 years or older) for patient data and 
four categories (25-39 years, 40-49 years, 50-59 years, and 60 years or older) for 
physician data.  The ethnicity variable was recoded into four categories: 
White/Caucasian, Hispanic/Latino, Black or African American, and other.  The area of 
living variable and the type of practice setting variable were recoded into three 
categories: urban, suburban, and rural.  The prior experience variable was recoded into 
two categories: yes or no. 
In the patient data set, the level of education variable was recoded into five 
categories: high school or GED, associate degree, baccalaureate degree, master's degree, 
and doctorate or professional degree.  The communication channel variable for patients 
was recoded into four categories: one source, two sources, three sources, and four or 
more sources.  The physicians’ medical specialty variable was recoded into three 
categories: internal medicine, family medicine, and others.  The communication channel 
variable for prescribers was recoded into four categories: zero source, one source, two 
sources, and three or more sources.  The duration of practice variable was recoded into 
three categories: 1-10 years, 11-20 years, and 21 years or more.  
Inferential Statistics 
Statistical packages IBM® SPSS version 24.0 and Stata version 14 were utilized 
to check all the assumptions of the One-way analysis of variance (ANOVA) and the 
linear regression models.  One-way ANOVA analysis was performed to address patients’ 
knowledge and identify significant differences within gender, age, ethnicity, level of 
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education, area of living, innovativeness, prior experience, perceived need for innovation, 
and sources of communication.  A similar analysis was conducted for prescribers’ 
knowledge, plus two predictor variables: duration of practice and medical specialty.  A 
power analysis was conducted to determine the minimum sample size required to achieve 
a power of 0.8. 
The assumptions of the One-way ANOVA model were assessed to determine the 
validity of the procedure.  Statistical tests for a normal distribution of errors (Shapiro-
Wilk’s test) and homoscedasticity (Levene’s test) across two or more groups (Levene, 
1960; Shaphiro and Wilk, 1965) were conducted.  The presence of asymmetry was 
addressed and handled using transformations (log10).  The presence of influential outliers 
in a set of independent variables was assessed using Cook’s distance (Cook and 
Weisberg, 1982).  
A multiple linear regression model was generated to predict the strength of the 
relationship between the overall PGx testing knowledge score and the significant 
predictor variables identified in the ANOVA model.  The assumptions of linear 
regression were assessed, including linearity (using a normal Q-Q scatterplot), 
autocorrelation (using the Durbin-Watson test), homoscedasticity (using Levene’s test), 
multicollinearity (using the variance inflation factor), and normality (using the Shapiro-
Wilk’s test).   
The multiple regression model was formulated separately for patients and 
physicians to estimate the overall knowledge and attitudes toward PGx testing as 
functions of sociodemographic variables and attributes of knowledge and attitude stages 
as follows: 
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Yijk = αij + Xijkl βlji + Aijkl λlji + εijk 
 
 
 
where 
Yijk was a vector of scores for the ith indicator and jth type of participant reported by the 
kth respondent; 
Xijkl was a matrix of values of sociodemographic variables (l = 6 including gender, age, 
ethnicity, level of education, area of living/type of practice setting, and duration of 
practice) reported by the kth respondent of the jth type of participant for the ith indicator; 
Aijkl was a matrix of attribute values for the ith indicator (when i = 1, then l = 4 including 
prior experience, innovativeness, perceived need, and communication behavior; when 
i = 2, then l = 5 including relative advantage, compatibility, complexity, trialability, and 
observability) reported by the kth respondent of the jth type of participant; 
αij was the independent term for the ith indicator and jth type of participant; 
βlji and λlji were vectors of l parameters for the jth type of participant for the ith indicator 
estimated within their respective matrix; 
εijk was a vector of normally and independently distributed stochastic error terms 
pertaining to the kth respondent of the jth type of participant for the ith indicator; 
i = 1 for knowledge and i = 2 for attitude; 
j = 1 for patients and j = 2 for physicians; 
k = 1, … , nj; and 
nj was the number of respondents in the jth type of participant category (n1 = 192 and  
n2 = 148). 
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One-way ANOVA and multiple regression models were also conducted to probe 
the association between patients’ and physicians’ attitudes toward PGx testing and 
relative advantage, compatibility, complexity, trialability, and observability of PGx 
testing.  Afterwards, sensitivity analysis using an alternative assumption (i.e., count data) 
was conducted to validate the findings of the linear regression model.  The possibility of 
measuring the outcome variables by counting the number of correct answers (i.e., the 
overall knowledge equals the number of correct answers, as shown in Table 4.2 and 
Table 4.14) explains the use of the Poisson model for count data.  The key assumption 
that the mean of the Poisson distribution should equal its variance was assessed in order 
to determine the goodness of fit of the Poisson model.  An ordered Probit model was also 
utilized since the categories of the dependent variables of this study were ranking with an 
arbitrary interval between the scores.  
Path analysis was performed to explore the influence of knowledge, attitudes, 
perceived characteristics of innovation, and sociodemographic characteristics on the 
acceptance or rejection of PGx testing among patients and physicians.  The implications 
of Rogers’s theory are based on the prediction of an individual’s decisions to either 
accept or reject an innovation; the decision-making process depends on the magnitude of 
the relationship between the individual’s knowledge and attitudes toward the innovation 
as well as the antecedent variables that potentially influence knowledge and attitudes. 
Considering only the direct effect of one variable on another (e.g., the relationship 
between attitude toward PGx testing and the adoption decision) may not be optimal; the 
relationship between two variables could influence or be influenced by a third variable.  
Therefore, to measure the total effect of a variable (e.g., level of education) on another 
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variable (e.g., attitude), both the direct and indirect effects of level of education must be 
considered.  
A generalized path analysis was created with a Probit link function and robust 
standard errors to examine the effect of the subscales (knowledge, attitude, and perceived 
characteristics of innovation), and demographic characteristics on the outcome variable 
(accept or reject PGx testing).  This analysis offered a better methodological tool to 
establish causality in correlated variables in a model (Wright, 1921).  (The following are 
assumptions of path analysis: linear and additive relations among variables that should be 
presented in the path diagram, the causal flow between independent and dependent 
variables should be one-way, the error terms should not be correlated with the 
independent variables in the model or among themselves, and the errors should be 
normally distributed.) 
Finally, the hypothesized causal relationships were evaluated using the overall 
goodness of fit.  The following tests were conducted: likelihood ratio chi-square (X2); the 
root mean square error of approximation (RMSEA), which according to Brown and 
Cudeck (1993) should be less than 0.08, but according to Steiger (2007) it is preferred 
when it is less than 0.07; and the Tucker-Lewis Index (TLI) and Comparative Fit Index 
(CFI), which compare the model of interest to a null model that assumes no correlation 
among variables.  As the values of both the TLI and CFI approach 1.0, the model 
represents a better fit than the null alternative model; a value of 0.90 is required for the 
model to be a more acceptable fit (Hu and Bentler, 1999).  
Based on Rogers’s theory-driven path, demographic characteristics, prior 
experiences, innovativeness, perceived need for innovation, communication channels, 
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were perceived characteristics of the innovation are exogenous variables that causally 
precede all dependent variables in the model.  Conversely, knowledge and attitudes were 
endogenous variables, and they might be either dependent or independent.  The adoption 
or rejection of PGx testing was the main outcome variable. 
Ethical Considerations  
After reviewing the study design, an exemption was granted from the Institutional 
Review Board (IRB) at NSU (see Appendix D).  The patient and prescriber surveys (see 
Appendices A and C), informed consent, promotional flyer, invitation e-mail, and 
participation letter were submitted and approved by NSU (see Appendix E) before the 
implementation of the study in compliance with the Health Insurance Portability and 
Accountability Act (HIPAA).  The data did not include direct patient or physicians 
identifiers.  
Summary 
A cross-sectional design was utilized in this study using data obtained from a 
convenient sample of patients and physicians.  Patients 18 years or older who self-
reported at least one chronic disease and physicians licensed to practice in Florida who 
were involved in medication therapy decisions were included.  Paper-based and online 
survey questionnaires were used to collect data from patients and physicians, 
respectively.  Several concepts (e.g., perceived need, relative advantage, compatibility, 
complexity, trialability, observability) adapted from Rogers’s diffusion of innovation 
theory were incorporated into the survey questions.  Statistical analyses including One-
way ANOVA and linear regression were performed to test the hypothesized relationships 
among the main concepts adapted from Rogers’s theory.  Then a generalized path 
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analysis was conducted to predict the factors that influence the acceptance of PGx testing 
among patients and physicians.  The results obtained from these procedures are presented 
in the next chapter. 
71 
 
Chapter 4 
Results 
 
The purpose of this chapter is to report the results of the statistical analysis 
performed in this study.  The characteristics of the sample are provided and the 
relationship between demographic variables and both knowledge and attitudes toward 
PGx testing is discussed.  The results from the various inferential analyses used to 
addresses the research questions are also presented.  Results are reported separately for 
patients and prescribers. 
Patient Descriptive Statistics 
Sample Characteristics 
The sample consisted of 192 patients with several chronic diseases.  Their 
distribution of selected demographic characteristics is presented in Table 4.1.  Most of 
them were women and the 40-59 age groups were the most numerous. 
Patients’ Knowledge of Pharmacogenetic Testing 
Seven questions were used to assess patients’ knowledge about PGx testing.  The 
mean score was 3.83 out of 7.00, with a standard deviation of 1.62.  Younger, White, and 
male participants with higher education had the highest mean scores.  A Cronbach’s 
alpha value of 0.65 was calculated for the PGx testing knowledge subscale, which 
indicated moderate internal consistency. 
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Table 4.1 
Percentage Distribution of Selected Demographic Variables 
of Patients in the Sample 
Variables Frequency (%) 
Gender  
Male  39.1 
Female  61.9 
Age (years)  
18-29 14.6 
30-39 19.3 
40-49  21.4 
50-59  25.0 
60 or older  19.7 
Ethnicity  
White/Caucasian 45.3 
Hispanic/Latino 25.0 
Black or African American 19.3 
Other 10.4 
Level of education  
High school or GED 13.5 
Associate degree 21.9 
Baccalaureate degree 25.5 
Master's degree 16.7 
Doctorate or professional degree 22.4 
Area of living  
Urban 38.0 
Suburban 58.8 
Rural 3.2 
 
 
More than 70% of patients were informed about general aspects of genetics and 
PGx testing, such as knowing that carrying a gene linked to a disease does not necessarily 
affect health status, and that the genetic makeup can influence drug response among 
different individuals.  Less than 70% correctly answered the question that assessed the 
association of genetic make-up with the severity of medication side effects, and less than 
50% correctly answered knowledge questions regarding availability of PGx testing and 
its ability to detect medication side effects (see Table 4.2). 
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Table 4.2 
Percentage of Correct Responses by Patients Pertaining to Knowledge of PGx Testing 
Questions 
Correct 
Answer (%) 
A person who carries a gene associated with a disease may be healthy 74.5 
A person's genetic make-up can influence how he or she responds to 
medicines 
72.9 
 
People with genetic differences can respond differently to the same 
medication (e.g., some patients may benefit; others may not) 
78.1 
 
A test that looks at an individual's genes will likely reveal whether a 
particular medicine would cause side effects for that person 
7.3 
 
A test that takes a cotton swab from the mouth of an individual and looks 
at genes is currently available for some medications (e.g., simvastatin, 
clopidogrel) 
34.9 
 
A test that looks at a person's genes will likely reveal whether a particular 
medicine would work for that person 
46.9 
 
The severity of side effects of some medications may depend on a person's 
genetic make-up 
68.2 
 
 
Patients’ Attitudes toward Pharmacogenetic Testing 
Ten questions were used to assess patients’ attitudes toward PGx testing.  The 
mean score was 4.80 out of 9.00, with a standard deviation of 2.17.  Female and White 
participants with higher education showed higher mean scores.  A Cronbach’s alpha 
value of 0.71 was calculated for the PGx testing attitude subscale, which indicated 
moderately high internal consistency. 
The majority of patients expressed favorable attitudes toward PGx testing and its 
perceived benefits on health.  Patients indicated willingness to take these tests as they 
believed the results would help their physicians make better treatment options.  There 
were concerns, however, about the financial cost of the testing as well as the potential for 
discrimination in health insurance and on the job (see Table 4.3). 
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Table 4.3 
Percentage of Favorable Responses by Patients Pertaining to Attitudes toward PGx 
Testing 
Questions 
Answers (%) 
SD or D   N A or SA 
It is important to look at my genes in order to know what 
is best for my health 
7.8 
 
29.2 
 
63.0 
I am willing to take a test that measures how a medicine 
works, based on my genes 
17.7 
 
24.0 58.3 
It is not useful to take genetic tests because my family 
physician may not know how to use my tests results 
52.6 
 
28.1 19.3 
If I had to pay for the genetic test myself, financial cost 
would be one of my concerns for taking these tests 
7.8 
 
9.4  82.8 
If I underwent testing, I would be concerned about the 
effect of the test results on my eligibility for private health 
insurance 
12.5 
 
17.2 
 
70.3 
If I underwent testing, I would be concerned about the 
effect of the test results on my employment opportunities 
29.1 
 
21.4 49.5 
I believe that physicians should have PGx testing 
information in their clinical practice 
2.2 
 
25.5 72.3 
If I took the test, I would be concerned that unauthorized 
persons may gain access to the results of that test 
27.0 
 
14.2 58.8 
PGx testing is a promising innovation in medicine 1.0 16.7 82.3 
PGx testing can help my physicians to make the right 
decisions about my health 
4.1 
 
21.4 74.5 
The attitude scale had five response options: Strongly Disagree (SD), Disagree (D), 
Neutral (N), Agree (A), and Strongly Agree (SA). 
 
Rogers’s Diffusion of Innovation-Based Questions 
This study adapted several variables within the content of Rogers’s diffusion of 
innovation theory.  These variables were prior experience, innovativeness, perceived 
need of adopters, and area of living.  The variables were included and measured as a 
subset of the knowledge stage.  The knowledge stage begins when an individual becomes 
interested in gathering more information about an innovation to develop a better 
understanding of what the innovation is and how and why it works.  According to 
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Rogers’s theory, the knowledge stage is influenced by demographic characteristics (e.g., 
age and education) and communication channels.  Other variables, including relative 
advantage, compatibility, complexity, trialability, and observability, were included as a 
subset of the persuasion stage. 
Almost 78% of participants indicated that they had never heard the term PGx 
testing, and only 11% had had their genes tested.  Many patients perceived the need for 
PGx testing in two different clinical situations.  Most views on relative advantages of 
PGx testing were positive.  Attitudes related specifically to the perceived need, relative 
advantage, compatibility, and trialability of PGx testing had more favorable responses 
than attitudes connected to the complexity and observability of PGx testing in general 
(see Table 4.4). 
The majority of participants reported that physicians and physician assistants were 
the major sources to obtain information about health issues.  The Internet was ranked 
second, followed by pharmacists.  Most participants relied on three or more sources of 
health information. 
Patient Inferential Statistics 
Research Question 1A Analysis 
In this section the findings pertaining to research question 1A, namely, the 
association between patients’ knowledge of PGx testing and their gender, age, ethnicity, 
level of education, area of living, prior experience, innovativeness, and perceived need 
for innovation, are reported.  Prior to conducting ANOVA tests, the results showed a 
violation of the normality assumption of ANOVA (i.e., Shapiro-Wilk’s p < 0.05, Jarque-
Bera test for Skewness-Kurtosis p < 0.05) due to negatively skewed data.  Consequently,  
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Table 4.4 
Percentage of Favorable Responses by Patients Pertaining to Rogers’s Theory-Based 
Questions about PGx Testing 
 Answers (%) 
Questions SD or D N A or SA 
Innovativeness 
I will be reluctant about accepting PGx testing until I 
see it providing useful results for people around me 
31.3 24.5 44.2 
Perceived need 
I think that PGx testing may prevent me from taking the 
wrong medicine 
 
7.3 
 
28.6 
 
64.1 
 
I believe that PGx testing will help reduce my current 
medications' side effects 
 
8.3 35.4 56.3 
Relative advantage 
I believe that PGx testing can help in the selection of 
medication that would better improve my medical 
condition 
 
0.5  
 
 
25.0 
 
 
74.5 
 
PGx testing can offer to me a useful alternative to the 
way that a physician usually prescribes medications 
 
7.8 31.2 61.0 
Compatibility 
PGx testing is a type of test that can invade my privacy 35.9 23.5 40.6 
Complexity 
The term “Pharmacogenetic Testing” is difficult to 
understand 
53.0 26.2 20.8 
Trialability 
I won't lose much by trying PGx testing, even if it 
doesn't benefit me directly 
12.5 28.7 58.8 
Observability 
I have discussed (at least once) PGx testing with my 
healthcare provider 
 86.0 9.9 4.1 
The attitude scale had five response options: Strongly Disagree (SD), Disagree (D), 
Neutral (N), Agree (A), and Strongly Agree (SA). 
 
the data were transformed using base 10 logarithms in order to bring the skewness score 
back to zero or close to normality. 
The One-way ANOVA results showed a significant effect of age, ethnicity, and 
level of education on the overall knowledge score.  There was also a significant effect of 
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prior experience, innovativeness, and perceived need.  The estimated F values are 
presented in Table 4.5.  
Table 4.5 
Estimated F Statistic Values of the One-Way ANOVA Model 
Pertaining to Patients’ Knowledge of PGx Testing 
Variables F Statistic 
Gender 0.56 
Age 2.76* 
Ethnicity 3.30* 
Level of education 11.50** 
Area of living 1.37 
Prior experience 22.00** 
Innovativeness 15.80** 
Perceived need 9.60* 
Communication channels 1.28 
* p < 0.05, ** p < 0.01 
 
Post-hoc Tukey tests were performed after completing the ANOVA tests to 
determine which groups differed from each other.  These showed that the mean score of 
White participants was significantly higher than the score of Black or African Americans.  
The mean score of participants who held a doctorate degree was significantly higher than 
those of the other levels of education.  The mean scores of participants who perceived 
one need or two needs were significantly higher than patients who did not express any 
need.  Mean difference scores and levels of significance are presented in Table 4.6. 
A multiple linear regression model was generated using the significant predictors 
found in the One-way ANOVA tests (age, ethnicity, level of education, prior experience, 
innovativeness, and perceived need).  Assumptions for normality, multicollinearity, 
autocorrelation, and homoscedasticity were tested prior to estimating the regression 
equation.  The results revealed that level of education, innovativeness, and prior  
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Table 4.6 
Results of Post-Hoc Pairwise Comparison of ANOVA Model Results Pertaining to 
Patients’ Knowledge of PGx Testing 
Variables Mean Difference 
Standard 
Error 
Age (years)   
18-29 vs. 40-49   0.114 0.041 
Ethnicity   
White/Caucasian vs. Black or African American 0.098* 0.033 
Level of education   
High school or GED vs. doctorate degree -0.159** 0.039 
Associate degree vs. master's degree -0.109* 0.037 
Associate degree vs. doctorate degree -0.220** 0.034 
Baccalaureate degree vs. doctorate degree -0.145** 0.033 
Master's degree vs. doctorate degree -0.112* 0.036 
Innovativeness   
Disagree/strongly disagree vs. agree/strongly agree -0.152**  0.027 
Neutral vs. agree/strongly agree -0.084* 0.034 
Perceived need   
No need vs. one need -0.084* 0.033 
No need vs. two needs -0.039** 0.028 
* p < 0.05, ** p < 0.01 
 
experience best fit the data (see Table 4.7).  The adjusted coefficient of multiple 
determination value was 0.31.  Stepwise regression was performed and similar results 
were found.  The results of sensitivity analysis using Poisson and ordered Probit models 
showed comparable results to the linear models (see Appendix F).  
Research Question 2A Analysis 
 The statistical analysis in this section was designed to address the association 
between patients’ attitudes toward PGx testing and relative advantage, compatibility, 
complexity, trialability, and observability of PGx testing.  One-way ANOVA tests were 
conducted to determine whether attitudes toward PGx testing differed significantly for 
each of the variables adapted from Rogers’s theory.  Gender and level of education  
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Table 4.7 
Predictors of Patients’ Knowledge of PGx Testing 
Predictors 
Regression 
Coefficient 
Standard 
Error 
Age  -0.003 0.008 
Ethnicity  -0.018 0.011 
Level of education    0.036** 0.008 
Prior experience  0.075** 0.027 
Innovativeness  0.043** 0.014 
Perceived need 0.027 0.014 
Independent term  -0.785 0.052 
* p < 0.05, ** p < 0.01 
 
yielded significant differences.  Relative advantage, compatibility, complexity, 
trialability, and observability of PGx testing were also significantly related to the total 
attitude score (see Table 4.8). 
Table 4.8 
Estimated F Statistic Values of the One-Way ANOVA Model 
Pertaining to Patients’ Attitudes toward PGx Testing 
Variables F Statistic 
Gender 10.10** 
Age 0.96 
Ethnicity 1.99 
Level of education 4.27** 
Area of living   1.25 
Communication channels    0.04 
Relative advantage 44.00** 
Compatibility 28.30** 
Complexity 25.80** 
Trialability 39.30** 
Observability 5.75** 
* p < 0.05, ** p < 0.01 
  
Post-hoc Tukey tests were performed for pairwise comparisons of means. 
These showed that master’s degree holders had higher attitude scores than those with 
associate degree or baccalaureate degree.  The mean score of participants who agreed on 
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two relative advantages of the testing was significantly higher than those who perceived 
only one advantage or did not perceive any advantages.  Additionally, participants who 
agreed or strongly agreed on the compatibility, easiness of PGx testing, and trialability 
showed significantly higher attitude mean scores than those who were neutral or 
disagreed.  The results of the post-hoc Tukey tests are presented in Table 4.9. 
Table 4.9 
Results of Post-Hoc Pairwise Comparison of ANOVA Model Results Pertaining to 
Patients’ Attitudes toward PGx Testing 
Variables 
Mean 
Difference 
Standard 
Error 
Level of education   
Master's degree vs. associate degree 1.835** 0.494 
Master's degree vs. baccalaureate degree 1.437* 0.479 
Relative advantage    
Two relative advantages vs. no relative advantage  2.903** 0.346 
Two relative advantages vs. one relative advantage 1.996** 0.311 
Compatibility   
Agree/strongly agree vs. disagree/strongly disagree 2.326** 0.317 
Agree/strongly agree vs. neutral  1.782** 0.368 
Complexity   
Agree/strongly agree vs. disagree/strongly disagree 2.185** 0.362 
Agree/strongly agree vs. neutral 1.855** 0.335 
Trialability   
Agree/strongly agree vs. disagree/strongly 
disagree 
2.770** 0.413 
Agree/strongly agree vs. neutral  2.188** 0.302 
Observability   
Agree/strongly agree vs. disagree/strongly disagree 2.150* 0.769 
 
* p < 0.05, ** p < 0.01 
 
A regression equation was estimated for the PGx testing attitude scores after 
evaluating the underlying assumptions of normality, multicollinearity, autocorrelation, 
and homoscedasticity.  The significant predictors found in the One-way ANOVA models 
were included as independent variables. The forward selection, backward elimination, 
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and stepwise models showed similar results.  Gender, relative advantage, compatibility, 
complexity, and trialability were statistically significant (see Table 4.10).  The adjusted 
coefficient of multiple determination value was 0.50.  The results of sensitivity analysis 
using Poisson and ordered Probit models showed comparable results (see Appendix F). 
 
 
 
 * p < 0.05, ** p < 0.01 
 
Research Question 3A Analysis 
 The analysis in this section was designed to assess whether knowledge, attitudes, 
perceived characteristics of innovation, and sociodemographic characteristics 
significantly influence the acceptance or rejection of PGx testing among patients.   
A generalized path analysis was conducted to determine the causal effect between 
knowledge, attitude, perceived characteristics of innovation, demographic characteristics, 
and the outcome variable, namely, acceptance or rejection of PGx testing.  Based on the 
initial model guided by Rogers’s theory, some reproduced correlations were not 
significant at the 0.05 level.  Finding the possible missing paths in the initial model 
showed that five additional paths significantly contributed to the model.  Two non-
significant paths to the adoption of PGx testing were removed.  The revised model was 
Table 4.10 
Predictors of Patients’ Attitudes toward PGx Testing 
Predictors 
Regression 
Coefficient 
Standard 
Error 
Gender -0.569* 0.234 
Level of education 0.100 0.087 
Relative advantage 0.948** 0.161 
Compatibility 0.548** 0.148 
Complexity -0.354* 0.162 
Trialability 0.637** 0.191 
Observability 0.409 0.237 
Independent term -0.520 0.530 
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statistically significant at the 0.05 level.  Computation of the reproduced direct, indirect, 
and total causal effects of the revised model indicated a good fit model for the collected 
data.  The coefficient of multiple determination values for the predictors were as follows:  
0.32 for knowledge, 0.52 for attitudes, and 0.38 for adoption of PGx testing.  The 
goodness of fit scores are presented in Table 4.11. 
 
Table 4.11 
Goodness of Fit Scores for Statistics Pertaining to Path 
Analysis of Patients’ Adoption of PGx Testing 
Goodness of Fit Test Value 
Likelihood Ratio 
 
chi2_ms 
p > chi2 
7.550 
0.374 
Population Error RMSEA 0.020 
Baseline Comparison CFI 0.998 
TLI 0.996 
 
The results of the path analysis showed that the overall attitude score and the total 
perceived innovation characteristic score were significant predictors of patients’ adoption 
of PGx testing (see Table 4.12).  Participants who scored higher on the attitude subscale 
and on the perceived characteristics of innovation subscale were more likely to accept 
PGx testing. 
Prescriber Descriptive Statistics 
Sample Characteristics 
Of the initial 1,000 physicians contacted via email, there were 850 deliverable 
messages and 60 participants successfully completed and submitted the online survey.  In 
addition, 70 physicians were contacted at regional conferences and 20 were contacted at 
NSU’s Health Professions Division.  In two surveys, the majority of the questions were  
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Table 4.12 
Predictors of Patients’ Adoption of PGx Testing 
Predictors 
Regression 
Coefficient 
Standard 
Error 
Knowledge   
Level of education 0.249** 0.062 
Prior experience  0.148* 0.064 
Innovativeness 0.122 0.073 
Perceived characteristics of innovation 0.281** 0.076 
Independent term   -5.606    0.360 
Attitude    
Perceived need 0.201** 0.059 
Perceived characteristics of innovation 0.706** 0.036 
Independent term   -1.404 0.223 
Adoption of PGx testing    
Knowledge  0.112 0.064 
Attitude 0.348** 0.078 
Perceived characteristics of innovation 0.258** 0.084 
Independent term -0.661 0.480 
* p < 0.05, ** p < 0.01 
 
blank, either due to a software error or due to lost Internet connection that led to data 
loss.  These surveys were deleted.  A total of 148 physicians completed the online survey 
for a response rate of 15.7%.  Most of them were men and White, and they were evenly 
distributed in terms of age groups.  The most numerous group had been in practice for 
over 20 years (see Table 4.13). 
Prescribers’ Knowledge of Pharmacogenetic Testing 
Six questions were used to assess physicians’ knowledge about PGx testing.  The 
mean score was 3.40 out of 6.00, with a standard deviation of 1.53.  Younger, non-White 
and female respondents practicing in suburban areas had higher mean scores than their 
counterparts.  A Cronbach’s alpha value of 0.60 was calculated for the PGx testing 
knowledge subscale, which indicated moderate internal consistency.  The majority of 
physicians answered correctly that PGx testing can determine whether people with  
84 
 
 
 
 
 
genetic differences can respond differently to the same medication.  Almost one-half felt 
challenged to find the correct answer about the availability of PGx testing (see  
Table 4.14). 
Prescribers’ Attitudes toward Pharmacogenetic Testing 
Eight questions were used to assess prescribers’ attitudes toward PGx testing.  
The mean score was 4.97 out of 8.00, with a standard deviation of 2.04.  Older, White, 
and female participants practicing in urban areas had relatively higher mean attitude  
Table 4.13 
Percentage Distribution of Selected Demographic Variables 
of Prescribers in the Sample 
Variables Frequency (%) 
Gender  
Male 66.4 
Female 33.6 
Age (years)  
25-39 18.4 
40-49 24.7 
50-59 29.5 
60 or older 27.4 
Ethnicity  
White/Caucasian 71.7 
Hispanic/Latino 10.3 
Black or African American 10.0 
Other 8.0 
Medical specialty  
Internal Medicine 18.4 
Family Medicine 31.3 
Others 50.3 
Type of practice setting  
Urban 45.3 
Suburban 48.7 
Rural 6.0 
Duration of practice (years)  
1-10 25.0 
11-20 31.1 
21or more 43.9 
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Table 4.14 
Percentage of Correct Responses by Prescribers Pertaining to Knowledge of PGx 
Testing  
Questions 
Correct 
Answers (%) 
Genetic variations account for as much as 95% of the variability of an 
individual's response to a medication 
43.2 
 
PGx testing can determine whether people with genetic differences can 
respond differently to the same medication 
89.2 
 
PGx testing of an individual's genes guarantees whether a particular 
medicine would cause adverse events for that person 
52.0 
 
PGx testing is currently available for all medications 59.5 
Some medications have FDA-approved PGx information in their 
package inserts 
50.7 
 
The package insert for clopidogrel (Plavix®) includes a warning about 
possible worse outcomes in individuals who have specific genetic 
variants 
44.6 
 
 
scores.  A Cronbach’s alpha value of 0.78 was calculated for the PGx testing attitude 
subscale, which indicated high internal consistency for this subscale. 
The majority of physicians expressed favorable attitudes toward the perceived 
benefits of PGx testing in prescribing effective medication, reducing medications side 
effects, and educating patients regarding PGx testing.  However, physicians expressed 
concerns about potential discrimination for their patients by health insurance companies 
and unauthorized access to testing results (see Table 4.15).   
Inhibitors of Recommending Pharmacogenetic Testing 
Physicians who had never ordered PGx testing for their patients or were not 
willing to accept it in routine medical practice identified several reasons for their 
response.  The most common reasons were lack of insurance support for these tests, 
unavailability of PGx testing at the workplace, and uncertainty about the clinical utility of 
these tests (see Table 4.16). 
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Table 4.15 
Percentage of Favorable Responses by Prescribers Pertaining to Attitudes toward PGx 
Testing 
 Answers (%) 
Questions SD or D N A or SA 
Prescribers should use PGx testing information in clinical 
practice 
8.1 
 
33.8 58.1 
Patients should be educated about the purpose, benefits, 
limitations, and risks of PGx testing 
5.4 
 
16.9 77.7 
PGx testing will potentially help decrease the number of 
adverse drug events 
4.7 
 
21.0 74.3 
PGx testing may prevent me from prescribing an 
ineffective medicine 
8.1 
 
17.5 74.4 
PGx testing is a promising innovation in medicine 5.4 14.9 79.7 
PGx testing can offer a useful tool to the way I usually 
prescribe/recommend medications 
8.1 
 
25.0 66.9 
I am concerned about the effect of the test results on my 
patients' eligibility for private health insurance 
26.4 
 
27.7 45.9 
I am concerned that unauthorized personnel may gain 
access to the results of that test 
39.9 
 
27.7 32.4 
The attitude scale had five response options: Strongly Disagree (SD), Disagree (D), 
Neutral (N), Agree (A), and Strongly Agree (SA). 
 
Table 4.16 
Barriers to Implementing PGx Testing in Clinical Practice Identified by 
Prescribers 
Barriers Frequency (%) 
PGx testing is not available at workplace 60.6 
Concerns about patient confidentiality 19.7 
Concerns about patients' employment opportunities 9.8 
Not enough time to order 16.4 
Waiting for PGx testing results would delay treatment 32.7 
Uncertain about the clinical utility of the test 55.7 
Insurance does not cover test 62.3 
Not applicable for my patients 14.8 
Patient refused test 14.8 
Other  6.6 
Respondents were allowed to answer one or more than one reason. 
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Rogers’s Diffusion of Innovation-Based Questions 
This study adapted several variables within the context of Rogers’s diffusion of 
innovation theory.  These variables were prior experience, innovativeness, perceived 
need of adopters, demographic characteristics (e.g., gender, age, ethnicity, and site of 
practice), and communication channels.  In addition, relative advantage, compatibility, 
complexity, trialability, and observability were included as a subset of the persuasion 
attitude stage. 
Only a fraction of respondents said that they had ever ordered PGx testing for a 
patient, and only about a third replied that they had ever talked with a patient about PGx 
testing.  Most participants expressed the need for PGx testing when information about the 
test is included in the package inserts and when the practice guidelines for the use and 
interpretation of these tests become available.  Likewise, the majority of prescriber 
agreed on the relative advantages of using PGx testing to avoid the risk of non-response 
to an essential drug and to select a medication that better controls a patient's health 
condition.  In general, attitudes toward the perceived need, relative advantage, and 
compatibility of PGx testing had more favorable responses than attitudes toward its 
trialability and complexity (see Table 4.17). 
Almost 16% of respondents reported that they had not received education in 
genetics, and about one-half identified the use of only one source of information about 
PGx testing.  Sources included genetics training in medical/pharmacy school, CME 
courses, graduate or undergraduate genetics courses, genetics-related seminars or 
workshops, grand rounds, genetics training in residency, and other sources such as direct 
experience, the Internet, and scientific articles (see Table 4.18). 
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Table 4.17 
Percentage of Favorable Responses by Prescribers Pertaining to Rogers’s Theory-
Based Questions about PGx Testing 
Questions 
Answers (%) 
SD or D  N A or SA 
Innovativeness 
I will be reluctant to adopt PGx testing until I see it 
working for patients 
39.0  26.0 35.0 
Perceived need 
When information about the test is included in the 
package inserts 
14.2 25.7 60.1 
When practice guidelines for the use and interpretation 
of these tests are available 
4.7 16.2 79.1 
Relative advantage 
In case of non-response to an essential drug (e.g., 
analgesic) / Refractory patients 
4.1 10.8 85.1 
In the selection of medication that better controls a 
patient's health condition 
11.5 16.9 71.6 
Compatibility 
PGx testing is not compatible with my personal values 78.0 12.0 10.0 
Complexity 
The application of PGx testing adds more complexity 
to the drug prescribing process 
13.0 15.0 72.0 
Trialability 
I would like to try PGx testing on some patients before 
I decide whether I will adopt it or not 
23.0 26.0 51.0 
Observability 
Have you ever talked with a patient about PGx 
testing? 
67.0   0.0  33.0 
The attitude scale had five response options: Strongly Disagree (SD), Disagree (D), Neutral 
(N), Agree (A), and Strongly Agree (SA). 
  
Prescriber Inferential Statistics 
Research Question 1B Analysis 
In this section, the findings pertaining to research question 1B, namely, the 
association between physicians’ knowledge of PGx testing and their gender, age, 
ethnicity, medical specialty, practice setting, duration of practice, prior experience,  
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Table 4.18 
Percentage Distribution of Sources of Genetic Information Reported 
by Prescribers 
 Source  Frequency (%) 
Genetics training in medical school   33.1 
Genetics training in residency     8.1 
Undergraduate genetics course 19.6 
Genetics course in graduate school 8.1 
Grand Rounds 15.6 
CME course 31.8 
Genetics-related seminar or workshop 17.6 
Other  18.2 
Respondents were allowed to answer one or more than one source. 
 
 
innovativeness, and perceived need for innovation, are reported.  As in the data analysis 
section, the assumptions of One-way ANOVA were tested to determine the applicability 
of the model.  The empirical evidence indicated that gender, type of practice setting, prior 
experience, perceived need, and sources of communication showed significant 
differences in scores of knowledge about PGx testing by physicians (see  
Table 4.19).   
Table 4.19 
Estimated F Statistic Values of the One-Way ANOVA Model 
Pertaining to Prescribers’ Knowledge of PGx Testing 
 Variables  F Statistic 
Gender 5.39* 
Age 0.21 
Ethnicity 0.39 
Medical specialty 1.94 
Type of practice setting 4.81* 
Duration of practice 1.66 
Prior experience  8.38** 
Innovativeness 1.79 
Perceived need 3.40* 
Communication channels  4.50** 
* p < 0.05, ** p < 0.01 
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Post-hoc Tukey tests were performed to determine which groups differed from 
each other.  The results showed that the mean PGx testing knowledge score of 
participants who perceived two needs was significantly higher than the score of those 
who expressed no need, and the mean scores of participants who used one or two 
resources were significantly greater than those who did not report any source of heath 
information (see Table 4.20). 
   
Table 4.20 
Results of Post-Hoc Pairwise Comparison of ANOVA Model Results 
Pertaining to Prescribers’ Knowledge of PGx Testing 
Variables 
Mean 
Difference 
Standard 
Error 
Perceived need   
Two needs vs. no need 0.900* 0.135 
Communication channels   
One source of information vs. no source 1.178** 0.359 
Two sources of information vs. no source 1.383** 0.407 
* p < 0.05, ** p < 0.01  
A multiple linear regression model was generated using the significant predictors 
found in the One-way ANOVA tests (gender, type of practice setting, prior experience, 
perceived need, and sources of communication).  The forward, backward, and stepwise 
regression versions revealed that gender, type of practice setting, and prior experience 
were significant variables that best fit the data (see Table 4.21).  The adjusted coefficient 
of multiple determination value was 0.22.  The results of sensitivity analysis using 
Poisson and ordered Probit models showed comparable results to the linear models (see 
Appendix F). 
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Table 4.21 
Predictors of Prescribers’ Knowledge of PGx Testing 
Predictors 
Regression 
Coefficient 
Standard 
Error 
Gender        0.798** 0.267 
Type of practice setting -0.742** 0.255 
Prior experience  0.771* 0.314 
Perceived need 0.255 0.179 
Communication channels 0.159 0.134 
Independent term  3.500 0.374 
* p < 0.05, ** p < 0.01 
 
Research Question 2B Analysis 
 The statistical analysis in this section was designed to address the association 
between physicians’ attitudes toward PGx testing and relative advantage, compatibility, 
complexity, trialability, and observability of PGx testing.  One-way ANOVA tests were 
conducted to determine whether attitudes toward PGx testing differed significantly for 
each of the variables adapted from Rogers’s diffusion of innovation theory.  Gender, 
relative advantage, compatibility, and observability were significantly related to the total 
attitude score (see Table 4.22).  
Post-hoc Tukey tests were performed to determine which groups differed from 
each other.  They showed that the mean score of participants who agreed on two relative 
advantages of PGx testing was significantly higher than the mean of those who did not 
report advantages.  The mean score of participants who agreed or strongly agreed with 
the statement about compatibility of PGx testing was significantly higher than the mean 
of those who disagreed or strongly disagreed.  The results of the post-hoc Tukey tests are 
presented in Table 4.23. 
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Table 4.22 
Estimated F Statistic Values of the One-Way ANOVA Model 
Pertaining to Prescribers’ Attitudes toward PGx Testing 
Variables F Statistic 
Gender 5.98* 
Age 0.53 
Ethnicity 0.83 
Medical specialty 0.32 
Type of practice setting  0.78 
Duration of practice 1.93 
Prior experience  2.42 
Relative advantage 6.52** 
Compatibility 11.50** 
Complexity 1.02 
Trialability 1.62 
Observability 6.52* 
Communication channels 0.76 
* p < 0.05, ** p < 0.01 
 
 
Table 4.23 
Results of Post-Hoc Pairwise Comparison of ANOVA Model Pertaining to Prescribers’ 
Attitudes toward PGx Testing 
Variables 
Mean 
Difference 
Standard 
Error 
Relative advantage    
Two relative advantages vs. no relative advantage 0.180** 0.057 
Compatibility   
Agree/strongly agree vs. disagree/strongly disagree 0.140** 0.056 
* p < 0.05, ** p < 0.01 
 
The predictors found to be significant in the One-way ANOVA tests were utilized 
as independent variables in the estimation of a regression equation.  Forward selection, 
backward elimination, and stepwise regressions were conducted.  All three models 
revealed that coefficients for gender, relative advantage, and compatibility were 
significant (see Table 4.24).  The adjusted coefficient of multiple determination value 
was 0.21.  The results of sensitivity analysis using Poisson and ordered Probit models 
showed comparable results (see Appendix F).  
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Table 4.24 
Predictors of Prescribers’ Attitudes toward PGx Testing 
Predictors 
Regression 
Coefficient 
Standard  
Error 
Gender 0.078* 0.037 
Relative advantage 0.061* 0.026 
Compatibility 0.155** 0.044 
Observability 0.061 0.038 
Independent term -0.730 0.060 
* p < 0.05, ** p < 0.01 
 
Research Question 3B Analysis 
The analysis in this section was designed to assess whether knowledge, attitudes, 
perceived characteristics of innovation, and sociodemographic characteristics 
significantly influence the acceptance or rejection of PGx testing among physicians.   
A generalized path analysis was conducted to determine the causal effect among 
knowledge, attitude, perceived characteristics of innovation, demographic characteristics, 
and the outcome variable, namely, acceptance or rejection of PGx testing.  Based on the 
initial model guided by Rogers’s theory, some reproduced correlations were not 
significant at the 0.05 level.  Finding the possible missing paths in the initial model 
indicated that seven additional paths significantly contributed to the model.  Two non-
significant paths to the adoption of PGx testing were removed from the model.   
Computation of the reproduced direct, indirect, and total causal effects of the revised 
model indicated a good fit model for the collected data.  The coefficient of multiple 
determination values for the predictors were as follows: 0.19 for knowledge, 0.23 for 
attitudes, and 0.18 for adoption of PGx testing.  The goodness of fit scores are presented 
in Table 4.25.  
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Table 4.25 
Goodness of Fit Scores for Statistics Pertaining to Path 
Analysis of Prescribers’ Adoption of PGx Testing 
Goodness of Fit Test Value 
Likelihood ratio 
 
 chi2_ms 
 p > chi2 
12.75 
0.388 
Population error  RMSEA 0.021 
Baseline comparison 
 
 CFI 0.998 
 TLI 0.997 
 
The results of the path analysis showed that the total perceived innovation 
characteristic score and the total perceived need score were significant predictors of 
prescribers’ adoption of PGx testing (see Table 4.26).  Participants who scored higher on 
the perceived characteristics of innovation subscale and on the perceived need items were 
more likely to accept PGx testing. 
Table 4.26 
Predictors of Prescribers’ Adoption of PGx Testing 
Predictors 
Regression 
Coefficient 
Standard 
Error 
Knowledge    
Age (years) -0.359** 0.129 
Type of practice setting -0.196** 0.074 
Duration of practice  0.401** 0.128 
Perceived need 0.151* 0.080 
Perceived characteristics of innovation 0.146 0.079 
Independent term 2.617 0.439 
Attitude   
Innovativeness 0.320** 0.075 
Perceived characteristics of innovation 0.261** 0.076 
Independent term   -1.732 0.339 
Adoption of PGx testing   
Knowledge  -0.028 0.079 
Attitude 0.128 0.081 
Perceived need 0.261** 0.079 
Perceived characteristics of innovation 0.197* 0.086 
Independent term 1.756 0.445 
* p < 0.05, ** p < 0.01 
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In the next chapter, a discussion of the empirical findings of this dissertation is 
undertaken.  Also discussed is the applicability of the adapted theoretical framework and 
how the evidence relates to previous scholarly works.  Limitations and recommendations 
for future research are addressed. 
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Chapter 5 
Discussion and Conclusions 
 
This study was guided by Rogers’s diffusion of innovation theory to test the 
relationship between patients’ and physicians’ willingness to use PGx testing and their 
knowledge of PGx testing, attitudes toward PGx testing, and sociodemographic 
characteristics.  Understanding these relationships may help promote the diffusion of 
these genetic tests, which may potentially predict medication response and improve 
medication safety in clinical practice.  In this chapter key findings and conclusions are 
addressed for both patients and physicians, along with the results of path analysis 
describing the relative importance of model-based relationships to the decision to adopt 
PGx testing.  Study limitations and recommendations for future research are also 
discussed.  
Patients’ Knowledge of PGx Testing 
In contrast with findings from previous studies that included patients with chronic 
diseases (Calsbeek et al., 2007; Cuffe et al., 2014; Morren et al., 2007; Nielsen and 
Moldrup, 2007; Rogausch et al., 2006), most patients here were knowledgeable about 
general aspects of genetics and PGx testing, although less than half were familiar with the 
availability of PGx testing and its potential to detect medication side effects.  Education 
and prior experience were significantly correlated with knowledge of PGx testing; 
educated patients with prior experience of PGx testing had greater overall knowledge of 
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it.  The relatively higher overall knowledge of patients who participated in this study 
might have reflected their higher level of education compared to participants in other 
studies.  In addition, patients’ knowledge about PGx testing might have been influenced 
by their previous awareness regarding PGx testing as a new clinical tool. 
Another explanation for the relatively higher knowledge scores observed in this 
study might have been the use of more than one resource of health information by 
patients to find out more about PGx testing.  The results indicated that healthcare 
professionals, including physicians, physicians’ assistants, and pharmacists, as well as the 
Internet, were the most popular sources of health information for patients.  
Variables Associated with Patients’ Knowledge 
Patients’ knowledge of PGx testing showed strong association with several factors 
of the Rogers’s diffusion of innovation theory such as prior experience, age, ethnicity, 
level of education, perceived need, and innovativeness.  Prior experience was associated 
with more knowledge about PGx testing; this finding was consistent with previous works 
that showed prior experience was related to patients’ acceptance of consumer health 
information technology applications (Or and Karsh, 2009), genetic knowledge 
(Henneman et al., 2004), patients’ support to PGx testing (Haga et al., 2012b), and better 
understanding of personalized medicine (Haddy et al., 2010).  The findings also revealed 
that young, White, and more educated patients were more knowledgeable about PGx 
testing than older, Blacks or African Americans, and those with lower levels of 
education.  Gender and area of living were not associated with overall knowledge of PGx 
testing.   
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The fact that gender was not associated with overall knowledge might be a sign 
that neither males nor females were aware of PGx testing.  Although the majority of 
studies reviewed by Or and Karsh (2009) showed that gender had no effect on the 
acceptance of health IT application, other studies reported that women had a higher level 
of genetic knowledge than men (Haga et al., 2012b; Henneman et al., 2004; Morren et al., 
2007).  
This study found no association between channels of communication of health 
information and patients’ knowledge of PGx testing.  The importance of effective 
communication in understanding the barriers to actual implementation of PGx testing, 
however, has been recognized in other studies, especially between patients and their 
healthcare providers (Haddy et al., 2010; Haga et al., 2012b; Henneman et al., 2006).  
Since PGx testing has been slowly integrated into clinical practice, it was not expected to 
be widely known among non-adopter medical groups and appear as a central issue in 
social media.  Additionally, evidence-based guidelines for PGx testing have not yet been 
developed for the majority of chronic medications.  Therefore, healthcare providers may 
not consider it to be a relevant point of discussion with patients.  Communication 
channels might have provided a better measurement if patients had been asked to mention 
the sources from which they received information about personalized medicine. 
No association between patients’ overall knowledge of PGx testing and area of 
living was found either.  This might have been due to the fact that most patients lived in 
either urban or suburban areas, so access to health information resources might have been 
equal across different areas; this would accord with Rogers’s diffusion of innovation 
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expectation about innovations occurring in large urban centers/hospitals due to greater 
availability of resources.  
This study also found a significant association between patients’ perceived need 
for PGx testing and their knowledge of it.  Most patients agreed on the need for PGx 
testing in order to avoid being prescribed the wrong medication and reduce ADRs that 
might be associated with their chronic medications.  Although this association has not 
been specifically addressed in the literature, several studies have reported that the 
perceived need among patients regarding genetic testing or other health-related 
innovations influenced the adoption of the studied innovations. Several studies stressed 
the importance of perceived need in decision-making.  For example, Shah (2004) 
expressed the medical need to improve patient’s quality of life as one of the criteria for 
the medical use of PGx testing.  Henneman et al. (2006) showed that less than half of 
participants in their study perceived a need for genetic testing; the perceived usefulness 
of these tests were linked with patients’ acceptance of genetic testing.  Cuffe et al. (2014) 
showed that the majority of cancer patients wanted PGx testing due to their high need to 
detect the risk of severe toxicity associated with chemotherapy.  Furthermore, Or and 
Karsh (2009) concluded that meeting patients’ needs was of great importance to 
implement and accept telemedicine among patients.  These studies support the view that 
increased perceived need for PGx testing as an antecedent of knowledge may play a 
pivotal role in decision making as described by Rogers’s theory.  
Another independent variable investigated here was innovativeness.  The 
empirical evidence revealed that patients who were more willing to adopt PGx testing 
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also were more knowledgeable, a clear illustration of adopters’ behavior as described by 
Rogers’s theory.  
Patients’ Attitudes toward PGx Testing 
The overall attitudes of patients with chronic diseases toward PGx testing were 
positive.  In line with previous studies (Fargher et al., 2007; Haga et al., 2013; Kobayashi 
and Satoh, 2009; Lachance et al., 2015), patients expressed high expectations and hopes 
regarding the benefits of PGx testing and its potential role in preventing medications 
prescribed erroneously and enhancing medication safety.  Most participants felt 
optimistic and preferred to have their genes tested to find the medications that best 
worked for them, and nearly all patients agreed or strongly agreed that PGx testing was a 
promising innovation in medicine that could eventually help physicians make educated 
decisions about their health.  
Yet most participants expressed concerns regarding the cost of testing, the 
handling of confidential testing results (e.g., unauthorized access to the results), 
employment opportunities, and their eligibility to purchase a health insurance plan.  
Previous studies also reported that patients were worried about confidentiality issues, the 
impact of testing results on their eligibility to private health insurance, and employment 
opportunities (Fargher et al., 2007; Haga et al., 2013; Kobayashi and Satoh, 2009; 
Lachance et al., 2015; Rogausch et al., 2006).  Patients from other studies were also 
concerned about the possibility of disclosing a future risk of chronic diseases after 
undergoing genetic tests (Cuffe et al., 2014; Rogausch et al., 2006). 
The optimistic attitudes revealed here indicated that patients’ high expectations of 
advancements in the field of genetics were not necessarily dependent on their knowledge.  
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According to Rogers’s diffusion of innovation theory, knowledge and comprehension 
among patients about PGx testing should precede the attitude stage; in this study, 
however, although patients’ knowledge of PGx testing was positively correlated with 
their attitudes, their high expectations of the role that PGx testing could play in effective 
therapeutic options seemed to be overrated because other factors (e.g., age, type of 
disease, health status) that also influence drug response were not studied.  This finding 
was consistent with the conclusions of Rogausch et al. (2006), who reported that patients 
were optimistic about the benefit of PGx testing but more than half of them would not 
change their ineffective current therapy if the PGx-recommended optimal therapy was 
not available.  Since this dissertation did not specifically measure patients’ overall 
knowledge of non-genetic factors that might also impact therapeutic outcomes, which is a 
fundamental concept of Rogers’s diffusion of innovation theory, the potential effect of 
this type of knowledge on patient attitudes cannot be overlooked. 
Variables Associated with Patients’ Attitudes 
The empirical evidence showed that patients’ overall attitudes toward PGx testing 
were correlated with the factors originated in Rogers’s diffusion of innovation theory.  
Women were more likely to have positive attitudes toward PGx testing than men.  
Women also were less likely to be concerned with the perceived disadvantages of PGx 
testing (i.e., cost of testing, confidentiality, insurability, employability).  This is the 
opposite of findings in other studies (Haga et al., 2013; Henneman et al., 2006; Rogausch 
et al., 2006).  The discrepancy might be explained by a higher percentage of women in 
this dissertation having attained higher levels of education.  The findings here were also 
consistent with previous studies (Haga et al., 2013; Haga et al., 2012b) insofar as more 
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educated patients expressed more positive attitudes toward PGx testing than those with a 
lower level of education. 
No significant association was found between patients’ attitudes toward PGx 
testing and either age or ethnicity.  Similar findings were reported in other studies 
(Henneman et al., 2006; Lanktree et al., 2014; Or and Karsh, 2009).  In line with the 
findings of Rogausch et al. (2006), area of living had no influence on patients’ attitudes 
toward PGx testing; the absence of a link might be attributed to 97% participants living in 
urban and suburban areas, with approximately the same access to resources and 
innovation. 
The results of this study revealed a significant relationship between patients’ 
attitudes toward PGx testing and relative advantage, complexity of understanding the 
term of PGx testing, compatibility, trialability, and observability of PGx testing.  This 
study showed that patients who agreed on at least one relative advantage (i.e., PGx 
testing may help in prescribing the best available treatment for chronic conditions) had 
more positive attitudes than those who did not perceive PGx testing as advantageous.  
Rogausch et al. (2006) also revealed that patients who perceived the potential advantages 
of PGx testing (e.g., reducing side effects, avoiding ineffective medications) were more 
optimistic about the advantages of PGx testing. 
Patients who were able to understand the term PGx testing expressed more 
positive attitudes toward PGx testing than those patients who perceived it as a complex 
concept.  Comparable results on adopting different innovation were reported by Or and 
Karsh (2009).  A strong correlation also was found between patients’ favorable attitudes 
towards PGx testing and standards of care that maintain health information privacy.  
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Similarly, Henneman et al. (2006) reported that compatibility of PGx testing with moral 
values played a role in patients’ acceptance of PGx testing.  Moreover, this dissertation 
illustrated the degree to which PGx testing could be tried by patients.  Patients willing to 
try PGx testing expressed more positive attitudes.  When measuring the level of 
observability, almost 86% of patients never had a discussion with their healthcare 
providers about PGx testing.  The observability of PGx testing was significantly 
associated with patients’ hopeful attitudes toward PGx testing.  Yet after conducting 
regression analysis, observability was not a significant predictor of patients’ attitudes 
toward PGx testing. 
Adoption of PGx Testing among Patients  
A distinguishing feature if this study is that different PGx testing predictors were 
measured to determine the factors that influence patients’ acceptance of PGx testing.      
A generalized path analysis was conducted to assess the factors that predict acceptance of 
PGx testing.  Path analysis is a subset of structural equation modeling that uniquely 
provides information about the strength of causal relationships between factors of a 
hypothesized model.  The results showed that more than 50% of patients with chronic 
conditions were willing to undergo PGx testing.  When path analysis was originally 
applied based on the initial model guided by Rogers’s diffusion of innovation theory, 
some reproduced correlations did not appear to be significantly associated with the 
acceptance of PGx testing; however, finding the possible missing correlations (i.e., direct 
and indirect pathways) using a path analysis model between the defined factors and the 
outcome variable (i.e., willingness to accept PGx testing) resulted in a well fit model for 
the collected data.  
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Patients’ attitudes, as well as the perceived characteristics of PGx testing (e.g., 
relative advantage, compatibility, complexity, trialability, and observability), had a direct 
and indirect influence on the acceptance of PGx testing, while knowledge was not 
significantly related to the outcome variable.  Rogers’s diffusion of innovation theory 
provides a plausible explanation for these findings about the relationship between 
attitudes toward PGx testing and the decision to adopt; the lack of association between 
the two reported in this study might be attributed to patients’ non-involvement in decision 
making about their healthcare needs that might affect their actual knowledge.  The 
association between knowledge and adoption may appear after patients acquire more 
detailed knowledge about PGx testing. 
Prescribers’ Knowledge of PGx Testing 
Most physicians knew that PGx testing can determine whether people with 
genetic differences respond differently to the same medication; they also were aware that 
PGx testing is not available for all medications.  Relatively few, however, knew about the 
impact of genetic variability on an individual's response to a medication or were familiar 
with the availability of PGx testing for Plavix® (clopidogrel).  Younger, non-White, and 
female participants practicing in suburban areas had the highest mean knowledge scores. 
Physicians’ overall knowledge of PGx testing in the sample was greater than the 
knowledge of  physicians who participated in other studies (Dressler et al., 2014; Haga et 
al., 2012a; Powell et al., 2012; Rogausch et al., 2006; Stanek et al., 2013; Taber and 
Dickinson, 2014).  Perhaps this differential reflects an ongoing trend in the growth of the 
PGx field and the surge in interest to know more about PGx testing.  
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Variables Associated with Prescribers’ Knowledge 
Physicians’ overall knowledge of PGx testing was significantly associated with 
gender, perceived need, prior experience, type of practice setting, and sources of 
communication.  The absence of association with age, ethnicity, and duration of practice 
might be explained by the fact that participants received similar education and training 
programs in genetics.  The lack of correlation between overall knowledge of PGx testing 
and type of specialty may reflect uniform genetics education and training across 
specialties. 
Physicians made conscious efforts to gain more information about genetics from a 
variety of sources.  Compared to other studies (Dressler et al., 2014; Haga et al., 2012a; 
Shields et al., 2005; Stanek et al., 2012), the percentage of physicians who reported 
receiving formal education in genetics was higher.  The majority reported using two or 
more sources of genetic information and testing.  These sources included genetics 
training in medical school, CME courses, undergraduate genetics courses, genetics-
related seminars or workshops, and grand rounds.   
Physicians who relied on at least one source of genetic information had a higher 
level of overall PGx knowledge than physicians who did not report any source.  This was 
consistent with other studies (Dressler et al., 2014; Haga et al., 2012a, Stanek et al., 2012, 
2013; Taber and Dickinson, 2014).  Physicians who perceived the need for PGx testing in 
reducing ADRs and preventing ineffective therapies were more knowledgeable about 
PGx testing than those who did not perceive the need.  Stanek et al. (2012), Stanek et al. 
(2013), and Haga et al. (2012a) reported similar findings. 
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Finally, the strength of the relationship between overall knowledge of PGx testing 
and the significant factors identified in the One-way ANOVA model was probed using a 
multiple linear regression model.  Forward selection and backward elimination regression 
models yielded similar results, with three significant predictors: gender, prior experience, 
and type of practice setting.  Female physicians practicing in suburban areas with prior 
experience had a higher overall PGx testing knowledge score.  Participants practicing in 
suburban areas might have had better access/exposure to educational resources regarding 
PGx testing.  More research is needed to confirm this finding and further investigate 
whether suburban-practice physicians are more likely to have longer interaction with 
patients over a longer period of time, which might lead to increased awareness of inter-
individual variation in drug response.  
Other studies showed findings different from those reported here.  Walden et al. 
(2015) found that more male than female physicians believed that they had a better 
understanding of the PGx report.  Klitzman et al. (2013) found that White and male 
physicians were associated with increased ordering of genetic testing.  Stanek et al. 
(2012) reported that physicians who were willing to accept PGx testing were more likely 
to be male, older, having practiced 30 years or more since graduation, practicing in urban 
settings, and working in general/family practice settings. 
Similar to the findings of this work, several studies revealed an association 
between lack of prior experience with PGx testing and the knowledge gap that influenced 
decision making toward the adoption of PGx testing (Haga et al., 2012a; Stanek et al., 
2012; Stanek et al., 2013).  According to these studies, physicians’ levels of knowledge 
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of PGx testing and experience with patients who undergo genetic tests might significantly 
impact their preparedness for accepting genetic tests.  
Prescribers’ Attitudes toward PGx Testing 
Physicians’ overall attitudes toward PGx testing were positive, which was 
consistent with the findings of other studies (Dressler et al., 2014; Haga et al., 2012a; 
Moaddeb et al., 2015; Shields et al., 2005; Walden et al., 2015).  Rogausch et al. (2006) 
revealed more reserved attitudes toward PGx testing among healthcare professionals 
when considering the potential discrimination by health insurance companies as well as 
employers; in this dissertation, however, the levels of concern shared by physicians were 
much lower. 
The findings here suggest that physicians’ attitudes toward PGx testing are 
becoming increasingly receptive, and this may be due to more perceived benefits of 
genetic tests in improving medication safety and efficacy.  Supporting the findings of 
other studies (Fargher et al., 2007; Haga et al., 2012a; Haga et al., 2012c; Rogausch et al., 
2006; Stanek et al., 2012) regarding physicians’ concerns about PGx testing, the results 
showed that some concern existed about the cost of PGx testing, patients' confidentiality, 
and the uncertainty about the clinical utility of these tests. 
Variables Associated with Prescribers’ Attitudes 
The regression model indicated that physicians’ total attitude score toward PGx 
testing was predicted significantly by gender, relative advantage, and compatibility.  
Duration of practice, medical specialty, and urban-rural practice setting were not 
significantly associated with attitudes toward PGx testing.  The lack of statistical 
significance of duration of practice might be due to a low comfort level of physicians’ 
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knowledge about these tests, regardless of years of practice, because of lack of exposure 
to, and experience with, PGx testing.  The lack of statistical significance of medical 
specialty might be due to a possible selection bias or because participants did not 
perceive the benefits of PGx to be directly related to their specialties.  The lack of 
statistical significance of practice setting might be attributed to the absence of substantial 
differences among rural, suburban, and urban areas in terms of accessibility to genetic 
information and/or type of patients encountered. 
The findings of this study did not accord with the results of Klitzman et al. (2013) 
and Walden et al. (2015), who showed that male physicians had more favorable attitudes 
than female physicians toward the clinical application of PGx testing.  This discrepancy 
might be due to the fact that female physicians in this study had higher level of 
knowledge about PGx testing than their male counterparts.  
A significant relationship was found between attitudes toward PGx testing and 
relative advantage, compatibility, and observability.  The significant effect of the 
observability variable, however, disappeared after conducting regression analysis.  Haga 
et al. (2012a) also reported an impact of the relative advantage of PGx testing toward 
predicting potential ADRs and improving therapeutic outcomes on physicians’ attitudes 
and their decision to accept PGx testing.  In this dissertation trialability and complexity 
were not significantly associated with attitudes toward PGx testing.  In contrast, Taber 
and Dickinson (2014) and Fargher et al. (2007) indicated that the complexity perceived 
by physicians in terms of describing the role of PGx testing in healthcare, ordering the 
tests and interpreting the results, and unperceived clinical benefits negatively impacted 
attitudes and the ordering of these tests.  Stanek et al. (2012) also indicated that the 
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complexity of multiple genetic predictors involved in the variability of drug response 
might present a barrier to adoption. 
Adoption of PGx Testing among Physicians  
The adoption of PGx testing by physicians was significantly influenced by the 
perceived characteristics of PGx testing as well as the perceived need for innovation. 
Along with the initial path-analysis model guided by Rogers’s diffusion of innovation 
theory, some reproduced correlations between variables were not significant.  After 
finding the possible missing correlations in the initial model and computing the direct, 
indirect, and total causal effects of the revised model, however, the model provided a 
good fit for the data.  
Over 50% of physicians were willing to accept PGx testing.  Supporting the 
results of other studies (Dressler et al., 2014; Haga et al., 2012a; Stanek et al., 2012; 
Taber and Dickinson, 2014), this dissertation showed that lack of knowledge and poor 
attitudes toward PGx testing negatively impacts the PGx-based prescribing decisions 
among physicians.  Other factors contributing to the low use of PGx tests included 
availability of PGx testing, the cost of testing, privacy issues, and absence of clinical 
guidelines.  Almost half of physicians agreed that pharmacists’ role was crucial in the 
process of ordering PGx testing and interpreting results. 
Limitations 
Although the response rate of patient participants was high, the convenient nature 
of the sample might limit the generalizability of the findings.  Underrepresentation of 
Hispanics/Latinos also might have affected the results.  Using flyers to recruit patients 
might have resulted in patients’ self-selection; thus the likelihood of selection bias should 
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be taken into consideration.  Finally, the knowledge instrument had a slightly lower than 
adequate internal reliability (Cronbach’s alpha) score.  Avoiding an excessively long 
questionnaire that might have limited participants’ response and caused survey fatigue 
was important; therefore, several redundant items, which might have increased the 
Cronbach’s alpha score but not necessarily provided additional information, were 
removed from the scale. 
The relatively low response rate of physicians might have limited the 
generalizability of the findings.  Since physicians had to answer and submit the 
questionnaires on line, some might not have participated due to the inconvenience of 
responding via e-mail.  Underrepresentation in some medical specialties was a limitation. 
Finally, using a relatively low reliability knowledge instrument also might have affected 
the findings. 
Recommendations for Future Research 
As the number of drug package inserts with FDA-approved PGx information 
increases, the need to measure physicians’ knowledge and attitudes becomes imperative.  
More accurate findings may be obtained from replicating this study, applying Rogers’s 
diffusion of innovation theory or other models to a larger sample of physicians from a 
wider variety of specialties.  It is also important to recruit a representative sample of 
patients with a wide array of chronic diseases to assess their knowledge of PGx testing.  
Different measurement instruments may be used to capture accurately separate factors 
such as trialability, observability, innovativeness, area of practice/living, and 
communication channels. 
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Future research should be geared toward recruiting physicians working in medical 
settings in which PGx testing is available and proportionately include minority 
ethnic/racial groups.  Younger and older physicians practicing in both rural and urban 
areas should be included.  Using a larger sample size would allow conducting additional 
subgroup analysis that may provide a better insight into the adoption behavior of patients 
and physicians as well as the predictors of knowledge and attitudes.  A mixed-methods 
approach using qualitative and quantitative data collected simultaneously may be best 
suited to provide a deeper understanding of the acceptance of PGx testing in medical 
practice. 
Significance of the Findings in the Field of Pharmacy  
Pharmacists play a key role in patient care through a wide array of services that 
focus on monitoring the prescription process and optimizing drug utilization to ensure the 
safety and effectiveness of prescribed medications (Bush and Daniels, 2017).  The unique 
position of pharmacists as access points to care has several advantages leading to the 
integration of patients’ health information with rational drug use.  As the focus of health 
care shifts into personalized medicine, pharmacists’ knowledge and awareness about 
genetic-based treatment have become a necessity.  The FDA has already approved more 
than 150 drug package inserts with pharmacogenetic information, and the Clinical 
Pharmacogenetics Implementation Consortium (CPIC) has published therapeutic 
guidelines based on individual genetic differences (Relling and Klein, 2011) that mandate 
healthcare providers, including pharmacists, to take the lead, seek education, and gain 
experience in the field of genetics.  
112 
 
Integrating genetic information with other health information may maximize the 
benefits of medications that patients should receive as well as diminish the occurrence of 
ADRs (Ma et al., 2011; Owczarek et al., 2005).  To fulfill the Accreditation Council for 
Pharmacy Education (ACPE) Standards, several pharmacy schools have included genetic 
courses in their curricula to fortify the level of knowledge pertaining to medication 
response (ACPE, 2015; Adams et al., 2016).  These pharmacogenetic courses are 
designed to familiarize future pharmacists with the genetic basis of diseases as well as the 
role of metabolizing enzymes, which are susceptible to inter-individual genetic variation 
in medication response. 
The American Society of Health-System Pharmacists (ASHP) has emphasized the 
role of pharmacists in promoting personalized medicine and taking the lead in 
understanding genetic variability among individuals responsible for aggravating the 
burden of preventable side effects (ASHP, 2015).  To maintain the ongoing responsibility 
of pharmacists toward optimizing therapeutic benefits and minimizing adverse drug 
reactions, the barriers to adopting PGx testing as a diagnostic tool should be studied 
further.  In addition, the interpretation of testing results and the most effective ways of 
communicating these results to patients and other healthcare providers should be 
investigated and evaluated.  The work described in this dissertation has revealed several 
factors that significantly influence acceptance of genetic tests by both physicians and 
patients.  In the presence of clinical guidelines (Relling and Klein, 2011; Swen et al., 
2011), the ability of a pharmacist to understand both physicians’ and patients’ motives 
and concerns regarding acceptance of PGx testing may help advocate its application in 
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practice and promote the optimal use of PGx testing in order to achieve positive health 
outcomes.  
Conclusion  
Advances in the field of PGx in modern medicine are increasingly becoming a 
transforming point in the way chronic conditions are treated, medications are prescribed, 
and in developing trusting relationships among patients, pharmacists, and physicians.  In 
a preliminary step toward searching for a more extensive acceptance of PGx testing in 
clinical practice, this study carefully assessed the decision-making process and 
subsequently provided a significant insight into factors pertaining to enhancing the rate of 
adoption of PGx testing among patients and prescribers.  
Incorporating patients’ genetic information as part of their medical history will 
optimize the use, safety, and effectiveness of many medications.  However, transforming 
this technology into practice can only be accompanied with increased knowledge and 
more positive attitudes among patients and physicians alike, as they play a key role in its 
diffusion.  This dissertation considered the fact that participating patients suffered from 
several chronic conditions that have a genetic predisposition.  Therefore, the research 
focused on measuring actual knowledge of genetics and PGx testing rather than perceived 
knowledge, and it was found predictive for less reluctance toward accepting the tests.  
This conclusion highlights the need for establishing educational programs and revising 
existing medical curricula geared toward gaining knowledge as a precedent factor to the 
formation of favorable attitudes toward PGx testing.   
This study measured the influence of sociodemographic characteristics on 
patients’ willingness to accept PGx testing and on prescribers’ understanding of patients’ 
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medical needs and the need for change in their current clinical practices.  It strongly 
suggested that obtaining higher levels of education, being innovative, and gaining prior 
experience with genetic testing should ultimately improve patients’ acceptance of this 
diagnostic tool.  The empirical evidence showed an increase in patients’ awareness and 
attitudes regarding genetic testing.  In addition, several factors connected to the 
characteristics of PGx testing were significantly linked to its future acceptance.  Thus, 
this study provided a thorough understanding of society’s need and opinions toward PGx 
testing.  Patients believed that PGx testing helps select the effective medication, avoid 
wrong medications, and reduce potential adverse events.  Several barriers reported here 
could contribute to reforming institutional policies regarding patients’ confidentiality and 
potential for discrimination that might impact patient’s attitudes and subsequently the 
decision to adopt.  
The findings also showed that general knowledge of, and attitudes toward, the use 
of PGx testing increased physicians’ tendency to select the technique and implement it on 
their patients to improve health outcomes.  Physicians’ acceptance of these tests was 
exclusively linked to their prior experience with, and perceived need for, genetic testing 
as well as perceived characteristics of PGx testing.  Also identified were several barriers 
for the adoption decision that need be considered by the medical community and 
healthcare systems to meet society’s need for PGx testing and reduce healthcare costs, 
unnecessary medications, and ADRs that will ultimately improve patient adherence.  
Moreover, the findings may help develop clinical trials and conduct epidemiological 
studies to promote the uptake of genetic tests and overcome the key barriers. 
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This dissertation added an additional value by delineating factors that need be 
addressed to foster PGx implementation in a clinical setting.  It may have a large impact 
on developing education and training programs, mitigating future concerns, and on PGx 
companies that could improve the characteristics of PGx testing and alleviate currently 
foreseen barriers.  It provided an insight into the perception of patients with chronic 
diseases that might represent and reflect comparable results drawn from a larger 
population.  The extent of the findings may be expanded to include pharmacoeconomic 
and health outcome measures.  The findings also may be used to assess the inhibitors of 
accepting individual PGx tests in different clinical settings and may be applied to other 
healthcare professionals and their response to health-related innovations. 
The theoretical framework, Rogers’s diffusion of innovation theory, was a useful 
and highly reproducible model.  A generalized path analysis method posed new correlates 
among different sets of adapted variables.  The modified data collecting instruments 
validated and used in this research significantly contributed to capturing patients’ and 
physicians’ factors that have not been investigated in prior studies. 
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Appendix A 
Research Questionnaire (Patient Version) 
 
Knowledge  
 
For each of the following items check (X) if you think it is true or false: 
 
1. A person who carries a gene associated with a disease may be healthy 
 True   False  Not Sure 
2. A person's genetic make-up can influence how he or she responds to medicines 
 True   False  Not Sure 
3. People with genetic differences can respond differently to the same medication (e.g.,   
some patients may benefit; others may not) 
 True   False  Not Sure 
4. A test that looks at an individual's genes will likely reveal whether a particular 
medicine would cause side effects for that person 
 True   False  Not Sure 
5. A test that takes a cotton swab from the mouth of an individual and looks at genes is 
currently available for some medications (e.g. simvastatin, clopidogrel) 
 True   False  Not Sure 
6. A test that looks at a person's genes will likely reveal whether a particular medicine 
would work for that person 
 True   False  Not Sure 
7. The severity of side effects of some medications may depend on a person's genetic 
make-up 
 True   False  Not Sure 
8. Before this survey, have you ever heard about the term "Pharmacogenetic Testing"?  
 True   False  Not Sure 
9. Have you ever had your gene(s) tested?  
 True   False  Not Sure 
10. Would you agree to take a pharmacogenetic test (via cotton swab from the mouth) for 
one of your chronic medications?  
 Yes   I already have one   No   Not Sure 
 
Attitude  
 
 This survey asks about your preference with regard to the following statements: 
 
11. It is important to look at my genes in order to know what is best for my health 
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 Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
12. I am willing to take a test that measures how a medicine works, based on my genes 
 Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
13. It is not useful to take genetic tests because my family physician may not know how 
to use my tests results 
 Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
14. If I had to pay for the genetic test myself, financial cost would be one of my concerns 
for taking these tests 
 Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
15. If I underwent testing, I would be concerned about the effect of the test results on my 
eligibility for private health insurance 
 Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
16. If I underwent testing, I would be concerned about the effect of the test results on my 
employment opportunities 
  Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
17. I believe that physicians should have pharmacogenetic testing information in their 
clinical practice 
  Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
18. I think that pharmacogenetic testing may prevent me from taking the wrong medicine 
  Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
19. I believe that pharmacogenetic testing will help reduce my current medications' side 
effects 
  Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
20. If I took the test, I would be concerned that unauthorized persons may gain access to 
the results of that test 
  Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
21. I believe that pharmacogenetic testing can help in the selection of a medication that 
would better improve my medical condition 
  Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
22. Pharmacogenetic testing can offer me a useful alternative to the way that a physician 
usually prescribes medications 
  Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
23. Pharmacogenetic testing is a promising innovation in medicine 
  Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
24. Pharmacogenetic testing can help my physicians to make the right decisions about my 
health 
 Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
25. I will be reluctant about accepting pharmacogenetic testing until I see it providing 
useful results for people around me 
  Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
26. Pharmacogenetic testing is a type of test that can invade my privacy 
  Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
27. The term pharmacogenetic testing is difficult to understand 
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  Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
28. I won't lose much by trying pharmacogenetic testing, even if it doesn't benefit me 
directly  
  Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
29. I have discussed (at least once) pharmacogenetic testing with my healthcare provider 
  Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
30. Which of the following sources, if any, do you usually use to get information about 
health issues (for example, medications, treatment, and side Internet effects)? (Check 
all that apply) 
 TV  Radio   Internet  Newspapers   Magazines 
 Physicians/Physician Assistants  Nurses   Pharmacists 
31. Gender  
 Male   Female 
32. Ethnic Group 
 White/Caucasian  Hispanic/Latino  Black or African American 
  Others 
33. Age Group (years) 
 18-29  30-39  40-49   50-59  60+ 
34. Education 
 High School or GED  Associate Degree  Bachelor's Degree 
 Master's Degree  Doctorate or Professional Degree 
35. Area where you live 
 Urban  Suburban  Rural 
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Appendix B  
Study Constructs and Corresponding Sources 
Table B.1 
Patient Survey Constructs 
Construct/Variable Survey Items Reference 
Knowledge of PGx testing 1 (Calsbeek et al., 2007) 
2,3, 5 (Roederer et al., 2012) 
4, 6, 7 (Lachance et al., 2014) 
Attitudes toward PGx testing 11, 17, 23, 24 Self-developed 
12, 20 (Rogausch et al., 2006) 
13 - 16 (Zhang et al., 2014) 
Prior experience 8, 9 Self-developed 
Perceived need 18, 19 (Rogausch et al., 2006) 
Innovativeness 25 Self-developed 
Area of living 35 (Dodson et al., 2012) 
Sociodemographic variables 31 - 34 Self-developed 
Communication channels 30 (Nielsen et al., 2007) 
Relative advantage 21, 22 Self-developed 
Compatibility 26 Self-developed 
Complexity 27 (Dodson et al., 2012) 
Trialability 28 Self-developed 
Observability 29 Self-developed 
Willingness to take the test 10 Self-developed 
Note. The patient survey used in this study was developed and modified from previously 
published studies to collect information about patients’ knowledge and attitudes toward 
PGx testing. Several survey questions were adapted from the above authors. 
*PGx = Pharmacogenetic 
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Table B.2 
Prescriber Survey Constructs 
Construct/Variable Survey Items Reference 
Duration of practice 1 Self-developed 
Knowledge of PGx testing 2, 3, 5 - 7 (Roederer et al., 2012) 
4 (Shaw et al., 2011) 
Attitudes toward PGx testing 11 (Rogausch et al., 2006) 
10,17,19 (Roederer et al., 2012) 
9 (Dodson et al., 2012) 
 8, 12, 15 Self-developed 
Prior experience 25 (Taber et al., 2014) 
Perceived need 21a, 21b (Rogausch et al., 2006) 
Area of Current Setting 32 (Dodson et al., 2012) 
Sociodemographic variables 28-31 Self-developed 
Communication channels 22 (Taber et al., 2014) 
Relative advantage 20a, 20b Self-developed 
Innovativeness 14 Self-developed 
Compatibility 13 Self-developed 
Complexity 18 Self-developed 
Trialability 16 Self-developed 
Observability 23 Self-developed 
Willingness to recommend PGx 24 Self-developed 
Factors affecting PGx adoption 26 (Taber et al., 2014) 
Pharmacist role in PGx testing 27 Self-developed 
Note. The prescriber survey used in this study was developed and modified from the 
relevant literature to collect information about physicians’ knowledge and attitudes 
toward PGx testing. Several survey questions were adapted from the above authors. 
*PGx = Pharmacogenetic 
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Appendix C 
Research Questionnaire (Prescriber Version) 
 
1. How long have you been in practice (years)? 
 1-10   11-20   21 years or more 
 
Knowledge  
 
For each of the following items, check if you think it is true or false. 
 
2. Genetic variations account for as much as 95% of the variability of an individual's 
response to a medication. 
 True   False  Not Sure 
3. Pharmacogenetic testing can determine whether people with genetic differences can 
respond differently to the same medication. 
 True   False  Not Sure 
4. Pharmacogenetic testing of an individual's genes guarantees whether a particular 
medicine would cause adverse events for that person. 
 True   False  Not Sure 
5. Pharmacogenetic testing is currently available for all medications. 
 True   False  Not Sure 
6. Some medications have FDA-approved pharmacogenetic information in their package 
inserts. 
 True   False  Not Sure 
7. The package insert for clopidogrel (Plavix®) includes a warning about possible worse 
outcomes in individuals who have specific genetic variants. 
 True   False  Not Sure 
Attitudes  
On a scale from 1 to 5, indicate your agreement with the following items:  
8. Prescribers should use pharmacogenetic testing information in clinical practice 
 Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
9. Patients should be educated about the purpose, benefits, limitations and risks of 
pharmacogenetic testing. 
 Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
10. Pharmacogenetic testing will potentially help to decrease the number of adverse drug 
events. 
 Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
11. Pharmacogenetic testing may prevent me from prescribing an ineffective medicine. 
 Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
12. Pharmacogenetic testing is a promising innovation in medicine. 
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 Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
13. Pharmacogenetic testing is not compatible with my personal values. 
 Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
14. I will be reluctant to adopt pharmacogenetic testing until I see it working for patients. 
 Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
15. Pharmacogenetic testing can offer a useful tool to the way I usually 
prescribe/recommended medications. 
 Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
16. I would like to try pharmacogenetic testing on some patients before I decide whether I 
will adopt it or not. 
 Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
17. I am concerned about the effect of the test results on my patients' eligibility for 
private health insurance. 
 Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
18. The application of pharmacogenetic testing adds more complexity to the drug 
prescribing process. 
 Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
19. I am concerned that unauthorized personnel may gain access to the results of that test. 
 Strongly Disagree/Disagree  Neutral  Agree/Strongly Agree 
20. There is a relative advantage for pharmacogenetic testing in the following cases: 
a. Non-response to an essential drug (e.g., analgesic) / Refractory patients 
 Yes   No   Not Sure 
b. Selection of medication that better controls a patient's health condition 
 Yes   No   Not Sure 
21. There is a need for pharmacogenetic testing in the following situations: 
a. When information about the test is included in the package inserts 
 Yes   No   Not Sure 
b. When practice guidelines for the use and interpretation of these tests are available. 
 Yes   No   Not Sure 
22. How/where have you learned about genetics and genetic testing? [Please select all 
that apply.] 
 No, I have not received education in genetics 
 Genetics training in medical/pharmacy school 
 Genetics training in residency 
 Undergraduate genetics course 
 Genetics course in graduate school 
 Grand Rounds 
 CME course 
 Genetics-related seminar or workshop 
 Other 
23. Have you ever talked with a patient about pharmacogenetic testing? 
 Yes   No   Not Sure 
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24. Would you recommend pharmacogenetic testing for medications that recommend 
such tests in their package inserts? 
 Yes   No   Not Sure 
25. Have you ever ordered pharmacogenetic testing for a patient? 
 Yes   No 
26. Which of the following factors would inhibit you from ordering/recommending 
pharmacogenetic testing for a patient? [Please select all that apply.] 
 Pharmacogenetic-testing is not available at my work place 
 Concerns about patients' confidentiality 
 Concerts about patients' employment opportunity 
 Not enough time to order 
 Waiting for pharmacogenetic testing results would delay treatment 
 Uncertain about the clinical utility of the test 
 Insurance doesn't cover test 
 Not applicable for my patients 
 Patient refused test 
27. Would you prefer a pharmacist order, interpret, and send you a report about your 
patients' pharmacogenetic testing results? 
 Yes   No   Not Sure 
28. Gender 
 Male   Female 
29. Ethnic Group: 
 White/Caucasian 
 Hispanic/Latino 
 Black or African American 
 Other 
30. Age Group (year) 
 25-39 
 40-49 
 50-59 
 60+ 
31. What is your medical specialty? 
 Internal Medicine 
 Family Medicine 
 Other 
32. Type of current setting: [Please select all that apply] 
 Urban 
 Suburban 
 Rural 
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Appendix D 
NSU-Institutional Review Board Approval Memorandum and Amendment Approval 
Letter 
 
D.1. MEMORANDUM 
To:  Suhaib Muflih Muflih 
  College of Pharmacy 
From:  William "Bill" R Wolowich, Pharm.D.,    
  Center Representative, Institutional Review Board  
Date:  March 22, 2016 
Re: IRB #:  2016-77; Title, “Measuring Knowledge and Attitudes Regarding 
The Use of Pharmacogenetic Testing Among Patients and Prescribers: 
Diffusion of Innovation Theory” 
I have reviewed the above-referenced research protocol at the center level.  Based on the 
information provided, I have determined that this study is exempt from further IRB review 
under 45 CFR 46.101(b) (Exempt Category 2).  You may proceed with your study as 
described to the IRB.  As principal investigator, you must adhere to the following 
requirements: 
 
1) CONSENT:  If recruitment procedures include consent forms, they must be 
obtained in such a manner that they are clearly understood by the subjects and the 
process affords subjects the opportunity to ask questions, obtain detailed answers 
from those directly involved in the research, and have sufficient time to consider 
their participation after they have been provided this information.  The subjects 
must be given a copy of the signed consent document, and a copy must be placed 
in a secure file separate from de-identified participant information.  Record of 
informed consent must be retained for a minimum of three years from the 
conclusion of the study. 
2) ADVERSE EVENTS/UNANTICIPATED PROBLEMS:  The principal 
investigator is required to notify the IRB chair and me (954-262-5369 and 
William "Bill" R Wolowich, Pharm.D., respectively) of any adverse reactions or 
unanticipated events that may develop as a result of this study.  Reactions or 
events may include, but are not limited to, injury, depression as a result of 
participation in the study, life-threatening situation, death, or loss of 
confidentiality/anonymity of subject.  Approval may be withdrawn if the problem 
is serious. 
3) AMENDMENTS:  Any changes in the study (e.g., procedures, number or types of 
subjects, consent forms, investigators, etc.) must be approved by the IRB prior to 
implementation.  Please be advised that changes in a study may require further 
review depending on the nature of the change.  Please contact me with any 
questions regarding amendments or changes to your study. 
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The NSU IRB is in compliance with the requirements for the protection of human 
subjects prescribed in Part 46 of Title 45 of the Code of Federal Regulations (45 
CFR 46) revised June 18, 1991. 
cc: Barry A. Bleidt, PhD, PharmD 
 
D.2. Amendment Approval Letter  
 
To: Suhaib Muflih, College of Pharmacy 
From: William Smith, JD Director, Institutional Review Board 
Date: August 3, 2016  
Re: 2016-77-Measuring Knowledge and Attitudes Regarding The Use of 
Pharmacogenetic Testing Among Patients and Prescribers: Diffusion of Innovation 
Theory 
 
I have reviewed the amendment to the above-referenced research protocol. On behalf of 
the Institutional Review Board of Nova Southeastern University, the amendment to 
Measuring Knowledge and Attitudes Regarding The Use of Pharmacogenetic Testing 
Among Patients and Prescribers: Diffusion of Innovation Theory is approved and the 
study is still EXEMPT. 
 
cc: Barry A Bleidt, PhD, PharmD; Matthew Seamon, JD, PharmD 
 
Institutional Review Board 
3301 College Avenue Ft. Lauderdale, Florida 33314-7796 
Phone: (954) 262-5369 Fax: (954) 262-3977 Email: irb@nova.edu Web Site: 
www.nova.edu/irb 
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Appendix E 
Adult Informed Consent, Promotional Flyer for Recruiting Patients, Prescriber Invitation 
E-Mail, Prescriber Participation Letter 
 
E.1. Adult Informed Consent  
Consent Form for Participation in the Research Study Entitled “Measuring 
Knowledge and Attitudes Regarding the Use of Pharmacogenetic Testing Among 
Patients and Prescribers: Diffusion of Innovation Theory” 
Funding Source: HPD Grant 
IRB protocol #: 2016-77 
  Principal Investigator 
Name Suhaib Muflih 
Complete mailing address 3301 College Avenue, Fort Lauderdale, Florida  33314-7796 
Contact phone number 954-980-3890 
E-mail sm231@nova.edu  
Degree PharmD 
 
  Co-Investigator 1 (Faculty Advisor) 
Name Barry Bleidt 
Mailing Address 
3301 College Avenue, Fort Lauderdale, Florida  
33314-7796 
Contact Phone Number 954-262-1855 
Email Address bbleidt@nova.edu  
Degree/Academic Information PhD, PharmD, FAPhA 
 
For questions/concerns about your research rights, contact: 
Human Research Oversight Board (Institutional Review Board or IRB)  
Nova Southeastern University 
954-262-5369/Toll Free: 866-499-0790 
IRB@nsu.nova.edu 
 
Site Information:  
NSU Clinic Pharmacy 
3200 S. University Drive 
Ft. Lauderdale, FL  33328 
Tel.: 954-262-4550 
Fax: 954-262-3865 
Why are you asking me? 
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You are invited to participate in a research study. Your participation is voluntary 
which means you can decide whether to participate. If you choose not to participate, there 
will be no loss of benefit to which you might otherwise be entitled. Before you can make 
your decision, you will need to know what the study is about, the possible risks and benefits 
of participating in this study, and what you will have to do in this study. If you decide to 
participate, you will be asked to sign this form.  
The purpose of this consent form is to provide you information so that you can 
decide whether you want to provide information about yourself, your knowledge and 
attitude toward the use of pharmacogenetic testing. The Principle Investigator (the 
researcher) will collect the information about you through a survey questionnaire. There 
are a particular number of participants expected to participate in this research, but we are 
aiming to recruit over 120 participants. 
 
What will I be doing if I agree to be in the study? 
 
If you agree to participate in the study and sign this informed consent, you will fill 
out a survey questionnaire (using clipboard survey or tablet computer) that will collect data 
that will assess your level of knowledge and attitude toward pharmacogenetic testing. After 
you complete the survey (the clipboard survey), please put it in the envelope and give it 
back to the Principle Investigator.  
 
Is there any audio or video recording? 
No 
What are the dangers to me? 
 
We do not anticipate any risks to your participating in this study by filling out a 
survey questionnaire. However, if you feel uncomfortable with any question in the survey, 
you don’t have to answer it. 
 
Are there any benefits for taking part in this research study? 
Although it is not anticipated that there will be any direct benefit to you as a result 
of your participation in this study, your participation may contribute to an increase in the 
knowledge and understanding of how different individuals pharmacogenetic testing. 
Will I get paid for being in the study?  Will it cost me anything? 
You will not be compensated for you participation in this study. There are no costs 
associated with participating in the survey. 
 
 
 
 
How will you keep my information private? 
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The Principle Investigator is the only person who will know who you are and any 
personally identifiable information about you. We will not share any information that you 
give us. The Principle Investigator will replace your personal information with a coded 
identification number. All of your information will be stored in a database which is 
password-protected and secure. Only the Principle Investigator will have the access to the 
database. The researcher will not use any information to identify or contact you. 
 
What if I do not want to participate or I want to leave the study? 
You have the right to leave this study at any time or refuse to participate. If you do decide 
to leave or you decide not to participate, you will not experience any penalty or loss of 
services you have a right to receive.  
 
Other Considerations: 
“If significant new information relating to the study becomes available, which may 
relate to your willingness to continue to participate, this information will be provided to 
you by the investigators.” 
 
Voluntary Consent by Participant: 
By signing below, you indicate that 
● this study has been explained to you 
● you have read this document or it has been read to you 
● your questions about this research study have been answered 
● you have been told that you may ask the researchers any study related questions in 
the future or contact them in the event of a research-related injury 
● you have been told that you may ask Institutional Review Board (IRB) personnel 
questions about your study rights 
● you are entitled to a copy of this form after you have read and signed it 
● you voluntarily agree to participate in the study entitled “Measuring Knowledge 
and Attitudes Regarding the Use of Pharmacogenetic Testing Among Patients and 
Prescribers: Diffusion of Innovation Theory” 
 
Participant's Signature: ___________________________ Date: ________________ 
Participant’s Name: ______________________________ Date: ________________ 
Signature of Person Obtaining Consent: _____________________________   
Date: _________________________________ 
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E.2. Promotional Flyer for Recruiting Patients 
 
 
 
E.3. Prescriber Invitation E-Mail 
 
Dear Physician, 
The link below will direct you to a survey on pharmacogenetic testing. The 
information this survey will collect is vital for an important research project regarding 
pharmacogenetic testing/patient personalized medicine. Your answers are important to 
publish and totally confidential. Please see the participation letter at the beginning of the 
survey for further information on IRB.  
Thank you for taking the time to answer this 4-minute survey. 
Please note that the survey should be completed in one sitting, and a $10 Starbucks code 
will be sent directly via email to the first 120 participants. 
 
Here is the URL: 
http://www.nova.edu/~snap/pharmacogenicprescriber.htm 
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E. 4. Prescriber Participation Letter 
 
Research Explanation and Letter of Consent 
Title of Study: Measuring Knowledge and Attitudes Regarding the Use of 
Pharmacogenetic Testing Among Patients and Prescribers: Diffusion of Innovation 
Theory. 
 
Principal Investigator: Suhaib Muflih 
Complete mailing address: 3301 College Avenue, Fort Lauderdale, Florida 33314-7796 
Contact phone number: 954-980-3890 
E-mail: sm231@nova.edu 
Degree: PharmD 
 
Co-Investigator (Faculty Advisor): Barry Bleidt 
Mailing Address: 3301 College Avenue, Fort Lauderdale, Florida 33314-7796 
Contact Phone Number: 954-262-1855 
Email: bbleidt@nova.edu 
Degree/Academic Information: PhD, PharmD, FAPhA 
 
Institutional Review Board 
Nova Southeastern University 
Office of Grants and Contracts 
(954) 262-5369/Toll Free: 866-499-0790 
IRB@nsu.nova.edu 
IRB #: 2016-77 
 
Site Information: 
NSU Clinic pharmacy 
3200 S. University Drive 
Ft. Lauderdale, FL 33328 
Tel.: 954-262-4550 
Fax: 954-262-3865 
 
Description of Study:  
Dr. Suhaib Muflih is a doctoral student at Nova Southeastern University engaged 
in research for the purpose of satisfying the requirements for a Doctor of Philosophy 
degree. The goal of this dissertation is to increase our understanding of several factors 
(e.g., sociodemographic knowledge, and attitudes) that may play a key role in the 
acceptance or rejection of pharmacogenetic testing among patients and prescribers. The 
process by which pharmacogenetics will be implemented in the future of both 
personalized medicine and routine medical practice will ultimately depend upon patients' 
and physicians' acceptance of these tests and related recommendations. If you agree to 
participate, you will be asked to complete the survey questionnaire below. The 
questionnaire will help the researcher assess prescribers' knowledge and attitudes toward 
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pharmacogenetics testing, and the barriers that interfere with its uptake in the routine 
clinical practice as a new diagnostic tool. The questionnaire will take approximately four 
minutes to complete. 
Risks/Benefits to the Participant:  
We do not anticipate any risks to your participation in this study. There are no 
direct benefits to you for agreeing to be in this study. Please understand that while you 
may not benefit directly from participation in this study, you have the opportunity to 
enhance the serious gap in our knowledge about the barriers that may prevent the 
adoption of pharmacogenetic testing. There is a growing body of evidence that 
pharmacogenetics will allow you as a prescriber to make improved prescribing choices 
that will increase drug efficacy and minimize adverse effects. If you have any concerns 
about the risks/benefits of participating in this study, you may contact the Principle 
Investigator and/or the university's human research oversight board Institutional Review 
Board at the numbers listed above. 
 
Cost and Payments to the Participant:  
There is no cost for participation in this study. Participation is completely 
voluntary, however, an incentive will be provided as a token of appreciation for giving 
your valuable time to complete the survey. 
 
Confidentiality:  
Information obtained in this study is strictly confidential unless disclosure is 
required by law. All data will be secured in password-protected computer. Your name 
will not be used in the reporting of information in publications or conference 
presentations. 
Participant's Right to Withdraw from the Study: You have the right to refuse to 
participate in this study and the right to withdraw from the study at any time without 
penalty. 
 
I have read this letter and I fully understand the contents of this document and 
voluntarily consent to participate. All of my questions concerning this research have been 
answered. If I have any questions in the future about this study, they will be answered by 
the investigator listed above or his/her staff. 
I understand that the completion of this questionnaire implies my consent to participate in 
this study.  
 
Please initial in the space provided below 
______________ 
Please provide the consent date in the space provided below 
______________ 
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Appendix F 
Sensitivity Analyses Using Count Models 
 
Table F.1 
Patient Data. Poisson Regression Model 
 Knowledge 
    95% Conf. Interval 
Variable IRR SE p-value LL                UL 
Gender (Male) 1.020 0.079 0.797 0.877 1.186 
Age 0.986 0.028 0.623 0.933 1.043 
Ethnicity 0.955 0.037 0.236 0.886 1.030 
Level of education 1.089 0.032 0.004 1.028 1.153 
Area of living 1.048 0.074 0.506 0.913 1.202 
Perceived need 1.080 0.055 0.131 0.977 1.193 
Innovativeness 1.119 0.056 0.024 1.015 1.233 
Prior experience 1.146 0.102 0.127 0.962 1.364 
Cons 2.154 0.502 0.001 1.364 3.402 
Note. Knowledge of PGx testing is the response variable in the Poisson regression.  IRR: 
incidence rate ratios for the Poisson model; SE:  standard errors of the individual regression 
coefficients; LL: Lower limit; UL: Upper limit. As a patient’s level of education increased 
by one unit, his/her knowledge of PGx testing would be expected to increase by a factor 
1.089, while holding all other variables in the model constant. Similarly, as a patient’s 
innovativeness score increased by one unit, his/her knowledge of PGx testing would be 
expected to increase by a factor 1.12, while holding all other variables in the model 
constant. 
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Table F.2.  
Patient Data. Ordinal Dependent Variable Regression Model 
 Knowledge 
    95% Conf. Interval 
Variables B SEB p-value   LL                UL 
Gender (Male) 0.090 0.157 0.565 -0.217 0.398 
Age -0.024 0.059 0.679 0.139 0.091 
Ethnicity -0.135 0.078 0.082 0.287 0.017 
Level of education 0.263 0.061 0.000 0.144 0.383 
Area of living 0.090 0.142 0.524 0.188 0.368 
Perceived need 0.208 0.100 0.038 0.012 0.405 
Innovativeness 0.322 0.103 0.002 0.120 0.524 
Prior experience 0.520 0.199 0.009 0.131 0.910 
Note. B: Standard interpretation of the ordered logit coefficient; SEB: Standard error of 
regression coefficients. Ordinal Probit Model is used when the dependent variable 
(knowledge) is neither interval nor ratio; the distances between different levels of 
knowledge are not equal. For a one unit increase in the level of education, the log-odds 
of having a higher level of knowledge would increase by 0.26, given that all of the other 
variables in the model are held constant. A one unit increase in the perceived need score 
would result in a 0.21 increase in the log-odds of having a higher level of knowledge. A 
one unit increase in the innovativeness score would result in a 0.32 increase in the log-
odds of having a higher level of knowledge, given that all of the other variables in the 
model are held constant. The log odds of having a higher level of knowledge is 0.52 
greater among patient with a prior experience of PGx testing than those have no prior 
experience, given that all of the other variables in the model are held constant. 
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Table F.3 
Patient Data. Poisson Regression Model 
 Attitudes 
    95% Conf. Interval 
Variables IRR SE p-value LL                UL 
Gender (Male) 0.883 0.063 0.082 0.767 1.016 
Level of education 1.023 0.026 0.365 0.973 1.076 
Relative Advantage 1.249 0.066 0.000 1.126 1.386 
Compatibility 1.112 0.048 0.014 1.021 1.210 
Complexity 0.915 0.054 0.075 0.991 1.205 
Trialability 1.187 0.076 0.007 1.047 1.344 
Observability 1.059 0.065 0.349 0.939 1.195 
Cons 1.323 0.239 0.121 0.929 1.885 
Note. Attitude toward PGx testing is the response variable in the Poisson regression. IRR: 
incidence rate ratios for the Poisson model; SE:  standard errors of the individual 
regression coefficients; LL: Lower limit; UL: Upper limit. As the relative advantage score 
increased by one unit, the patient’s attitude toward PGx testing would be expected to 
increase by a factor 1.25, while holding all other variables in the model constant. As 
compatibility score increased by one unit, the patient’s attitude would be expected to 
increase by a factor 1.11, while holding all other variables in the model constant. As 
trialability score increased by one unit, the patient’s attitude would be expected to increase 
by a factor 1.19, while holding all other variables in the model constant. 
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Table F.4 
Patient Data. Ordinal Dependent Variable Regression Model 
 Attitudes 
    95% Conf. Interval 
Variables B SEB p-value       LL               UL 
Gender (Male) -0.408 0.158 0.010 -0.718 -0.099 
Level of education 0.070 0.059 0.233 -0.045 0.185 
Relative Advantage 0.629 0.113 0.000 0.408 0.849 
Compatibility 0.375 0.101 0.000 0.177 0.573 
Complexity -0.210 0.109 0.054 -0.424 0.004 
Trialability 0.434 0.130 0.001 0.179 0.689 
Observability 0.268 0.160 0.094 -0.046 0.582 
Note. B: Standard interpretation of the ordered logit coefficient; SEB: Standard error of 
regression coefficients. Ordinal Probit Model is used when the dependent variable 
(knowledge) is neither interval nor ratio; the distances between different levels of 
attitude are not equal. The log-odds estimate for males being in a higher level of attitude 
is -0.41 less than females when the other variables in the model are held constant. A one 
unit increase in the relative advantage score, the log-odds of having a higher level of 
attitude would increase by 0.63, given that all of the other variables in the model are 
held constant. A one unit increase in the compatibility score would result in a 0.38 
increase in the log-odds of having a higher level of attitude. A one unit increase in the 
complexity score would result in a 0.21 decrease in the log-odds of being having a higher 
level of knowledge, given that all of the other variables in the model are held constant. 
A one unit increase in the trialability score would result in a 0.43 increase in the log-
odds of being having a higher level of knowledge, given that all of the other variables 
in the model are held constant. 
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Table F.5 
Prescriber Data. Poisson Regression Model 
 Knowledge 
    95% Conf. Interval 
Variables IRR SE p-value LL                UL 
Gender (Male) 0.777 0.078 0.013 0.638 0.948 
Type of practice setting 1.248 0.102 0.007 1.063 1.465 
Prior-experience 1.257 0.143 0.044 1.006 1.571 
Perceived need 1.087 0.077 0.238 0.947 1.247 
Communication Channels 1.039 0.054 0.462 0.938 1.150 
Cons 2.179 0.407 0.000 1.512 3.142 
Note. Knowledge of PGx testing is the response variable in the Poisson regression.  IRR: 
incidence rate ratios for the Poisson model; SE:  standard errors of the individual 
regression coefficients; LL: Lower limit; UL: Upper limit. The knowledge scores among 
male physicians would be expected to decrease by a factor 0.78 compared to female 
physicians, while holding the other variable constant in the model. Knowledge among 
physicians who practiced in non-urban areas would be expected to increase by a factor 
1.25 compared to physicians who practiced in urban areas, while holding the other 
variable constant in the model. Knowledge among physicians who had prior experience 
with PGx testing would be expected to increase by a factor 1.26 compared to physicians 
with no experience, while holding the other variable constant in the model. 
 
Table F.6 
Prescriber Data. Poisson Regression Model 
 Attitude 
    95% Conf. Interval 
Variables IRR SE p-value LL               UL 
Gender (Male) 0.876 0.068 0.087 0.753 1.020 
Relative Advantage 1.160 0.071 0.016 1.029 1.308 
Compatibility 1.195 0.079 0.007 1.049 1.361 
Observability 1.049 0.042 0.229 0.970 1.135 
Cons 3.063 0.495 0.000 2.231 4.205 
Note. Attitude toward PGx testing is the response variable in the Poisson regression. IRR: 
incidence rate ratios for the Poisson model; SE:  standard errors of the individual regression 
coefficients; LL: Lower limit; UL: Upper limit. The attitude scores among male physicians 
would be expected to decrease by a factor 0.88 compared to female physicians, while 
holding the other variable constant in the model. As the relative advantage score increased 
by one unit, the physician’s attitude toward PGx testing would be expected to increase by 
a factor 1.16, while holding all other variables in the model constant. As compatibility 
score increased by one unit, the physician’s attitude would be expected to increase by a 
factor 1.20, while holding all other variables in the model constant. 
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Appendix G 
FDA-Approved Drugs with Package Inserts Containing PGx Information in Warnings 
and Precaution Labeling Sections  
 
Table G 
Examples of Medications with FDA-Approved PGx information 
Drug Therapeutic Area Biomarker 
Abacavir Infectious Diseases HLA-B*57:01 
Amitriptyline Psychiatry CYP2D6 
Atomoxetine Psychiatry CYP2D6 
Azathioprine Rheumatology TPMT 
Capecitabine Oncology DPYD 
Carbamazepine Neurology HLA-B*15:02 
Carbamazepine Neurology HLA-A*31:01 
Cetuximab Oncology EGFR 
Cetuximab Oncology EGFR 
Cevimeline Dental CYP2D6 
Chloroquine Infectious Diseases G6PD 
Chlorpropamide Endocrinology G6PD 
Citalopram Psychiatry CYP2C19 
Clomipramine Psychiatry CYP2D6 
Clopidogrel Cardiology CYP2C19 
Codeine Anesthesiology CYP2D6 
Dabrafenib Oncology BRAF 
Dabrafenib Oncology G6PD 
Dapsone  Dermatology G6PD 
Dapsone  Infectious Diseases G6PD 
Denileukin Diftitox Oncology IL2RA (CD25 antigen) 
Desipramine Psychiatry CYP2D6 
Dextromethorphan and 
Quinidine 
Neurology CYP2D6 
Eltrombopag Hematology F5 (Factor V Leiden) 
Erythromycin and 
Sulfisoxazole 
Infectious Diseases G6PD 
Everolimus Oncology ERBB2 (HER2) 
Everolimus Oncology ESR1 
Fluorouracil Dermatology DPYD 
Fluorouracil Oncology DPYD 
Fluoxetine Psychiatry CYP2D6 
Glimepiride Endocrinology G6PD 
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Glipizide Endocrinology G6PD 
Glyburide Endocrinology G6PD 
Iloperidone Psychiatry CYP2D6 
Imipramine Psychiatry CYP2D6 
Irinotecan Oncology UGT1A1 
Lenalidomide Hematology del (5q) 
Lidocaine and Prilocaine Anesthesiology Not specified 
Lidocaine and Prilocaine Anesthesiology G6PD 
Lomitapide Endocrinology Not specified 
Mafenide Infectious Diseases G6PD 
Mercaptopurine Oncology TPMT 
Methylene Blue Hematology G6PD 
Metoclopramide  Gastroenterology G6PD 
Mipomersen Endocrinology Not specified 
Mycophenolic Acid Transplantation HPRT1 
Nalidixic Acid Infectious Diseases G6PD 
Nefazodone Psychiatry CYP2D6 
Nitrofurantoin Infectious Diseases G6PD 
Nortriptyline Psychiatry CYP2D6 
Olaparib Oncology BRCA1, BRCA2 
Oxcarbazepine Neurology HLA-B*15:02 
Pegloticase Rheumatology G6PD 
Perphenazine Psychiatry CYP2D6 
Pertuzumab Oncology ERBB2 (HER2) 
Phenytoin Neurology HLA-B*15:02 
Pimozide Psychiatry CYP2D6 
Primaquine Infectious Diseases G6PD 
Propafenone Cardiology CYP2D6 
Protriptyline Psychiatry CYP2D6 
Quinidine Cardiology CYP2D6 
Rasburicase Oncology G6PD 
Sevoflurane Anesthesiology RYR1 
Sodium Nitrite Toxicology G6PD 
Sulfasalazine Gastroenterology G6PD 
Tamoxifen  Oncology F5 (Factor V Leiden) 
Tamoxifen Oncology F2 (Prothrombin) 
Tetrabenazine Neurology CYP2D6 
Thioguanine Oncology TPMT 
Thioridazine Psychiatry CYP2D6 
Tolterodine Urology CYP2D6 
Trastuzumab Oncology ERBB2 (HER2) 
Tretinoin Oncology PML-RARA 
Trimipramine Psychiatry CYP2D6 
Valproic Acid  Neurology POLG 
Vemurafenib Oncology BRAF 
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Vemurafenib Oncology NRAS 
Venlafaxine Psychiatry CYP2D6 
Warfarin Hematology PROS1 
Warfarin Hematology PROC 
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Measuring Knowledge and Attitudes Regarding the Use of Pharmacogenetic 
Testing Among Patients and Prescribers: Diffusion of Innovation Theory 
 June 2016: Awarded $4,990 by HPD Research Committee. Measuring knowledge 
and attitudes regarding the use of pharmacogenetic testing among patients and 
prescribers: diffusion of innovation theory 
 February 2016: Awarded $450 from Pan SGA Professional Development Grant 
to present at the 2015 ASHP Midyear Clinical Meeting, 12/06/2015-12/10/2015. 
Knowledge and attitudes towards pharmacogenetic testing among a cohort of 
patients and prescribers: diffusion of innovation theory (New Orleans, LA) 
POINTS OF INTERESTS 
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 I am interested the outcomes of therapeutics using Pharmacogenetic testing. 
 I am interested in continuing to learn more about pharmacoepidemiological 
research and the outcomes of therapeutics 
 I am interested in doing research about good pharmacy practice especially the 
collaboration between physicians and pharmacists to choose the best healthcare 
plan that decrease the economic burden on healthcare system 
 I am interested in conducting more research on knowledge and attitudes towards 
pharmacogenetic testing among patients, pharmacists, and prescribers using 
diffusion of innovation theory 
 
AWARDS AND HONORS 
 February 2016: Award received for poster presentation, HPD Research Day. The 
award is given for the outstanding poster presentation of my research 
titled Knowledge and attitudes towards pharmacogenetic testing among a cohort of 
patients and prescribers: diffusion of innovation theory, during NSU Research Day, 
held on February 12, 2016 
 September 2014: Member of Rho Chi national pharmacy honor society 
 
HOBBIES 
 Swimming, Kayaking, Biking, Ping Pong, Chess 
 
 
